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Résumé en français 
 
1. Introduction 
Le travail présenté ici a pour but de contribuer à mieux définir les facteurs impliqués dans 
le développement et la croissance du pancréas. Pour cela nous avons divisé notre étude en 
deux parties:  
- rôle de la voie de signalisation Wnt, et plus précisément de l’activation de la  β caténine, 
dans le pancréas 
- rôle du polypeptide pancréatique dans le développement du pancréas. 
Afin de mieux comprendre les implications de ce travail, nous allons tout d’abord définir 
les principales notions que nous utiliserons ensuite. 
 
1.1. La voie de signalisation Wnt 
Les cascades de signalisation interviennent dans la régulation de la communication entre 
cellules et jouent un rôle important pendant l’embryogenèse mais aussi à l’âge adulte, 
lors de la régénération des tissus ou tout simplement dans le maintien de l’homéostasie 
cellulaire. Une activité déréglée d’une voie de signalisation intracellulaire peut être à 
l’origine de défauts pendant le développement ou causer des maladies plus tard dans la 
vie.  
La voie de signalisation Wnt est hautement conservée dans les différentes espèces et joue 
un rôle essentiel dans de nombreux processus tels que la prolifération, la différenciation 
ou la migration cellulaire. De part ces rôles, la voie de signalisation Wnt intervient 
positivement dans le remodelage de l’embryon et le maintien d’une population de cellules 
souches dans différents tissus. Par contre sa dérégulation a une implication négative de 
part le développement de tumeurs.  
La voie Wnt se décompose en: sécrétion de molécules appartenant à la famille Wnt, 
liaison à des récepteurs de surface, activation d’une série d’évènements intracellulaires 
qui conduisent à un changement dans l’expression de gènes cibles. La protéine qui est au 
centre de cette cascade de signalisation est la β caténine, dont la voie Wnt empêche la 
dégradation.  
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Dans des cellules non stimulées par Wnt, le niveau de la β caténine intracellulaire est 
minimal, à cause de son interaction avec le complexe de dégradation formé de trois 
protéines : l’Axine, l’APC et la kinase GSK3-β. Ce complexe est responsable de la 
phosphorylation de la β caténine, ce qui amène à sa dégradation par le protéasome.  
Lors de l’activation de la voie de signalisation Wnt, cette phosphorylation est inhibée et 
ainsi la β caténine peut s’accumuler dans la cellule et entrer dans le noyau, où elle 
interagit avec les facteurs TCF/LEF pour activer la transcription des gènes cibles.  
La protéine APC (Adenomatous Polyposis Coli) joue un rôle essentiel dans la régulation 
de la β caténine. Elle se retrouve mutée dans 80% des cancers du colon chez les humains. 
La majorité de ces mutations conduisent à une protéine APC tronquée, qui n’est plus 
capable de contrôler le niveau de la β caténine dans la cellule. Ces mutations se situent 
très souvent dans le domaine de liaison à β caténine et à l’Axine. 
La protéine β caténine a tout d’abord été isolée pour son rôle dans l’adhésion cellulaire. 
En effet elle lie la E-cadhérine qui est responsable de la connexion entre cellules voisines, 
et se connecte au cytosquelette via sa liaison à la α caténine. La β caténine membranaire 
est stable, alors que la β caténine cytoplasmique soluble est fortement instable en 
l’absence d’une signalisation Wnt. En présence de cette signalisation par contre, la β 
caténine participe activement à la transcription des gènes cibles. Cette double fonction de 
la β caténine, adhésion et transcription, assure une architecture tissulaire correcte pendant 
le développement embryonnaire. Le choix entre ces deux fonctions de la β caténine se fait 
par un changement de conformation de la protéine suite à l’activation de la voie Wnt, qui 
favorise la liaison aux facteurs TCF dans le noyau plutôt que celle aux molécules 
d’adhésion.  
Les facteurs TCF/LEF jouent un rôle critique pendant l’embryogenèse, dans 
l’établissement de l’axe antéro-postérieur, pour la détermination cellulaire et la régulation 
de la prolifération et de la survie de la cellule. Ce sont les médiateurs ultimes de la voie 
de signalisation Wnt. Ces facteurs sont incapables d’agir seuls pour activer la 
transcription car ils ne possèdent pas de domaine de transactivation.  
En l’absence d’une signalisation Wnt, les protéines TCF/LEF répriment la transcription 
de part leur liaison avec des co-répresseurs tels que Groucho et CtBP, alors qu’ils 
deviennent des activateurs transcriptionnels quand ils lient la β caténine.  
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Les activateurs et répresseurs de la β caténine et du TCF agissent dans le noyau pour 
réguler leurs interactions de manière très précise, de façon à ce que l’activation de la 
transcription des gènes cibles soit finement contrôlée. Les gènes cibles de la voie Wnt 
sont nombreux et impliqués dans divers processus tels que la prolifération cellulaire (par 
exemple cMyc, cJun ou la cycline D1) ou la migration (comme la métalloprotéinase 
MMP-7). La majorité de ces gènes a été identifié dans les cellules tumorales de colon et 
les cibles qui sont activées par la β caténine  et TCF peuvent être différentes en fonction 
des tissus. 
La première partie de ma thèse porte sur le rôle de la signalisation par la β caténine dans 
le pancréas et je vais donc introduire cet organe plus en détails. 
 
1.2. Le développement du pancréas 
Le pancréas se développe à partir d’une région endodermique comprise entre l’estomac et 
le duodénum qui exprime le facteur de transcription Pdx1. Tous les types cellulaires qui 
composent le pancréas adulte dérivent d’un progéniteur commun qui exprime Pdx1. Chez 
la souris, très précocement (au jour embryonnaire E8.5), cet endoderme forme deux 
bourgeons pancréatiques, dorsal et ventral. Ces deux bourgeons se développent à partir de 
deux domaines endodermiques indépendants qui reçoivent des signaux différents de part 
leur contact avec des structures différentes. Le bourgeon dorsal se développe à proximité 
de la notocorde alors que le ventral est connecté au foie et à l’épithélium du canal biliaire. 
L’expression de Sonic Hedgehog (Shh) dans l’endoderme dorsal est inhibée par la 
notocorde, alors que la partie ventrale est dépourvue de Hedgehog, ce qui permet le 
développement du pancréas à partir de cette région endodermique.  
L’épithélium pancréatique, au fur et à mesure que le développement embryonnaire se 
poursuit, envahit le mésenchyme avoisinant et prolifère. Les interactions épithélium-
mésenchyme jouent un rôle fondamental dans la croissance et la différenciation de 
l’ébauche pancréatique et sont essentielles afin d’assurer un développement pancréatique 
correct. Lors de la rotation du tube digestif, les deux bourgeons fusionnent pour former 
un organe bipolaire mature. 
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Les différences apparues au cours du développement embryonnaire se reflètent dans le 
pancréas adulte, dont la partie dorsale contient plus de cellules exprimant le glucagon 
alors que la partie ventrale est riche en cellules exprimant le polypeptide pancréatique. 
Le pancréas adulte est une glande composée de deux parties distinctes : le tissu endocrine 
et exocrine. Les cellules endocrine sécrètent différentes hormones dans le sang afin de 
réguler l’homéostasie du glucose et se regroupent en amas appelés îlots de Langerhans, 
qui représentent 1-2% du pancréas adulte. Un îlot chez la souris est composé d’un 
« cœur » de cellules β produisant l’insuline, entouré de trois autres types cellulaires : les 
cellules α qui produisent le glucagon, les cellules δ pour la somatostatine et les cellules à 
PP produisant le polypeptide pancréatique. Les îlots endocrine sont dispersés dans le tissu 
exocrine, qui est composé d’acini sécrétant des enzymes digestives, tels que l’amylase, et 
de canaux responsables du transport des sécrétions acinaires dans l’intestin. La sécrétion 
pancréatique est régulée par des stimulations hormonales et neuronales. Le pancréas joue 
donc un rôle central dans la balance énergétique et la nutrition, en fournissant les 
enzymes digestives nécessaires ainsi que les signaux hormonaux qui régulent l’absorption, 
l’utilisation et le stockage des nutriments digérés. 
De plus, le pancréas est un organe important d’un point de vue médical car son 
dysfonctionnement est à l’origine de deux maladies très importantes chez les humains: le 
cancer pancréatique et le diabète.  
Le cancer pancréatique est pratiquement incurable à cause de sa résistance à toute 
chimiothérapie; pour cette raison est l’un des cancers les plus lethaux.  
Le diabète est une maladie endocrinienne très répandue dans les pays industrialisés, causé 
par une incapacité à contrôler le taux de glucose dans le sang. Cela peut-être du à une 
destruction auto-immune des cellules produisant l’insuline (diabète de type I) ou à une 
résistance périphérique à l’insuline des organes cibles (tels que le foie, les muscles ou le 
tissu adipeux) accompagnée d’une sécrétion affaiblie d’insuline par les cellules β (type II). 
Comprendre quel est le mécanisme qui gouverne la formation de ces cellules est crucial 
pour envisager une thérapie de remplacement cellulaire. 
Comme je l’ai déjà mentionné auparavant, l’endoderme pré-pancréatique est caractérisé 
par l’expression du facteur de transcription Pdx1, qui agit comme principal régulateur du 
développement pancréatique, étant donné que tous les progéniteurs pancréatiques 
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expriment Pdx1. Ptf1a est un facteur de transcription capable de complémenter Pdx1 dans 
la spécification des précurseurs pancréatiques, vu que les cellules positives pour Ptf1a 
contribuent aux trois types de lignages cellulaires (endocrine, acinaire et ductal) du 
pancréas adulte.  
Ptf1a est exprimé très précocement pendant le développement du pancréas, tout comme 
Pdx1, et son expression se restreint aux précurseurs des cellules acinaires à partir de 
E13.5. L’expression de Pdx1 est aussi restreinte plus tard dans le développement, à partir 
de E15.5 elle devient spécifique aux cellules β différentiées.  
La transition pour ces deux facteurs de transcription coïncide avec la conversion de tous 
les progéniteurs en cellules matures, période que l’on appelle « transition secondaire ». 
C’est à ce moment là que les différents types cellulaires du pancréas commencent leur 
différenciation et expriment une variété de facteurs de transcription spécifiques, 
responsables de leur devenir cellulaire. A titre d’exemple je citerai juste la Neurogénine 3, 
un facteur commun à toutes les cellules qui s’engagent dans la voie endocrine.  
Après cette transition, l’expansion des différents types cellulaires du pancréas se fait par 
prolifération des cellules différenciées. Les cellules exocrines sont très prolifératives 
après leur différenciation, alors que l’index mitotique des cellules endocrines est plus 
élevé à la naissance. Les cellules endocrines apparaissent à différents stades du 
développement pancréatique: les cellules glucagon d’abord à E12.5, puis les insuline un 
jour plus tard, les cellules somatostatine à E15.5 et finalement les cellules PP après E16-
18.  
Le modèle généralement accepté prédit que les précurseurs indifférenciés qui expriment 
Pdx1 émergent des canaux pendant le développement, migrant ensuite pour générer des 
cellules endocrines et acinaires. Une fois différenciées, les cellules endocrines sortent de 
l’épithélium, migrent dans la matrice extracellulaire et se regroupent pour former les îlots 
de Langerhans.  
Vu que la deuxième partie de ma thèse porte sur le rôle du polypeptide pancréatique au 
cours du développement du pancréas, je vais introduire plus en détails ce peptide qui fait 
partie des îlots de Langerhans. 
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1.3. PP 
Le polypeptide pancréatique (PP) fait partie d’une famille comprenant aussi le 
neuropeptide Y (NPY) et le peptide YY (PYY). Cette famille de peptides représente un 
exemple de duplication multiple de gènes qui donne naissance à des protéines 
structurellement liées mais fonctionnellement distinctes.  
NPY est l’un des peptides les plus abondants dans le système nerveux des mammifères et 
régule une vaste série d’activités physiologiques importantes tels que l’appétit, la 
pression sanguine, la sécrétion endocrine et la reproduction.  
PYY est une hormone intestinale qui agit en inhibant le système gastro-intestinal, c'est-à-
dire en inhibant la sécrétion des sucs gastriques, celle du pancréas exocrine, ainsi que la 
motilité de l’estomac et du tube digestif. Dans le pancréas, des cellules PYY positives 
apparaissent très précocement au cours du développement, lors de la « transition 
primaire » à E8-8.5 (où l’on ne trouve que quelques cellules glucagon dans le territoire 
présomptif du pancréas). A ce moment là, on peut observer quelques cellules exprimant à 
la fois PYY et glucagon, mais des études de lignage cellulaire ont montré que ces cellules 
ne sont pas les précurseurs des cellules endocrines matures. Le rôle de PYY pendant le 
développement du pancréas reste donc à élucider. 
Le polypeptide pancréatique est une hormone endocrine qui inhibe spécifiquement la 
sécrétion d’enzymes et de bicarbonate par le pancréas exocrine. L’ARN messager de PP 
est exprimé très tôt au cours du développement, à partir de E10.5, même si la protéine 
n’est détectée que plus tard (E16-18). Les cellules PP ne représentent qu’une très faible 
proportion des cellules composant l’îlot (moins de 2%). Nous avons montré, au sein du 
laboratoire, que les cellules exprimant PP étaient les précurseurs des lignages des cellules 
insuline et somatostatine.  
PP joue aussi un rôle dans le contrôle de la sécrétion d’insuline: des souris transgéniques 
surexprimant PP sont intolérantes au glucose et ont une sécrétion d’insuline réduite. De 
plus, des taux de PP dans le sang plus élevés que la normale ont été relevés chez des 
patients diabétiques.  
PP et PYY sont aussi connus pour agir comme des hormones anorexiques, inhibitrices de 
l’appétit et de la prise de nourriture. 
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2. Résultats première partie: inactivation d’APC dans le pancréas 
murin 
 
Plusieurs composants de la voie Wnt sont présents dans l’épithélium et le mésenchyme 
pancréatique mais, lorsque j’ai débuté cette étude, il n’existait aucune donnée sur leur 
action dans le pancréas. Nous avons donc voulu caractériser le rôle de la voie Wnt dans la 
régulation du développement et de l’homéostasie du pancréas, mais aussi son impact en 
terme temporel au cours de la vie. 
J’ai donc utilisé comme approche expérimentale un modèle de souris avec une 
invalidation génique conditionnelle qui permet l’activation spécifique de cette voie de 
signalisation exclusivement dans le pancréas et j’en ai étudié les effets à différents 
moments de la vie de ces souris transgéniques (stade embryonnaire, jeunes adultes et plus 
âgés). 
 
2.1. Modèle d’invalidation génique de l’APC 
Des souris dans lesquelles les deux allèles du gène Apc sont flanqués par deux sites loxP 
(Apcfl/fl) ont été croisées avec des souris Pdx1-Cre (générées dans notre laboratoire) qui 
expriment la Cre recombinase dans tous les types cellulaires du pancréas. Dans les souris 
Pdx1-Cre, le promoteur Pdx1 est actif à partir de E10.5 et ceci permet, grâce au système 
de recombinaison Cre-Lox, une ablation du gène Apc dans tous les progéniteurs 
pancréatiques des souris Apcfl/fl ;Pdx1-Cre (ApcP-/-). Dans le pancréas des souris ApcP-/-, 
l’exon du gène Apc contenant les domaines de liaison à l’Axine et à la β caténine est 
délété, ce qui résulte dans la production d’une protéine APC tronquée incapable de 
réguler les niveaux intracellulaires de la β caténine. 
 
2.2. Phénotype pancréatique  
La délétion d’Apc dans le pancréas est très efficace et a été validée par RT-PCR 
quantitative aux différents stades étudiés. Le pancréas des animaux ApcP-/- est normal tout 
au long de l’embryogenèse et à la naissance, mais à partir de trois semaines une 
pancréatomégalie apparaît, associée à une augmentation de la taille du pancréas qui 
perdure jusqu’à un an. D’un point de vue histologique, les compartiments acinaire, ductal 
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et endocrine des ApcP-/- sont similaires à ceux des souris contrôles, avec une expression 
normale des divers marqueurs de différenciation. A cause de l’hypertrophie du pancréas 
chez les ApcP-/-, les îlots de Langerhans semblent dilués dans le compartiment exocrine, 
mais la masse pancréatique endocrine totale reste inchangée, ainsi que le contenu 
pancréatique total d’hormones telles que l’insuline et le glucagon. Le compartiment 
endocrine ne semble donc pas être affecté par la pancréatomégalie. L’homéostasie et la 
fonction du pancréas endocrine, notamment la sécrétion d’insuline, chez les mutants sont 
d’ailleurs normales.   
 
2.3. Accumulation de la β caténine suite à la délétion d’Apc 
APC est un régulateur clé des niveaux endogènes de la β caténine dans les cellules et sa 
délétion est censée induire l’accumulation de la forme non-phosphorylée de la β caténine 
ainsi que sa translocation nucléaire. C’est en effet ce que l’on observe dans le pancréas 
des souris invalidées pour le gène Apc à deux mois: chez les souris contrôles, la β 
caténine est principalement membranaire, quel que soit le type cellulaire. Par contre, chez 
les souris ApcP-/-, elle est nucléaire pour les cellules acinaires mais reste localisée à la 
membrane des canaux et des îlots de Langerhans, malgré l’inactivation efficace d’Apc 
dans ces compartiments.  
La localisation nucléaire de la β caténine, selon le modèle d’activation de la voie Wnt, est 
associée à une transcription accrue de gènes cibles impliqués dans la prolifération 
cellulaire. En accord avec ça, le taux d’expression de gènes tels que cMyc, la cycline D2 
ou cJun est augmenté dans des extraits pancréatiques de souris ApcP-/- à deux mois, 
montrant que la voie de signalisation est activée. En conséquence, le taux de prolifération 
du pancréas des souris ApcP-/- est accru chez les jeunes adultes, mais ce phénomène est 
transitoire et ne persiste que jusqu’à l’age de six mois, la prolifération redevenant alors 
normale. Cette hyperplasie du pancréas observée chez les jeunes souris ApcP-/- ne 
concerne que la partie acinaire, en accord avec l’accumulation nucléaire de la β caténine 
restreinte à ce compartiment.  
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2.4. Role de cMyc 
Chez les jeunes adultes ApcP-/-, l’expression de cMyc est augmentée suite à l’activation de 
β-catenin. Afin d’évaluer le rôle de cMyc dans cette hyperplasie acinaire, nous avons 
généré des souris doublement mutantes pour Apc et cMyc. Ces souris ApcP-/- ; cMycP-/- ont 
un pancréas de taille normale, montrant ainsi que la délétion de cMyc induit un 
renversement de la pancréatomégalie observée chez les ApcP-/-. L’accumulation de la 
forme non-phosphorylée de la β caténine et sa localisation nucléaire dans les acini 
persiste néanmoins chez les doubles mutants, due à la délétion d’Apc. Ces résultats 
montrent clairement que l’effet prolifératif de l’activation de la β caténine sur les cellules 
acinaires, observé chez les ApcP-/-, se fait par l’intermédiaire de cMyc. 
 
2.5. Activation temporelle de la voie Wnt 
Etonnement, l’inactivation d’APC dans le pancréas n’a pas d’effet pendant 
l’embryogenèse. A E15.5, à la fin de la « transition secondaire », la masse pancréatique 
est comparable à celle des embryons contrôles et le taux de prolifération est inchangé. A 
ce stade, la forme non-phosphorylée de la β caténine ne s’accumule pas chez les 
embryons ApcP-/- et sa localisation reste membranaire, comme chez les souris contrôles. 
La voie de signalisation de la β caténine semble donc être inactive pendant 
l’embryogenèse et ceci est confirmé par un niveau d’expression des gènes cibles tout à 
fait normal. 
A la naissance néanmoins, la prolifération cellulaire est augmentée chez les souris ApcP-/-, 
mais la taille du pancréas n’est pas encore accrue à ce stade. De plus, la β caténine 
commence à s’accumuler dans le pancréas des mutants nouveaux-nés, et de manière plus 
spécifique dans le noyau des cellules acinaires. C’est cela qui va conduire au 
développement d’une pancréatomégalie chez les ApcP-/- à partir de trois semaines. 
La taille du pancréas reste accrue mais stable tout au long de la vie des souris APC 
mutantes, et la localisation nucléaire de la β caténine persiste dans les cellules acinaires 
des souris âgées d’un an. On peut observer des foyers de cellules acinaires hypertrophiées 
contenant des noyaux dysplasiques dans le pancréas des souris mutantes âgées, ainsi que 
quelques îlots de forme irrégulière, mais aucun signe de pancréatite, de fibrose ou de 
lésions cancéreuses. Le taux de prolifération à ce stade est redevenu normal chez les 
 14
souris ApcP-/- (et ceci à partir de six mois), et le niveau d’expression des gènes cibles de la 
β caténine, fortement augmenté dans le pancréas des jeunes mutants, est similaire à celui 
d’un pancréas contrôle du même âge. Tous ces résultats peuvent en partie expliquer 
l’absence de tumeurs pancréatiques après la mutation d’APC de part une activation 
transitoire de la voie de signalisation de la β caténine, contrairement à ce qui se passe 
dans l’intestin, dans le foie ou dans les reins où cette même mutation est 100% 
tumorigène.  
Les mécanismes moléculaires à la base du blocage de la transcription des gènes cibles de 
la β caténine et de TCF dans le pancréas des souris âgées malgré la permissivité du 
système (la délétion d’Apc créant les conditions pour une activation constitutive de la 
voie) reste à élucider dans les détails. 
 
2.6. Conclusion  
En conclusion, l’étude de ces souris transgéniques où l’inhibiteur endogène de la β 
caténine, Apc, a été inactivé dans le pancréas révèle que l’activation de la voie Wnt/β 
caténine dans cet organe est soumise à d’importantes restrictions spatio-temporelles. Elle 
provoque en effet une hyperplasie uniquement acinaire, avec aucun effet pour le tissu 
endocrine; de plus la voie de signalisation s’avère inactive pendant l’embryogenèse et 
bloquée au niveau transcriptionnel dans les souris âgées. Reste à étudier quels facteurs 
sont impliqués dans cette régulation spatio-temporelle de l’activité de la β caténine dans 
le pancréas. 
 
3. Résultats deuxième partie: rôle de PP dans le développement du 
pancréas murin 
 
Dans la deuxième partie da ma thèse je me suis intéressée au rôle de l’hormone 
polypeptide pancréatique (PP) au cours du développement du pancréas. 
Dans ce but, trois approches expérimentales différentes ont été utilisées: l’inhibition de 
l’expression du polypeptide pancréatique, l’inactivation du gène PP, et l’étude du lignage 
cellulaire des cellules PP pendant le développement pancréatique. 
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3.1. Inhibition de l’expression de PP par siRNA 
Le processus de l’ARN interférence (RNAi) est un mécanisme très conservé qui permet 
de détruire rapidement l’ARN double brin présent dans les cellules. Une technique 
dérivée de l’RNAi utilise des petites molécules d’ARN de 21 nucléotides (siRNA) pour 
induire l’inhibition spécifique de l’expression d’un gène d’intérêt.  
On a utilisé des siRNA dirigés contre l’ARN messager du polypeptide pancréatique afin 
d’abolir son expression dans le pancréas en développement. Des lentivirus exprimant ces 
siRNA de façon ubiquitaire ont été produits. 
Des siRNA localisés à différents endroits de la région codante de PP ont été sélectionnés 
et testés en culture cellulaire. Les plus efficaces dans l’inhibition du transcript PP ont été 
ensuite sous clonés dans un vecteur lentiviral contenant aussi le marqueur EGFP. Les 
lentivirus exprimant ces siRNA ont été générés et ont permis de réaliser l’étude in vitro, 
avec des bourgeons pancréatiques en culture, et in vivo, avec des souris transgéniques. 
Des explants de pancréas murin au stade E11.5 ou E12.5 en culture grandissent et se 
ramifient de manière similaire à ce qui se passe au cours du développement. Après une 
semaine de culture, ces bourgeons expriment tous les marqueurs (exocrines et 
endocrines) de différenciation du pancréas adulte.  
Un jour après leur mise en culture, ces explants sont transduits avec des lentivirus 
contrôle (exprimant uniquement la GFP) ou qui portent les PP-siRNA et analysés par 
immunofluorescence. La proportion de cellules infectées est assez faible, et ceci est 
probablement du à l’accessibilité réduite du virus à l’intérieur du bourgeon. Néanmoins, 
l’expression de PP est absente dans les cellules infectées, ce qui démontre une bonne 
efficacité de ces lentivirus. De plus, nous n’avons observé aucune cellule qui exprime 
l’insuline parmi les cellules exprimant les PP-siRNA, contrairement aux bourgeons 
infectés avec le virus contrôle. Ces résultats suggèrent que les cellules exprimant le 
polypeptide pancréatique jouent un rôle dans la formation des cellules insuline.  
Ceci est en accord avec des études effectuées précédemment dans notre laboratoire qui 
suggéraient que les cellules exprimant PP étaient les précurseurs du lignage des cellules 
insuline. Ces études in vitro sont encourageantes, malgré le faible taux d’infection des 
explants en culture.  
 16
C’est pourquoi nous avons décidé d’utiliser les même lentivirus afin de générer des souris 
transgéniques exprimant les PP-siRNA. Ces lentivirus ont donc été injectés dans des 
embryons au stade une cellule et les blastocystes infectés, transférés dans des mères 
porteuses, ont donné lieu à des souris transgéniques qui ont été analysées à E17.5 ou un 
jour après la naissance. Cependant aucune des souris transgéniques génotypées positives 
pour le marqueur EGFP, contenant donc le transgène, n’exprime la EGFP ni par 
conséquent le PP-siRNA dans le pancréas. L’utilisation d’un promoteur pancréas 
spécifique pour diriger l’expression des siRNA devrait permettre d’améliorer le système 
et d’obtenir des résultats plus probants. 
 
3.2. Modèle d’invalidation génique de PP et de PYY 
Afin de mieux comprendre le rôle du polypeptide pancréatique in vivo, nous avons généré 
des souris invalidées pour le gène PP, nous permettant d’étudier le phénotype 
pancréatique et les conséquences sur l’homéostasie du pancréas dues à l’absence de PP.  
Les gènes PP et Pyy sont localisés sur le même chromosome, à une très courte distance 
l’un de l’autre dans le génome de la souris (ainsi que dans celui de l’homme). Afin 
d’éviter toute redondance de fonction pouvant dériver de l’inactivation du seul gène PP, 
nous avons décidé de supprimer les deux gènes par recombinaison homologue dans les 
cellules ES. Tout d’abord nous avons construit un « vecteur cible », qui permet la 
substitution de la région génomique d’intérêt (comprenant PP et Pyy) avec une cassette 
composée de la Cre recombinase, suivie par un marqueur EGFP. Dans ce vecteur, cette 
cassette est entourée par deux régions homologues à celles qui se trouvent avant la région 
codante pour Pyy et après celle pour PP. Ces régions ont été sélectionnées à partir d’une 
librairie de clones BAC, contenants des séquences génomiques identiques (et du même 
fond génétique) à celles endogènes se trouvant dans les cellules ES qui doivent subir la 
recombinaison. Une fois le vecteur généré, et après son électroporation dans les cellules 
ES suivie d’une sélection rigoureuse des clones positifs, la région où se trouvaient les 
gènes Pyy et PP sera substituée par cette cassette.  
De part cette stratégie, la Cre va s’exprimer sous le contrôle du promoteur Pyy, ce qui 
permettra l’étude du lignage des cellules PYY. Parallèlement, les deux gènes Pyy et PP 
vont être éliminés du génome des souris doublement invalidées.  
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Au même moment, un autre groupe de chercheurs a généré des souris invalidées pour Pyy 
dans lesquelles l’expression de PP est complètement absente. Ces chercheurs se sont 
intéressés au rôle de PYY dans la régulation de la balance énergétique ainsi que dans la 
différenciation endocrine du système gastro-intestinal. Le rôle de PP et PYY pendant le 
développement et dans l’homéostasie du pancréas n’a pas été adressé. Nous avons obtenu 
ces même souris et allons les analyser à différents stades embryonnaires afin d’élucider 
cette question. 
 
3.3. Lignage cellulaire des cellules PP par recombinaison de BAC 
Afin de pouvoir suivre le sort des cellules exprimant le polypeptide pancréatique au cours 
du développement embryonnaire, nous avons généré des souris transgéniques qui 
expriment la Cre recombinase ou sa forme inductible (CreERT), suivie par le marqueur 
EGFP, sous le contrôle du promoteur PP. Pour cela, nous avons modifié la région 
codante de PP contenue dans un BAC par recombinaison homologue dans des bactéries 
spécifiques, et ces BAC recombinés ont ensuite été utilisés comme transgène.  
Actuellement nous analysons divers fondateurs pour les deux BAC recombinés et ceci va 
nous permettre de suivre les cellules qui ont exprimé PP à un moment donné pendant le 
développement du pancréas ou au cours de la régénération, chez des souris adultes (en 
utilisant la forme inductible PP-CreERT).  
 
4. Conclusions 
Au cours de cette thèse, plusieurs souris transgéniques ont été générées et leur étude nous 
a permis d’approfondir nos connaissances des mécanismes qui régulent le développement, 
la croissance et l’homéostasie du pancréas murin.  
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I. General Introduction 
 
I.1. Wnt signaling pathway 
 
Signaling pathways are critical for the regulation of cell-to-cell communication both 
during embryogenesis and in adults, where their role is to maintain tissue homeostasis 
and achieve regeneration. Deregulated activity from a signal transduction pathway can be 
responsible for developmental defects or, later in life, disease onset.  
The wingless (Wnt) signaling, first discovered in Drosophila [1], is conserved in various 
species from worms to mammals and plays a crucial role in cellular processes such as 
proliferation, differentiation and migration. It has been shown to be critical in embryonic 
patterning as well as in cancer [2-4].  
Wnt signaling is initiated via secreted molecules of the Wnt family, which bind to a 
surface receptor and activate an intracellular cascade that ends in the nucleus, where it 
leads to changes in gene expression. Therefore Wnt act as a paracrine signaling system.  
 
I.1.1. Wnts 
Wnt proteins have been defined historically by their amino-acid sequence rather than by 
functional properties [5, 6]. They all contain a signal sequence followed by a highly 
conserved distribution of cysteine residues and several N-linked glycosylation sites. 
Following their synthesis, Wnt proteins are dynamically modified (lipid modification 
such as palmitoylation for example) before being secreted, and these modifications are 
essential for Wnt function. The protein Porcupine is required for secretion of Wnt from 
cells and it is though to act as the enzyme responsible for palmitate addition before 
secretion. Wnt secreted molecules are therefore hydrophobic and have been found mostly 
associated with cell membranes and extracellular matrix [7]. The function of Wnt 
molecules has been investigated since 20 years and actual knowledge has come from 
genetic studies in Drosophila, mouse, zebrafish and C.elegans as well as from 
biochemical and cellular studies using Xenopus, sea urchin, chicken embryos and 
mammalian cultured cells [8, 9]. Mammals have 19 Wnt genes that, through phylogenic 
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analysis, can be placed into 12 subfamilies [10, 11]. These subfamilies are not a result of 
a recent evolutionary diversification but appeared early in the evolution of metazoans 
[12]. Wnt genes are expressed in spatially restricted and dynamic patterns in embryos and 
in adults and mutations in Wnts have been associated with diseases that cover a wide 
spectrum from arthritis to schizophrenia [13]. 
Wnts may also play an important role in stem cell expansion and maintenance [14]. 
 
I.1.2. Frizzled  
Wnt proteins bind to receptors of the Frizzled family on the cell surface [15]. As its name 
implies, the first fz gene described was not discovered for its role in Wnt signaling, but 
rather for its function in organizing the bristles and hairs of the adult Drosophila cuticle 
[16]. In fly mutants for fz, the uniform direction of bristles and hairs of the wings and 
thorax is perturbed, disrupting the planar cell polarity pathway [17]. All Frizzled are 
seven-pass transmembrane proteins and contain a large extracellular domain with a 
conserved motif of several cysteine residues called CRD [18]. This domain from various 
Frizzled has been shown to bind multiple Wnts with high affinity [19]. In the mouse and 
human genome 10 Frizzled genes are known until now, but the basis of specificity 
between Wnt ligands and their receptors remains totally unknown.  
 
I.1.3. Intracellular signaling pathway 
Wnt regulates at least three distinct pathways: the canonical β-catenin, planar cell polarity 
and Ca2+ pathway [20-22] (Fig. 1).  
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Figure 1. Three different pathways (β-catenin, planar cell polarity and calcium signaling) are stimulated 
by the binding of Wnt to its receptors. Reproduced from [23].  
 
Among these, the most extensively studied has been the canonical β-catenin pathway 
because it influences cell proliferation, survival and differentiation. It has been shown 
that abnormalities of this pathway lead to several human diseases including tumor 
formation [13, 24, 25]. Signaling initiated by Wnt ligand is mediated by Frizzled receptor 
and Lrp5/6 (lipoprotein receptor-related protein 5/6) co-receptor, a single pass 
transmembrane protein belonging to the LDL family [26, 27]. The central player is the 
cytoplasmic β-catenin (called armadillo in Drosophila), which escapes degradation as a 
consequence of Wnt signaling activation (Fig. 2). In cells not exposed to the signal, β-
catenin levels are kept low through interaction with the so-called destruction complex 
composed of two scaffolding proteins Axin and APC (Adenomatous Polyposis Coli) and 
two kinases GSK3-β (glycogen synthase kinase 3β) and CK1α (casein kinase 1α) [28]. 
This complex promotes the sequential phosphorylation of conserved residues in the 
amino terminus of β-catenin, which triggers its ubiquitylation and proteosomal 
degradation [29]. In the nucleus, TCF (T-cell factor)/LEF (Lymphoid enhancer-binding 
protein) transcription factors interact with associated co-repressors and, as a consequence, 
putative target genes of the Wnt pathway are kept inactive.  
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Extracellular Wnt ligands can interact with specific antagonists, including sFRP (secreted 
frizzled-related protein) and DKK (Dickkopf), which prevent activation of the pathway. 
sFRP are secreted forms of frizzled that contain the CRD but no transmembrane segments 
[30]; they bind directly to Wnt molecules inhibiting their activity. DKK is also a secreted 
protein rich in cysteines but interacts with LRP co-receptor to block Wnt signaling [31].  
If the local concentration of Wnt ligands exceeds the capacity of inhibitors, then the 
pathway is activated and β-catenin phosphorylation and degradation are blocked. This is 
mediated at least in part by Dishevelled, a protein activated upon Wnt binding. As a 
consequence, β-catenin levels rises and the protein accumulates in the nucleus, where it 
interacts with TCF/LEF and activates transcription of target genes [32]. 
 
 
 
 Figure 2. Wnt/β-catenin pathway. In the absence of Wnt ligands (a), β-catenin is phosphorylated and 
degraded by the destruction complex (APC, Axin and GSK3-β). As a consequence Wnt target genes are not 
transcribed. If Wnt signaling is active (b), β-catenin is no longer degraded and can accumulate. β-catenin 
goes into the nucleus where it interacts with TCF and activates transcription of target genes Reproduced 
from [13]. 
 
Having given an overview of this complex pathway, in the next part I will recall in more 
detail the crucial components of the pathway. 
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I.1.4. Dishevelled 
Dishevelled is a very complicated protein since it binds many proteins and it is involved 
both in canonical and non-canonical Wnt pathways [33, 34]. Following Wnt binding to 
Frizzled receptors, the phosphoprotein Dishevelled (DVL or DSH) is activated by CK1-
dependent phosphorylation, which enhances its binding to another protein called Frat-1 
(frequently rearranged in advanced T cell lymphomas). Frat-1 binds to and inhibits 
GSK3β, forming a bridge between Dsh and GSK after Wnt signaling, and this event 
results in a reduction of β-catenin phosphorylation by GSK3 kinase (Fig. 3) [23]. 
Moreover, activated Dsh probably recruits Axin and the destruction complex at the 
plasma membrane [35]. Axin can then directly bind to the cytoplasmic tail of LRP5/6, 
phosphorylated by CK1 upon Wnt signaling, leading to Axin degradation [36] and 
destabilizing the destruction complex. All these events finally decrease β-catenin 
degradation and trigger its accumulation.  
 
Figure 3. Wnt signaling stabilizes β-catenin. (A) Following Wnt binding to its receptor, Dvl is 
phosphorylated and binds to Frat-1. Frat-1 then binds to GSK3-β and inhibits the phosphorylation and 
degradation of β-catenin. (B) Upon Wnt signaling, the co-receptor LRP6 is phosphorylated and recruits 
Axin at the plasma membrane. This results in Axin degradation and, as a consequence, β-catenin can 
accumulate in the cytoplasm and in the nucleus. Reproduced from [23]. 
 
Dishevelled, as a positive regulator of Wnt signaling, would be expected to promote 
neoplastic transformation but its involvement in human cancers has not been reported, 
probably due to its other function in the activation of Jun kinases [37]. 
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I.1.5. Axin 
Axin is the product of the fused locus in mouse and mutations in this gene result in axial 
duplications in embryos [38]. Two different Axin genes exist upon vertebrates, and both 
act as negative regulators of the pathway.  Axin 1 is constitutively expressed whereas 
Axin 2 (also called conductin) is induced by Wnt signaling, acting in a negative feedback 
loop [39]. The Axin protein is part of the destruction complex that binds to β-catenin in 
absence of Wnt signaling and it is implicated in β-catenin downregulation [40]. In fact, 
this scaffolding protein is at the center of the complex: it binds and brings into proximity 
the other components, playing an essential role in the regulation of the pathway. 
Moreover, the number of Axin molecules in cells appears to be much lower (5000 fold) 
than other proteins in the complex [41], acting therefore as a limiting component of the 
Wnt signaling cascade.  
Mutations of Axin1 have been detected in human hepatocellular carcinomas [42] and 
germ line mutations in Axin2 cause familial tooth agenesis and predispose to colorectal 
cancer [43]. 
 
I.1.6. GSK3β 
GSK3 is a ubiquitously expressed serine/threonine kinase that has been implicated in 
multiple processes including cell fate determination, metabolism, transcriptional and 
translational control, oncogenesis and neurological diseases [44]. There are two 
mammalian isoforms of GSK3, encoded by different genes, GSK3α and β, that are highly 
homologous and share substrate specificity in vitro. Unlike other kinases, GSK3 is 
constitutively active in resting cells and is inactivated by cellular stimulation with growth 
factors or hormones, such as Wnt ligands or insulin. GSK3β binds to and phosphorylates 
several proteins in the Wnt pathway and is essential for the downregulation of β-catenin. 
In absence of any Wnt signal, GSK3β is recruited to the destruction complex by Axin [45, 
46] and then phosphorylates Axin and APC [47, 48], increasing their interaction with β-
catenin. Subsequently the amino-terminal region of β-catenin is phosphorylated, first by 
CK1 at Ser45 [49] and this event primes GSK3β for phosphorylation at conserved Ser 
and Thr residues (S33, S37, Thr41 and S45). The resulting β-catenin phosphorylated 
footprint leads to the recruitment of a β-TRCP-containing E3 ubiquitin ligase, which 
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transfers multiple ubiquitins to β-catenin. The poly-ubiquitinated β-catenin is 
subsequently degraded by the proteosome. 
As a negative regulator of the Wnt signaling, GSK3β would qualify as a potential tumor 
suppressor. However, mutations or deletions in the gene coding for GSK3β were not 
detected in a survey of colorectal tumors [50]. This can be due to the fact that this kinase 
also participates in other pathways independent of Wnt where such mutation would be 
detrimental to cell viability. 
  
I.1.7. APC 
The Adenomatous Polyposis Coli protein is a very large protein mutated in over 80% of 
colon cancers [51]. Mutations in the Apc gene in humans are the initiating event for both 
familial and sporadic colorectal carcinogenesis. First identified by genetic analysis of 
FAP (Familial Adenomatous Polyposis) families, which reveals germline mutations in 
Apc gene [52], this tumor suppressor plays a key role in the regulation of β-catenin 
turnover since cells containing a mutant APC protein have elevated β-catenin levels [53]. 
The majority of Apc mutations are insertions, deletions and nonsense mutations that lead 
to frameshifts and/or premature stop codons in the resulting Apc transcript [54]. This 
leads to the expression of a carboxy-terminal truncated protein missing some or all β-
catenin binding and down regulation sites, in addition to Axin binding sites, making APC 
unable to regulate β-catenin levels in the cell.  
APC protein is composed of different domains that bind to various factors (Fig. 4). The 
amino-terminal end of APC contains repeats involved in oligomerization [55], as well as 
armadillo repeats that binds to Asef (APC stimulated guanidine nucleotide exchange 
factor). This binding enhances Asef interaction with Rac, a member of the Rho family of 
small GTPases, therefore modulating the actin cytoskeleton [56]. 
The central region of the APC protein contains three repeats with the sequence serine-
alanine-methionine-proline (SAMP) that mediate the interaction with Axin [45] as well as 
three 15 amino acids repeats and seven 20 amino acids repeats that bind β-catenin [57, 
58]. This region is called mutation cluster domain (MCR) and is associated with severe 
pathogenesis of thousands of polyps at young age and additional extracolonic 
manifestations such as desmoid tumors or gastric polyps [59, 60], whereas mutations in 
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the first or last third of the Apc gene are associated with an attenuated polyposis with late 
onset and small number of polyps [61, 62]. 
The carboxy-terminal region of the APC protein contains a basic domain that binds 
directly to microtubules, inducing their stabilization [63], as well as a binding site for EBI, 
another microtubule binding protein that is required for the attachment of microtubules to 
chromosomes’ kinetochores. This ensures the proper segregation of chromosomes during 
mitosis [64], which is very important to avoid chromosomal instability and cancer.   
 
Figure 4. Schematic view of the APC protein, showing all its interaction domains. 
 
APC contains also two intrinsic nuclear localization signals (NLS) [65] located in the 
central region of the protein, and two nuclear export signals near the amino terminus. 
Those sites have been shown to be important for the binding of APC to nuclear β-catenin 
in order to stimulate its nuclear export and to facilitate its cytoplasmic degradation [66]. 
Moreover, APC truncated protein localizes in the nucleus of colorectal cancer cells and 
adenocarcinomas, and this correlates with high levels of β-catenin-TCF-mediated 
transcription in those cells [67]. Therefore there is a strong correlation between APC 
subcellular localization and its role as a tumor suppressor protein.  
APC not only shuttles in and out from the nucleus but it can also associates with the 
plasma membrane in a dynamic manner that requires an intact cytoskeleton [68, 69]. APC 
truncated protein fails to associate with the plasma membrane and impair cell adhesion 
may also contribute to the onset of tumorigenesis [70].  
A paralog of APC called APC2 or APCL have been identified in humans and mouse [71, 
72]. APC2 bears significant homology to APC at the amino terminus and in the central 
region, so that it can bind and regulate β-catenin as efficiently as APC. However no 
specific mutations in APC2 in tumors have been reported yet [73]. 
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I.1.8. β-catenin 
The β-catenin protein was initially discovered for its role in cell adhesion [74]. 
Subsequently the homology between β-catenin and armadillo in Drosophila led to the 
discovery of an additional role for β-catenin as a key mediator of the Wnt signaling 
pathway [75]. As a component of adherens junctions, β-catenin promotes cell-cell 
interaction by binding to the intracellular domain of the transmembrane protein E-
cadherin, and links cadherin to the actin cytoskeleton through its binding with the adaptor 
protein α-catenin (Fig. 5). This function is based on a subcellular pool of β-catenin that is 
membrane associated and stable. In fact, β-catenin is mainly found at the plasma 
membrane [76], whereas the soluble cytoplasmic pool is highly unstable in the absence of 
a Wnt signal, due to multiple phosphorylations of the protein in its amino terminus that 
marks β-catenin for degradation. However, in the presence of Wnt signaling, β-catenin is 
no longer phosphorylated, which impedes its degradation and leads to its nuclear 
accumulation. Once in the nucleus, β-catenin can activate transcription of specific genes 
by binding to TCF/LEF factors. The amino terminus of β-catenin is important to regulate 
its stability, whereas the carboxyl terminus of the protein works as a transcriptional 
activator domain [77]. The central region of the protein contains armadillo repeats 
required for the interaction with E-cadherin, Axin, APC as well as TCF/LEF factors. 
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Figure 5. β-catenin is also an essential component of the cell-cell junctions. It is mainly found at the 
plasma membrane where it binds to E-cadherin but also to α-catenin, to connect to the actin cytoskeleton. 
Reproduced from [78]. 
 
Therefore, β-catenin has a dual function both in cell adhesion and transcription and this 
ensures proper tissue architecture and cell fate decisions during normal development, 
whereas misguided interactions can be oncogenic. How does β-catenin choose between 
its different functions [79]? This event is regulated by a molecular switch that involves 
BCL9-2 [80] as well as through conformational changes of the β-catenin protein 
following Wnt signaling [81]. BCL9-2 is a paralog of the human proto-oncogene BCL9, 
mutated in B cell lymphomas, and is homologous to the Drosophila Legless, which 
functions in Wt signaling [82]. Like Legless, BCL9-2 interacts with β-catenin at the 
amino terminus, in a portion overlapping α-catenin binding [83]. In this portion, a 
specific tyrosine residue (Y142) needs to be phosphorylated for efficient interaction 
between β-catenin and BCL9-2. This phoshorylation weakens the binding to its cell 
adhesion partner α-catenin, and BCL9-2, as a nuclear protein, can sequester (phospho-
Y142) β-catenin in the nucleus, promoting its transcriptional function [80]. 
 28
Moreover Wnt signaling induces a conformational change of β-catenin, favoring TCF 
over α–catenin binding [81]. Therefore, participation of β-catenin in adhesion or 
transcriptional complexes is not only a matter of competition between cadherins and 
TCFs for β-catenin binding, but is regulated by distinct molecular forms of β-catenin with 
different binding properties (Fig. 6). 
 
 
 
Figure 6. Structural changes in β-catenin alter its affinity for either adhesion complexes (blue) or 
transcription complexes (green). Wnt signaling or a specific β-catenin phosphorylation on the Y142 residue 
favors its nuclear translocation and binding to TCF over its interaction with α-catenin at the cell 
membrane. Reproduced from [79]. 
 
Mutations in β-catenin linked to cancer development are frequently located in exon 3, 
where they alter specific residues important for GSK3 phosphorylation thus enhancing β-
catenin stability. Those activating mutations have been found in human colon cancer and 
melanomas [84], as well as in a large number of other tumors like gastrointestinal cancer, 
pilomatricomas, hepatocellular carcinomas, ovarian carcinomas, hepatoblastomas, 
medulloblastomas and desmoid tumors [85].  
 
I.1.9. TCF/LEF 
The family of T-cell factor (TCF) and lymphoid enhancer factor (LEF) proteins are part 
of the high mobility group (HMG) box superfamily of transcription factors [86, 87].  
TCFs are highly conserved throughout evolution and they play critical roles during 
embryogenesis [88-90]. They are required for establishing the embryonic body plan, 
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specifying cell fate, regulating cell proliferation and for survival. In humans, four 
different homologs have been identified, LEF1, TCF1, TCF3 and TCF4. They all 
recognize the same DNA sequence but display tissue specific expression patterns.  
TCF/LEF mRNAs undergo alternative splicing and alternative promoter usage which 
give rise to multiple isoforms [91], and they all bind DNA as monomers. The HMG box 
not only mediates DNA sequence recognition but induces a dramatic bending in the DNA 
[92], therefore coordinating the binding of other transcription factors. In fact, TCF/LEF is 
unable to activate transcription alone, since it lacks the transactivating domain. 
Interestingly TCF factors act in a bimodal fashion, as clearly showed for transcription of 
target genes, with TCFs either activating or repressing the expression of the same gene in 
different subset of cells [93, 94].  
In the absence of any Wnt stimulation, TCF/LEF proteins repress transcription of Wnt 
target genes by binding to co-repressors like Groucho and CtBP, whereas upon Wnt 
binding, they act as transcriptional activators in complex with β-catenin. Nuclear β-
catenin makes a heterodimeric complex with the N-terminal region of TCF/LEF, 
providing the transactivation domain whereas TCF/LEF contributes for the DNA-binding 
domain [95]. Therefore, TCFs are the ultimate mediators of Wnt signaling.  
 
I.1.10. Transcriptional regulation: activators and repressors of β-catenin and 
TCF/LEF 
Wnt-mediated gene transcription plays a key role in embryonic development and its 
deregulation can cause cancer and other diseases. Therefore, this step has to be 
temporally and spatially regulated, and this is achieved by a combination of activators 
and repressors which act in the nucleus influencing β-catenin and TCF/LEF interactions 
[23, 96, 97](Fig. 7).  
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Figure 7. Regulation of β-catenin/TCF interactions in the nucleus. In the absence of Wnt signaling, 
multiple repressors bind to either β-catenin or TCF in the nucleus to inhibit transcription of target genes. 
Upon Wnt binding to its receptor, these repressors are displaced by β-catenin and by additional co-factors, 
resulting in the activation of transcription. Reproduced from [23]. 
 
All TCF/LEFs recruit Groucho/TLE (transducin-like enhancer of split) for transcriptional 
repression [98] and those complexes are bound to target genes until Wnt signals direct β-
catenin to competitively displace Groucho/TLE [99]. Groucho mediates repression 
primarily through recruitment of histone deacetylases [100] and SWI/SNF like complexes, 
which act in concert to position nucleosomes on the promoter of target genes in order to 
exclude assembly of the basal transcription machinery [101, 102]. β-catenin and 
Groucho/TLE proteins occupy endogenous gene targets in mutually exclusive patterns. 
Interestingly, at least in colon cancer cells, β-catenin is bound to cMyc target gene even 
though there is plenty of Groucho in the nucleus [103]. 
Another transcriptional repressor of TCF/LEF factors is HBP1, which physically 
interferes with the HMG-box DNA binding domain of TCF4 preventing transcriptional 
activity [104].  
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Some other co-repressors may influence β-catenin/TCF interactions such as CtBP (C-
terminal binding protein) [105]. In mammalian cells, it was shown that CtBP represses 
Wnt targets, although a direct interaction between TCF and CtBP could not be detected in 
vivo. More specifically, CtBP interacts with APC in a complex that displace β-catenin 
from gene targets and this seems necessary for further association between TCF and 
Groucho to repress transcription [103, 106]. One of the CtBP-associated proteins, 
HIC1(hypermethylated in cancer 1), also acts as an antagonist of β-catenin and TCF/LEF 
factors, sequestering them away from target genes and inhibiting active transcription. 
HIC1 gene encodes a zinc-finger transcription factor that acts as a transcriptional 
repressor by sequestering TCF4 and β-catenin to specific nuclear bodies, preventing their 
association with Wnt-responsive genes [107].  
Other factors that interfere with the formation of β-catenin-TCF/LEF complexes are 
duplin (axis duplication inhibitor) [108, 109] and ICAT [110] which, through their direct 
binding to β-catenin, prevent its interaction with TCF. 
Moreover TCF/LEF loci produce antagonizing isoforms that limit Wnt signaling by 
preventing β-catenin access to targets. In fact those TCF mutants behave as dominant 
negatives since they lack β-catenin binding domains. These isoforms are co-expressed 
with their full-length counterparts and switches between the two can influence cell 
growth and differentiation [111]. 
TCF/LEF factors can also be antagonized by covalent modifications. CK1 
phosphorylation on a specific LEF1 residue disrupts binding with β-catenin [112], 
whereas NLK (nemo-like kinase) phosphorylation of Lef1 and TCF4 inhibits their 
binding to DNA [113, 114]. The result of these phosphorylations is to suppress the 
transcriptional activity of β-catenin-TCF/LEF complexes. Sumoylation of TCF/LEF can 
both act as a negative regulator of Wnt signaling by inhibiting LEF1 activity [115], or as 
a positive one, enhancing transcriptional activity in the case of TCF4 sumoylation [116]. 
The same is true for acetylation, which can either repress or activate transcription via β-
catenin and TCF/LEF complexes, depending on the organism studied. In Drosophila, 
CBP acetylation of TCF has been shown to inhibit its binding to β-catenin [117], 
negatively regulating the Wnt pathway. On the contrary, in vertebrates, acetylation by 
p300 and CBP (CREB binding protein) acts as a co-activator for β-catenin transcription 
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[118]. CBP and p300 are bimodal co-activators because they can either link activator 
proteins to the basal transcription machinery or they can use their histone acetylase 
activities to alter chromatin structure [119].  
β-catenin can also supply additional co-factors needed for transcriptional activation such 
as the DNA ATPase/helicase TIP49a/Pontin52 [120], which could bridge β-catenin and 
the basal transcription apparatus since it copurifies with native RNA polymerase II, or 
Brg1 (Brahma related gene1) as part of a chromatin remodeling complex which interacts 
with β-catenin and promotes target gene activation [121]. The C-terminal region of β-
catenin contains a very strong activation domain, which binds to multiple chromatin 
remodeling subunits and mediates for example tri-methylation of histone H3-Lys-4, a 
chromatin modification found in highly active genes and associated with open chromatin 
structures in vivo [103].  
Recently MED12 and Parafibromin, which are part of the MED and PAF1 complex, have 
also been found associated with this region of β-catenin, and provide a possible link with 
the RNA polymerase II. In fact, the two proteins may bind Pol II and play important roles 
in transcriptional initiation and elongation [122-124]. 
In summary, multiple factors act on β-catenin and TFC/LEF in the nucleus to determine 
whether new gene transcription is favored or not, and this further level of complexity thus 
represents an important mechanism for the tight regulation of the Wnt pathway. 
 
I.1.11. β-catenin target genes 
Several individual target genes of β-catenin-TCF/LEF complexes have been identified, 
some of which have important roles in cancer development. Among them, multiple genes 
are involved in cell proliferation like cMyc [125] and cJun [126], as well as cyclinD1 
[127, 128]. Others are involved in tumor invasion and extracellular matrix degradation 
such as the matrix metalloproteinase MMP-7 [129]. A complete list of Wnt-target genes 
can be found in the website of R. Nusse’ laboratory: 
(www.stanford.edu/~rnusse/wntwindow.html). 
Target genes have been demonstrated to be tissue-specific [130, 131] and the vast 
majority of them have been identified in colon cancer cells. Moreover, some are 
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specifically found activated only in human colorectal carcinomas, such as PPARγ [132] 
or gastrin [133]. 
Activation of the Wnt pathway needs to be tightly regulated in time to avoid uncontrolled 
cell growth and to favor normal development. Consistent with this idea, Axin2 is a direct 
target of the pathway, being upregulated at the transcriptional level upon Wnt signaling 
[39]. Axin2 downregulates β-catenin to normal levels after a Wnt signal, acting therefore 
in a negative feedback loop to silence the pathway upon activation. This kind of feedback 
regulation seems to be quite common for the Wnt signaling, as TCF1 is also a direct 
target of β-catenin and TCF4 in epithelial cells. The most abundant TCF1 isoforms lack a 
β-catenin interaction domain, acting therefore as a dominant negative able to down 
regulate transcription [134]. 
Moreover, the β-TrCP ubiquitin ligase receptor, which mediates the degradation of β-
catenin, is also induced by Wnt signaling through a post-transcriptional mechanism [135], 
providing another level for controlling the duration and intensity of the Wnt pathway 
activation. 
 
I.1.12. Wnt signaling during mammalian development: axis formation and patterning  
All vertebrates share a homologous body plan established by the formation of the 
anterior-posterior axis. The embryo arises from the epiblast, a sheet of pluripotent cells 
which, upon gastrulation, is converted into the three primary germ layers: the ectoderm, 
the mesoderm and the endoderm. The skin and the nervous system arise from the 
ectoderm, the mesoderm generates the skeletal system and internal organs, whereas the 
endoderm gives rise to the gut and associated organs. In the mouse embryo, the anterior-
posterior axis appears upon gastrulation, with the formation of the primitive streak at the 
posterior end at E6.5 [136] (Fig. 8). The mesoderm and endoderm progenitors arise from 
the primitive streak and migrate anteriorly, distributing all along the axis in an anterior to 
posterior fashion. At the same time, patterning events lead to the emergence of more 
differentiated and specialized regions along this axis, such as the head, the trunk and the 
tail.  
The specification of the anterior-posterior axis in mouse embryo occurs one day prior the 
emergence of the primitive streak with the formation of the anterior visceral endoderm 
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(AVE). Cells from the AVE are extraembryonic and do not contribute to the embryo, but 
the AVE secrete signals that control the patterning of adjacent embryonic tissues. It has 
been shown that these signals, together with the ones coming from the primitive streak, 
are sufficient to induce anterior neural development [137].  
Mesodermal cells are the first induced in the primitive streak when gastrulation begins, 
and migrate by E7.5 in anterior location when they will form the heart. Heart precursors 
migrate in association with the definitive endoderm, and signals from anterior definitive 
endoderm participate in heart induction [138]. Finally, the anterior definitive endoderm 
will give rise to the foregut, whereas the anterior neural plate will form the forebrain. 
 
 
Figure 8. Establishment of the anterior-posterior (AP) axis and gastrulation in the mouse embryo. DVE: 
distal visceral endoderm; AVE: anterior visceral endoderm; PS: primitive streak; ADE: anterior definitive 
endoderm. The dashed line overlying the 5.5dpc embryo indicates the junction between extraembryonic and 
embryonic ectoderm (epiblast) cells, which give rise to all cells of the embryo. Gastrulation begins at E6.5 
with the formation of the primitive streak at the posterior end of the embryo. The curved line indicates the 
proximal–distal length of the primitive streak, which increases as gastrulation proceeds. Reproduced from 
[136]. 
 
In this context, Wnt signaling has been crucial in the evolution of axial differentiation in 
multicellular animals [9] [139]. β-catenin and members of the Wnt signaling pathway are 
essential for the establishment of body axis in Hydra [140], as well as in Xenopus and 
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Zebrafish [141, 142]. Moreover, overexpression of β-catenin induces the formation of an 
additional embryonic axis in Xenopus [143] and the same phenotype is observed in 
mouse embryos lacking Axin, due to ectopic activation of β-catenin [38]. Therefore, β-
catenin is required for anterior-posterior axis formation in mouse and lack of β-catenin 
during early embryogenesis results in the absence of mesoderm and head structures [144]. 
A similar phenotype, with inhibition of primitive streak formation, and consequently 
block of the mesoderm and definitive endoderm formation, is found in wnt3 mutants 
[145] as well as in Lrp5/6 mutants [146]. All these patterning defects occur very early 
during embryogenesis, and reveal that Wnt signaling activation is required during 
gastrulation for the specification of the anterior-posterior axis.  
However, at later stages, inhibition of Wnt signaling rather than stimulation is necessary 
for subsequent induction of the forebrain [136]. The anterior visceral endoderm as well as 
the axial mesendoderm, both derived from the primitive streak, expresses Dkk1, the Wnt 
antagonist, which have been shown to be required for mammalian head induction [147, 
148]. Accordingly, mouse embryos carrying hypomorphic mutations of Apc, which 
activates β-catenin, display forebrain truncation [149].  
Moreover, inhibition of Wnt signaling is also required for heart formation [150, 151]. 
Low levels of Wnt activity are therefore necessary in anterior regions for specification of 
anterior fates, whereas high levels of Wnt signaling in posterior domains induces 
posterior fates: mouse embryos lacking Wnt3a expression lack caudal somites and fail to 
form a tailbud [152]. 
In conclusion, a gradient of Wnt signaling leads to the specification of the anterior-
posterior axis and to the establishment of a correct patterning of the embryo. Of course 
this is achieved in collaboration with other signaling molecules (belonging to FGF, BMP 
or Hedgehog families), which contribute to specify the correct location of various organs 
along the embryonic axis. 
 
I.1.13. Wnt signaling in stem cell maintenance and cancer 
Stem cells are pluripotent cells found in many tissues that can adopt different fates 
according to their environment. When exposed to growth factors they generate 
progenitors that proliferate transiently and then exit the cell cycle to differentiate [153]. 
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Due to its role in regulating proliferation and differentiation processes during 
development, the activation of the Wnt signaling pathway has been implicated in the 
expansion of progenitor cells in different organs as well as in cell fate specification of 
these progenitors [9, 24, 85].  
Probably the most well-known example is the intestinal epithelium, normally composed 
of alternating crypts and villi. The proliferating stem cell population is located in the 
crypts, from which cells migrate slowly towards the villus, differentiating into various 
cell types. Activation of Wnt signaling in the intestine by mutations in the tumor 
suppressor APC leads to an increased size in the crypt stem cell compartment [154, 155]. 
On the contrary, inhibition of Wnt receptor complex by overexpression of Dkk1 induces 
the complete loss of crypts [156] and mutations in the Tcf4 gene lead to loss of stem cells 
in the crypt [157], showing that Wnt signaling regulates the proliferation of intestinal 
progenitors in the crypts [158]. Wnt signaling in the intestine has also an important role 
in specifying cell fate since APC loss perturbs differentiation of enterocytes, goblet cells 
and enteroendocrine cells. Along the axis of the villus, APC loss also promotes 
commitment to Paneth cells, normally residing at the bottom of the crypts [154]. 
Activation of the Wnt pathway has been shown to be important for the maintenance and 
self renewal of other multipotent stem cells such as haematopoietic stem cells. When a 
purified population of bone marrow haematopoietic stem cells was treated with Wnt 
ligands they were able to proliferate and remained in undifferentiated state [14]. The 
same occurs when those cells were infected with a virus overexpressing β-catenin [159], 
whereas they lose their proliferative capacity upon inhibition of the Wnt pathway. 
Interestingly, haematopoietic stem cells that overexpress β-catenin are able to reconstitute 
blood cells in vivo, when injected into lethally irradiated mice, highlighting the essential 
role of β-catenin activation in stem cell renewal. Wnt signaling not only maintains cells 
in a stem-cell like status by enhancing their proliferation potential, but it also regulates 
their differentiation. In haematopoietic progenitors, which can develop into red blood 
cells, monocytes, macrophages, granulocytes and thrombocytes, this broad differentiation 
program was shown to be dependent on Wnt11 expression [160]. Loss of Wnt11 induces 
differentiation of haematopoietic progenitors into the macrophage lineage, whereas 
overexpression of Wnt increases the number of red blood cells.  
 37
Another example of active Wnt signaling influencing cell differentiation is found in 
adipocytes, where Wnt10b expression maintains preadipocytes in an undifferentiated 
state through repression of adipogenic transcription factors [161].  
The canonical Wnt pathway is also involved in the control of stem cell specification in 
the skin, by regulating the development of epidermal cells and hair follicle stem cells 
[162]. Skin stem cells reside in the bulges of hair follicles and are bipotent, since they can 
give rise either to keratinocytes of the hair follicle or to the epidermis. These stem cells 
are the reservoir that allows self-renewal of epidermis and regeneration of hair follicles. 
When β-catenin is mutated specifically in the skin, differentiation of follicular 
keratinocytes is blocked, revealing an essential role of the Wnt signaling in fate decision 
of skin stem cell. 
Wnt signaling activation is also required in mammalian neuronal development, as 
overexpression of β-catenin increases cycling and expansion of neural progenitors 
whereas its loss induces a reduction of the progenitor compartment [163, 164]. Moreover, 
β-catenin is required for specification of melanocytes and sensory neuronal lineages in 
the neural crest [165]. 
 
In all the tissues where Wnt signaling participates in stem cell renewal, its aberrant 
activation results in tumor development. In fact, progenitor cells must adopt a stem-cell-
like ability to renew before their oncogenic transformation, and constitutive Wnt 
signaling is responsible for this. A well known example is the colon cancer where, upon 
APC loss, β-catenin-TCF4 complex was shown to activate the same genetic program in 
colorectal cancer cells than in crypt stem cells [166]. APC mutated adenoma cells 
therefore would represent the transformed counterpart of proliferative crypts progenitors. 
Once the Wnt signaling is constitutively activated due to mutations, adenoma cells will 
maintain their status of progenitor cells indefinitely, causing the persistence of adenomas. 
Activation of Wnt signaling, which normally influences growth and differentiation of 
haematopoietic stem cells, has also been implicated in leukaemias. In patients with 
chronic myeloid leukemia, granulocyte-macrophage progenitor cells display nuclear β-
catenin accumulation, and inhibition of β-catenin by overexpressing Axin decreases their 
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proliferative capacity in vitro, suggesting that leukaemia precursor cells are dependent on 
Wnt signaling for growth and renewal [167]. 
Activation of the Wnt pathway is involved in skin stem cell specification and mutations 
that stabilize β-catenin, or in which APC is lost, have been found in melanomas [168]. 
Moreover, β-catenin activation is directly involved in the majority of human hair matrix 
cell tumors called pilomatricomas [169], and transgenic mice overexpressing β-catenin in 
the epidermis undergo a process resembling de novo hair morphogenesis and finally 
develop pilomatricomas [170]. 
Another example in which normal activation of Wnt signaling promotes stem cell 
renewal whereas its aberrant activation is tumorigenic is the nervous system. 
Medulloblastoma, a brain tumor of the cerebellum found in children, harbors β-catenin 
[171] and Axin mutations [172, 173], suggesting that this tumor may arise from a 
progenitor that becomes transformed upon uncontrolled Wnt stimulation. 
Finally, overexpression of Wnt1 has been shown to be responsible for mammary tumors, 
at least in mice [174]. Therefore, it has been proposed that Wnt activation plays a role in 
inducing proliferation of mammary progenitors, which correlates with breast tumor 
development [175, 176]. 
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I.2. Pancreas development 
 
The pancreas arises from a distinct endodermic region located between the stomach and 
the duodenum [177, 178]. During embryogenesis, endoderm committed to a pancreatic 
fate evaginates early (by embryonic day E8.5 in the mouse, corresponding to the 21-29 
somite stage) to form two different primordia, the dorsal bud and the ventral bud. As 
development proceeds, the pancreatic epithelium invades the surrounding mesenchyme 
and, upon epithelial-mesenchymal interactions, proliferates and branches. When the gut 
rotates, the two buds fuse to form a mature bipolar organ. The mature pancreas is a 
compound gland composed of endocrine and exocrine tissue. Endocrine cells secrete 
different hormones in the bloodstream in order to regulate glucose homeostasis and are 
clustered to form islets of Langerhans, which represent 1-2% of total pancreas. An islet is 
composed of α-cells producing glucagon, β-cells producing insulin, δ-cells producing 
somatostatin and PP-cells producing pancreatic polypeptide. Endocrine islets are 
embedded in the exocrine tissue, which is organized into acini secreting digestive 
enzymes such as amylase, and ducts producing a bicarbonate fluid to flush acinar 
secretions into the intestine. Most digestive enzymes are secreted as inactive precursors 
and become activated when they enter the duodenum. Pancreatic secretion is regulated by 
hormonal stimulation, principally by secretin, cholecystokinin and gastrin, and by neural 
stimuli. Therefore, the pancreas plays a central role in the regulation of energy balance 
and nutrition, supplying both digestive enzymes and hormonal signals that regulate the 
absorption, use and storage of digested nutrients.  
The pancreas is particularly important from the perspective of human medicine because 
its disfunction may lead to two groups of diseases: pancreatic cancer and diabetes 
mellitus. Pancreatic cancers are almost incurable due to their resistance to 
chemotherapeutic agents and they are asymptomatic until late stages; for this reason, they 
are one of the most common causes of cancer-related death in the world. The lethal 
nature of pancreatic cancer is due to its propensity to rapidly disseminate through the 
lymphatic system to distant organs. Therefore, the knowledge on the molecular 
pathogenesis of this type of cancer is crucial for designing new drugs for targeted therapy 
[179]. 
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Diabetes is one of the most common endocrine disorders, which is due to the inability of 
controlling glycemia. There are two main types of diabetes, type1 or insulin-dependent 
and type 2, non-insulin dependent diabetes. In type 1 diabetes, insulin producing cells are 
destroyed by an autoimmune reaction that leads to severe and permanent insulin 
deficiency. This type of diabetes appears in childhood, whereas type 2 sets up often after 
puberty and is characterized by insulin resistance as well as by impaired insulin release 
from β cells. Understanding what are the molecular mechanisms governing the formation 
of β cells during normal development is a crucial step towards a potential cell 
replacement therapy. 
 
I.2.1. Pancreas formation during embryogenesis: extrinsic signals 
All pancreatic cell types are derived from a common progenitor of endodermal origin (for 
a recent review, see [180]). During gastrulation, the definitive endoderm is recruited from 
the epiblast and forms the epithelium of the primitive gut tube [181, 182]. The early 
patterning of the foregut endoderm has been shown to be dependent on FGF signaling, as 
it is required to establish and maintain gut tube domains along the anterior-posterior axis. 
In particular Fgf4 is expressed in the ectoderm and mesoderm adjacent to the developing 
endoderm, and acts to promote a posterior gut cell fate [183]. The pancreas arises from 
cells that receive intermediate doses of Fgf4 and manipulation of Fgf4 levels in early 
embryos can expand or contract the pre-pancreatic domain [184].  
The first extrinsic signals that have been implicated in pancreas specification are TGFβ 
and retinoic acid. TGFβ signaling has been shown to be required for endoderm 
specification first in Xenopus [185] and later in mouse [186]. Moreover, transient 
exposure to activin and retinoic acid can induce pancreas development in frog embryos 
[187] and zebrafish deficient for retinoic acid have no liver and no pancreas due to the 
anteriorization of the endoderm [188]. 
The pre-pancreatic endoderm is marked by Pdx1 expression before it has visibly 
thickened [189]. It then emerges as two buds developing on the dorsal and ventral side of 
the duodenum [190]. The ventral bud arises immediately adjacent to the hepatic 
diverticulum whereas the dorsal bud arises on the opposite side of the gut (Fig. 9).  
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Figure 9. Pancreas development in mouse. a)Schematic representation of the pancreas during 
embryogenesis. b) Pdx1 immunostaining, showing that Pdx1 expression marks the developing pancreas. 
Reproduced from [191]. 
 
The dorsal and the ventral programs of the pancreas are similar but not identical and 
slightly asynchronous, probably because they come from independent endodermal 
domains that receive distinct signals from surrounding tissues  [192-194](Fig. 10).  
The dorsal pancreatic bud is in close proximity with the notochord whereas the ventral 
bud is connected to the liver and the bile duct epithelium. The notochord has been shown 
to be required specifically for dorsal pre-pancreatic endoderm to develop and not for the 
ventral counterpart [195]. This is due to the notochord inhibition of Sonic Hedgehog 
(Shh) in the dorsal endoderm, which allows pancreas development [196]. Purified activin 
βB and FGF2 can mimic notochord function. The ventral endoderm is devoid of 
Hedgehog and is therefore biased towards a pancreatic fate [197]. Later during 
development (around E9-9.5) the notochord is displaced by the dorsal aorta, which also 
comes in close proximity to signal to the dorsal endoderm [198]. Shortly after, the dorsal 
aorta is separated from the endoderm by intervening splanchnic mesoderm, which then 
also signals to the endoderm [199]. The splanchnic mesenchyme and vitelline veins are 
the only tissues to signal to the ventral pre-pancreatic endoderm, and they are able to 
induce Pdx1 expression. Those in vivo signals are most likely part of BMP/activin and/or 
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retinoic acid pathways, which have been shown to induce Pdx1 expression in in vitro 
cultures [200].  
 
 
Figure 10. Interactions between the foregut endoderm and mesoderm derived tissues are responsible for 
pancreas development. a) At E8, the notochord is in direct contact with the midline endoderm 
corresponding to the dorsal pre-pancreatic endoderm, and this contact favors the expression of Pdx1 (in 
yellow). The endoderm located lateral to the midline expresses Shh (in blue) but not Pdx1. b) At E8.5-E9 
the formation of the dorsal and ventral pancreatic buds occurs. c) At E9.5, the dorsal and ventral buds are 
separated but the duodenal epithelium expressing Shh. Reproduced from [193]. 
 
The ventral pancreatic development is related to that of liver [197], which receives 
instructive signals from the cardiac mesoderm that trigger its specification [201]. Those 
signals, like FGF2, need to be absent for the ventral pancreas to develop, therefore the 
ventral fate can be considered as a default state. Even in the adult mouse pancreas, there 
is a certain degree of plasticity between liver and pancreas [202, 203]. This flexibility 
exists also between pancreas and stomach [204] as well as between duodenal and 
pancreatic cell fate [205, 206]. 
Several transcription factors have been identified to be important in either dorsal or 
ventral pancreatic development [207]. Hlxb9 is a homeobox gene which is expressed, like 
Pdx1, in the pre-pancreatic endoderm before bud formation. It is required for dorsal 
pancreas specification, as mice knockout for Hlxb9 lack dorsal pancreas whereas the 
ventral bud develops normally [208, 209]. However, Hlxb9 is also expressed in the 
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notochord, where it plays an essential role in dorsal endoderm development; therefore the 
knockout phenotype may be due to defects in this latter tissue rather than in the pancreas 
per se.  
The idea of distinct dorsal and ventral programs is also supported by the phenotype of 
different mutant mice. This is the case of transgenic mice bearing an SV40/α-amylase-Cre 
transgene, in which the whole endoderm comprising the dorsal pancreatic bud, but not the 
liver nor the ventral pancreas, is tagged by the activity of Cre [210]. In addition, mice 
lacking specific endoderm transcription factors, such as Pdx1 and HNF1β for example, 
have a dorsal bud formed (even if it poorly develops thereafter) whereas the ventral bud 
is undetectable [189, 211]. This is also the case in Ptf1a mutants, where a fragment of the 
dorsal bud forms whereas the ventral bud contributes to the intestine [206]. 
Several other factors expressed outside the pancreatic endoderm are differentially 
required for dorsal and ventral pancreatic development. Isl1 is a LIM box homeodomain 
protein which is expressed in the peripancreatic mesenchyme and disruption of Isl1 in 
mice results in early arrest of embryonic development at E9.5 along with dorsal pancreas 
agenesis [212]. The mesenchymal expression of Isl1 is lost in retinoic acid deficient mice, 
probably accounting for the lack of dorsal pancreas in these mutants [213].  
Another gene differentially required for dorsal bud development, which also acts outside 
the endoderm, is the cell adhesion molecule N-cadherin, whose absence results in dorsal 
pancreas agenesis due to its function as a survival factor for dorsal pancreatic 
mesenchyme [214].  
Precise spatial relationships between mesoderm and endoderm are essential for proper 
pancreas development as revealed by studies on Bapx1 mutants, which lack the 
homeodomain transcription factor bagpipe homeobox 1 [215], and mutants for the 
hematopoietically-expressed homeobox Hex gene [216]. These two genes act outside the 
pancreas to mediate morphogenetic movements that are important to separate dorsal 
(Bapx1) and ventral (Hex) pancreas from inhibitory signals. 
These differences during development lead to significant differences in the mature dorsal 
and ventral pancreas. In rat and humans [217] as well as in mice (unpublished 
observations), PP cells reside selectively in the ventral pancreas whereas the dorsal part 
has a significantly higher proportion of glucagon expressing cells. 
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I.2.2. Pancreatic commitment and intrinsic signals: Pdx1 and Ptf1a 
The presumptive territory where pancreas will form expresses the transcription factor 
Pdx1 from embryonic day E8.5 in the mouse, and at E9.5 it marks the dorsal and ventral 
pancreatic buds as well as the duodenal endoderm. The transcription factor HNF6 
controls the timing of pancreas specification by regulating Pdx1 expression both in dorsal 
and ventral endoderm [218]. First identified as a regulator of the rat insulin 1 gene [219], 
Pdx1 is not only necessary for pancreatic development [189, 220] but also for cell 
differentiation in the stomach and the duodenum. The role of Pdx1 during the embryonic 
development of the pancreas is conserved in human, as a mutation that impairs the 
transcription of a functionally active Pdx1 protein results in pancreas agenesis [221]. 
Pdx1 serves as a master regulator of pancreatic development, as every pancreatic cell 
types derive from Pdx1-expressing progenitors [222-224]. However, its expression is not 
needed for the initiation of pancreatic budding from the endoderm [225] and its ectopic 
expression in the anterior endoderm is not sufficient to induce pancreatic tissue [226].  
Furthermore, the activity of Pdx1 is modulated by Pbx1, a homeodomain factor which is 
expressed in the pancreatic epithelium and the surrounding mesenchyme [227] and 
interacts with Pdx1 to promote cell growth [228]. Pdx1/Pbx1 complexes are necessary for 
the expansion of the pancreatic buds but not for the specification of the different cell 
types [227]. 
Ptf1a is able to complement Pdx1 in the specification of precursor cells in the pancreas, 
as it was shown that Ptf1a positive cells contribute to all three mature pancreatic cell 
lineages [206]. Ptf1a is a bHLH transcription factor encoding for the pancreas-specific 
p48 protein, which forms heterodimers with the ubiquitous factor E2A creating a 
complex that binds and activates transcriptional enhancers of the acinar hydrolytic 
enzyme genes [229]. Ptf1a is expressed broadly at early stages of pancreas development, 
like Pdx1, and then its expression becomes restricted to acinar precursor cells from E13.5 
[230]. Pdx1 expression is also restricted later during development, from E15.5 onwards it 
is found specifically in differentiated β cells, and the transition of those two transcription 
factors coincides with the overall conversion of progenitors to mature endocrine and 
exocrine cells (secondary transition) (Fig. 11). 
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Figure 11. Pancreas organogenesis in mouse. Schematic view of pancreas development with the different 
transcription factors involved at the various steps. In yellow the Pdx1 territory, in grey early-differentiated 
endocrine cell clusters. Reproduced from [193]. 
 
Recently, the molecular signature of pancreatic precursor cells has been further 
characterized. Sox9, a transcription factor of the SRY box-containing family, is required 
for maintenance of pancreatic progenitor cells [231]. In the developing pancreas, Sox9 
expression is restricted to a proliferative subset of Pdx1+ progenitors and is absent from 
commited endocrine precursors or differentiated cells. Sox9 has been shown to maintain 
pancreatic progenitors by stimulating their proliferation, survival and persistence in an 
undifferentiated state, through regulation of the Notch effector Hes1. In humans, 
haploinsufficiency of Sox9 is associated with defective endocrine cell differentiation and 
islet hypoplasia [232]. 
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I.2.3. Primary and secondary transitions in mammalian pancreas development 
In the 1970s Rutter et al proposed a model for pancreas differentiation consisting of two 
major transitions [190]: the primary transition refers to the start of budding and expansion 
of progenitors whereas the secondary transition describes the differentiation of exocrine 
and endocrine cells.  
During the primary transition (E8-8.5), cells in the appropriate regions of the gut become 
destined to form pancreas, and the only differentiated cell type present in the presumptive 
pancreas territory at this time are few glucagon-expressing cells. Neither exocrine or β 
cells are present during primary transition, and these early glucagon cells do not express 
Pdx1 [233], but co-express the peptide PYY [234, 235]. Islet precursors arise during the 
secondary transition beginning at E13.5, forming a distinct lineage from those early 
endocrine cells. This was demonstrated by different studies where islet and acinar 
formation were blocked (either forcing expression of Hlxb9 in pancreatic epithelium 
[236], in the absence of Pdx1 [225] or Ptf1a [206]), but not the appearance and 
persistence of these early glucagon-expressing cells. Their fate is not known but their 
progeny may contribute to the glucagon cells found in the mantle of mature islets [233]. 
In early pancreatic buds, cells positive for both glucagon and insulin are also present [233, 
237, 238]. These double positive cells also express PYY and proliferate actively at E15.5, 
suggesting that they may represent precursors of mature islet cells [234]. However, cell 
lineage tracing analysis demonstrated that these cells are different from mature endocrine 
cells and that adult insulin and glucagon producing cells come from distinct and 
independent precursors [239, 240]. The number of double insulin and glucagon 
expressing cells decreases during gestation, and by E14.5 a significant number of cells 
express only one hormone.  
The secondary transition occurs between E13.5 and E15.5 in mouse, and is characterized 
by a dramatic increase in the synthesis of exocrine and β cell proteins [241]. A 
concomitant increase is observed for insulin, amylase, carboxypeptidase A, lipase and 
chymotrypsin. At this time point the structure of the adult pancreas begins to be 
recognizable. After the secondary transition, few progenitor cells are left and expansion 
occurs by growth of fully differentiated cell types. Exocrine cells are strongly 
proliferative after their differentiation, whereas endocrine cells show a higher mitotic 
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activity closer to birth. It has been shown that endocrine cell fate happens temporally, 
with glucagon-expressing cells being the first to develop at E12.5, followed by β cells at 
E13.5, somatostatin producing cells at E15.5 and PP cells after E16-18 [238]. The 
transcripts of these hormones were found, however, at much earlier developmental stages 
[235, 242]. It is generally believed that undifferentiated precursor cells that express Pdx1 
arise from pancreatic ducts and then migrate away to generate both endocrine and acinar 
cells. Once differentiated, the endocrine cells delaminate from the epithelium, migrate 
into the extracellular matrix and aggregate to form well organized clusters called islets of 
Langerhans. Islets of Langerhans have been shown to be of polyclonal origin, i.e not 
deriving from a single precursor [243]. These islets form right before birth (at e18.5), and 
have a very precise organization in mice, with a core of β cells (approximately between 
60 and 80%) surrounded by the other cell types: glucagon producing cells (15-20%), 
somatostatin producing δ cells (5-10%) and pancreatic polypeptide cells (PP cells 
represent less than 2%). Insulin is released from β cells in response to increased levels of 
sugar in the blood after food intake and signals to target tissues (liver, fat, muscle) for the 
glucose uptake. Moreover, insulin inhibits glucose production by the liver. In contrast, 
glucagon secretion is stimulated by low levels of sugar in the blood and promotes 
glycogenolysis and gluconeogenesis. Somatostatin and pancreatic polypeptide exert an 
inhibitory effect on both endocrine and exocrine pancreatic secretion. 
 
I.2.4. Transcription factors specific for exocrine and endocrine cell differentiation 
Unique sets of transcription factors determine the identity and function of a cell. During 
the secondary transition, the different cell types in the developing pancreas (acinar, ductal 
and endocrine cells) begin their differentiation process and express specific transcription 
factors, which are responsible for their cell fate [178, 244, 245] (Fig. 12).  
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Figure 12. Transcription factors implicated in mouse pancreatic development. After the specification of a 
common Pdx1 progenitor, differentiation throughout the different lineages (ductal, acinar or endocrine) is 
characterized by the expression of specific transcription factors in a temporally regulated fashion. 
Reproduced from [246]. 
 
The acinar cells are characterized by the expression of Ptf1a/p48 from E15 through 
adulthood [247]; mice which lack this transcription factor die at birth and have no 
detectable exocrine tissue [230]. The transcriptional repressor Hes1, effector of the Notch 
signaling pathway, is coexpressed with Ptf1a in exocrine precursor cells but not in 
differentiated amylase expressing acinar cells [248]. In fact, high levels of Hes1 have 
been suggested to be necessary for Ptf1a expression [249]. In addition to this, Ptf1 is 
required for efficient expression of the amylase gene, as well as the hepatic nuclear 
factors HNF3β (also called Foxa2) and HNF3γ, which have been shown to bind to 
regulatory DNA sequences in the amylase promoter and contribute to exocrine-specific 
gene expression [250]. Interestingly, transcription of the amylase gene is also stimulated 
by insulin [251], providing a possible mechanism for cross-talk between genes specific 
for the exocrine and endocrine compartments.  
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Another transcription factor which is expressed specifically in acinar cells is Mist1 [252], 
a key regulator of acinar cell function [253]. Mice lacking Mist1 exhibit an extensive 
disorganization of exocrine pancreas with the concomitant activation of intracellular 
enzymes that leads to the deterioration of acinar tissue. Since cells in these focal lesions 
co-express acinar and ductal markers, Mist1 knockout mice represent a good genetic 
model for chronic pancreatitis. However, loss of Mist1 does not abrogate transcription of 
acinar specific genes, thus pointing towards a redundant role for Mist1 and Ptf1a to 
ensure continued activity of exocrine genes. 
At present, very little is known about the transcription factors that are specific for duct 
cell differentiation. HNF1β serves as a specific marker for this domain, as it is expressed 
in the pre-differentiated ductal epithelium but no longer in differentiated acinar or 
endocrine cells [254]. HNF1β plays an essential role very early during development, in 
the specification of visceral endoderm [255, 256]. Moreover, lack of HNF1β specifically 
in the liver leads to loss of intrahepatic bile duct development [257]. Pancreatic ducts are 
essentially composed of HNF1β positive cells from E13.5 up to birth [254] and endocrine 
progenitors, expressing Ngn3, are intercalated within HNF1β positive cells in the ductal 
epithelium. Mutations in HNF1β in humans are responsible for a syndrome called 
maturity-onset diabetes of the young (MODY5) [258], characterized by the progressive 
impairment of insulin secretion and accounting for 5-10% of type 2 diabetes.  
An important regulator of HNF1β is HNF6, as embryos deficient for HNF6 have 
markedly reduced HNF1β in primitive pancreatic ducts [254]. HNF6 also controls 
HNF1β in the bile duct epithelium, as both liver-specific HNF1β and HNF6-deficient 
mice show arrested bile duct differentiation [257, 259]. Moreover, HNF6 regulates 
endocrine cell differentiation and the formation of endocrine progenitors, as shown by the 
HNF6 knockout mouse which develops a pancreas devoid of endocrine cells [260].  
Endocrine cells originate from committed progenitors that express the bHLH 
transcription factor neurogenin 3 (Ngn3) and mice deficient for Ngn3 die soon after birth 
from diabetes, whereas exocrine cells develop normally [261]. Moreover, cell lineage 
tracing analyses have shown that Ngn3 expressing cells do not give rise to exocrine cells, 
whereas they give rise to all endocrine cell types [222, 224]. Ngn3 expression has been 
shown to be both necessary and sufficient for islet formation during pancreas 
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development [249]. Ngn3 is expressed in endocrine precursors of both the pancreas and 
gastrointestinal tract [262].  
However, Ngn3 expressing cells are transient endocrine progenitor cells: few Ngn3 
positive cells can be found in the early pancreas (E12.5), but a major peak of expression 
is observed around E14.5-15.5 which is then completely turned off before terminal 
endocrine differentiation [263]. Premature expression of Ngn3 in the pancreas [249] and 
endoderm [226] results in the production of mostly α cells, and it was suggested that 
these are the default endocrine cells to be formed. Recently, the use of transgenic mice in 
which Ngn3 activity can be temporally forced (Pdx1-Ngn3-ERTM) suggested that the 
differentiation potential of Ngn3+ progenitors is defined by a competence window that 
allows the generation of all islet cell types [264]. 
In a normal developing pancreas, Ngn3 positive cells exit the cell cycle, shut off Ngn3 
expression and differentiate into mature endocrine cells. This occurs because Ngn3 
positive cells activate a battery of transcription factors that are required for the 
development of all endocrine cell types, such as Isl1, NeuroD and Insm1.  
Isl1 is required for dorsal pancreatic bud formation, but Isl1 is also required for endocrine 
formation, as Isl1 knockout mice lack all endocrine cells [212]. Moreover, when wild-
type mesenchyme (derived from wild-type pancreas or lung) was added to explants of 
Isl1-null dorsal pancreatic epithelium, exocrine tissue developed but no endocrine cells 
were generated, demonstrating that Isl1 plays a role in the differentiation of the dorsal 
pancreatic epithelium towards endocrine cells. 
Ngn3 can directly activate the promoter of NeuroD1 (neurogenic differentiation 1), 
another bHLH transcription factor which appears slightly later than Ngn3 during pancreas 
development and persist in mature islets [265]. NeuroD1 heterodimerizes with ubiquitous 
proteins of the E2A family to regulate insulin transcription [266]. NeuroD1 is not 
absolutely critical for endocrine differentiation, as knockout mice generate all islet cell 
types. However, NeuroD1 has been shown to regulate the survival and terminal 
differentiation of β cells, and mutations in NeuroD in humans are associated with the 
onset of diabetes (MODY6 [267]). 
The insulinoma-associated Insm1/IA1 was shown to be another direct target of Ngn3, as 
its expression is suppressed in Ngn3 knockout pancreas. First found in pancreatic 
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endocrine tumors [268], Insm1 is a zinc-finger transcription factor recently identified in 
human ductal cells ectopically expressing Ngn3, and has been shown to be essential for 
endocrine differentiation [269, 270]. Inhibition of Insm1/IA1 expression in the embryonic 
pancreas decreases the formation of endocrine cells, more specifically of β cells, whereas 
its ectopic expression amplifies the effect of Ngn3 on neuroendocrine cell differentiation 
in adult duct cells.  
 
I.2.5. Genes involved in islet subtype specification 
The transcription factor paired box gene 4 (Pax4) is expressed early in both ventral and 
dorsal pancreatic buds and by birth is restricted to β cells. Ngn3 binds to and 
transactivates the Pax4 promoter [271], and mice deficient for Ngn3 do not express Pax4 
mRNA [261] suggesting that Pax4 is also a direct target of Ngn3. Pax4 knockout animals 
fail to produce both β and δ cells whereas α cells are increased, and mice die soon after 
birth [272].   
An opposite phenotype to Pax4 knockout is that of Arx (aristaless related homeobox) 
deficient mice, in which β and δ cell commitment are favored [273]. Arx is also a Ngn3 
target gene which promotes the differentiation of glucagon cells and represses Pax4 
expression. Interestingly, it was recently shown that Arx misexpression in mature β cells 
is sufficient to reprogram them towards the acquisition of α and PP phenotypes [274]. 
Moreover, Arx and Pax4 antagonize each other through direct physical repression, so that 
simultaneous loss of both Arx and Pax4 favors somatostatin/PP cell fates at the expense 
of α and β cell lineages [275]. 
Pax6 is another paired-box homeoprotein important for endocrine development. It is 
expressed early in the epithelium of developing pancreas in both dorsal and ventral buds 
and later in all differentiated islet cells. Mice deficient for Pax6 die at birth and have very 
few α cells in their pancreas [276]. Combined mutations of Pax4 and Pax6 completely 
abrogate endocrine cell development. However, analysis of a mouse strain carrying a 
spontaneous mutation in Pax6 (known as small eye) revealed an abnormal organization of 
islets with decreased in all endocrine cell types and reduced glucagon and insulin 
production [277]. Pax6 was shown to regulate the promoters of glucagon, insulin and 
somatostatin genes, suggesting a mechanism to explain the decreased hormone 
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production in those mice. Moreover, conditional inactivation of Pax6 in the endocrine 
pancreas causes diabetes, showing that Pax6 plays an essential role in the maintenance of 
β cell function after birth [278]. Pax6 is thus needed in all the endocrine cell types but at 
different levels.  
Another Ngn3 target called Nkx2.2 also drives endocrine differentiation [279, 280] as 
Nkx2.2 deficiency results in impaired maturation of endocrine cells at the secondary 
transition. Nkx2.2 is expressed in the precursor epithelium slightly after Pdx1 activation. 
It persists during progenitor cell expansion and is later restricted to α, β and PP cells. In 
the absence of Nkx2.2, β cells fail to activate the insulin gene and display a loss of 
Nkx6.1, suggesting that Nkx2.2 is essential for the specification of mature β cells. Nkx2.2 
has been shown to act in concert with Pax4 to promote β cell differentiation [281]. 
Downstream of Nkx2.2 in the pathway of β cell formation lies Nkx6.1, a transcription 
factor specific for adult β cells, which is expressed shortly after Pdx1 activation in dorsal 
and ventral bud and, like Nkx2.2, is dispensable for embryonic pancreas growth [282]. 
Nkx6.1 is required for β cell formation, as a complete absence of mature β cells but 
normal development of α cells is observed in the pancreas of Nkx6.1 knockout mice. 
Induction of Nkx6.1 expression requires Pdx1 [283].  
Pdx1 is a key regulator of differentiated β cells, in addition to its role previously 
described in early organogenesis. Shortly after Ngn3 positive cells are turned off, Pdx1 is 
induced in insulin-expressing cells and remains highly expressed throughout adult life. 
Mutations of Pdx1 in humans cause MODY4 [284] and, accordingly, conditional 
inactivation of Pdx1 in mouse after the pancreas has develop results in diabetes due to 
impaired β cell function [285, 286]. This is associated with reduced activity of specific 
genes regulated by Pdx1 in islets such as insulin, IAPP, glut2 and Nkx6.1 [285, 287]. 
Therefore Pdx1 is a glucose-responsive regulator of insulin gene expression, but it is also 
regulated in response to glucose by both its phosphorylation and nuclear translocation 
[288]. Moreover, Pdx1 is able to regulate itself at the transcriptional level [289]. Finally, 
Pdx1 may also have a critical role in defining the different islet cell lineages as 
suppression of its function in differentiated β cells is sufficient to reverse the β cell 
phenotype, allowing expression of glucagon [285, 290]. 
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Brn4 is a POU-homeodomain factor that is expressed specifically in the α cell lineage and 
regulates the glucagon promoter [291]. However, pancreas from Brn4 null mice displays 
no defects in endocrine cell formation, showing that Brn4 is not essential for glucagon 
cell fate determination.  
Endocrine cell differentiation has also been shown to be dependent of the Maf family of 
basic leucine zipper transcription factors, which comprise MafA, MafB and c-maf. 
MafA expression is restricted to β cells [292] where it activates the insulin promoter [293, 
294] and regulates glucose-stimulated insulin secretion [295]. MafA knockout mice have 
normal islet morphology at birth, probably due to redundancy with other members of the 
Maf family. However, later in their life MafA deficient mice develop diabetes, due to 
age-dependent loss of β cells [295]. MafA also controls Pdx1 expression and therefore is 
crucial for the generation and maintenance of mature β cells [296]. 
MafB expression in adults is restricted to α cells, whereas during embryogenesis a 
significant portion of MafB-expressing cells also express insulin. It is thought that these 
latter are intermediate cells and that upon differentiation of mature β cells there is a 
switch between MafB and MafA dependent on Pdx1 expression [297]. 
Recently, MafB was shown to be required for β cell maturation, through direct 
transcriptional regulation of key factors such as Pdx1, Nkx6.1 and Glut2 [298]. 
 
I.2.6. Epithelial-mesenchymal interactions establish exocrine and endocrine 
compartments 
Classical embryological experiments of tissue recombination have shown that epithelial-
mesenchymal interactions are very important to ensure a correct pancreatic development 
[299]. A pancreatic explant from E11 mouse embryo cultured in vitro without the 
surrounding mesenchyme displays minimal growth and branching and fails to produce 
acinar cells [300]. In fact endocrine differentiation is enhanced in the absence of 
mesenchyme [301-304], as if either multipotent progenitors choose islet fate by default or 
a pool of endocrine-restricted progenitors was stimulated by mesenchyme removal. 
Recombination of the naked epithelium with pancreatic mesenchyme rescued its growth 
and morphogenesis, and the same occurred when it was recombined with mesenchyme of 
non-pancreatic origin [299], demonstrating that pancreas identity is dependent on 
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intrinsic signals in the pancreatic epithelium. Therefore, epithelial-mesenchymal 
interactions play a fundamental role in specifying the growth and differentiation of the 
pancreatic primordia [191, 207].  
Among the different molecules involved in this process, growth factors like EGFs and 
FGFs are essential for the proliferation of pancreatic progenitors as well as for their 
subsequent differentiation. Members of EGF and FGF families are expressed in the 
developing pancreas and signal by activating tyrosine kinase receptors. Mice lacking a 
functional EGF receptor exhibit attenuated growth as well as delayed differentiation of 
endocrine cells [305], even if the mature pancreas functions normally probably due to 
redundancy with other EGF receptors. Moreover, the in vitro growth of an E13.5 rat 
pancreatic explant depleted of mesenchyme was stimulated by treatment with EGF and 
both exocrine and endocrine differentiation were inhibited [306], showing the importance 
of EGF signaling in regulating growth and morphogenesis in the pancreas epithelium. 
Different FGF ligands are able to stimulate the in vitro growth of embryonic pancreatic 
rudiments [307], whereas signaling via FGF receptor 2b (FGFR2b) induces exocrine 
differentiation [308]. Moreover, mice inactivation of FGF10, which displays a high 
affinity for FGFR2b [309], results in a hypoplastic pancreas due to loss of proliferative 
progenitor cells [310].  This was confirmed by further studies in which E10.5 pancreatic 
buds grown in vitro in the presence of FGF10 showed a 10 fold increase in size and in the 
ratio of undifferentiated progenitors (i.e. cells positive for both Pdx1 and Ptf1a) [311]. 
FGF10 acts by maintaining persistent Notch signaling [311-313], which prevents the 
differentiation of precursor cells.  
FGF signaling also plays a role in the mature pancreas, controlling β cell function and the 
maintenance of normal levels of sugar in the blood. In adult mice, FGFR1 and 2 along 
with their ligands as well as FGF10 are selectively expressed in β cells. Attenuation of 
FGFR1c signaling in mouse β cells leads to diabetes [314, 315], as normal FGFR1c 
signaling is required for the expansion of β cells after birth and for the expression of the 
glucose transporter Glut2 and the proconvertase PC1/3, which processes proinsulin into 
active insulin. 
Another signaling that regulates pancreatic growth and differentiation is the Notch 
pathway, which controls the choice between endocrine differentiation and maintenance of 
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undifferentiated pancreatic progenitors [249]. All the components of the Notch pathway 
are expressed in the pancreas [316, 317]. Notch receptors Notch1 and Notch2 are 
expressed in the pancreatic epithelial precursors between E11 and E12, Notch3 in the 
surrounding mesenchyme and Notch4 in endothelial cells. Notch ligands Jagged1 and 2 
are also expressed in endothelial cells, whereas Delta-like1 (Dll1) is found in the early 
dorsal bud. In addition, the Notch target gene Hes1 (hairy/enhancer-of-split 1) is 
expressed in pancreatic epithelial precursors, where it acts as a dominant repressor and 
inhibits the Ngn3 promoter [318].  
Lateral inhibition is a mechanism of cell fate decision in a variety of organisms and 
tissues [319, 320] and is controlled by the Notch pathway. This mechanism is believed to 
prevent Ngn3 expression in all the cells of the pancreatic epithelium and restrict 
endocrine differentiation only to scattered cells [249]. According to this model, when 
Ngn3 is expressed in an endocrine progenitor cell it inhibits its neighbors from entering 
the endocrine differentiation pathway. Ngn3 expression induces the activation of the 
Notch ligand Delta in this cell, which binds to the Notch1 receptor on the adjacent cell 
and triggers its activation. Therefore, in this neighboring cell Hes1 repression is 
stimulated and Ngn3 is downregulated thereby inhibiting endocrine differentiation. Cells 
in which Ngn3 expression is extinguished by Notch signaling can then become part of the 
exocrine pancreas (Fig. 13).  
 
Figure 13. Lateral inhibition model. Pro-endocrine factors like Ngn3 induce the activation of the Notch 
ligand Delta, which binds to the Nocth1 receptor on the adjacent cell and triggers its activation by 
proteolytic cleavage. In this neighboring cell, Hes1 transcription is stimulated by the binding of the Notch 
intracellular domain with RBP-Jk. As a consequence of Hes-1 activation, Ngn3 is downregulated in this 
cell, inhibiting its endocrine differentiation. Reproduced from [246]. 
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This model has been supported by several experiments in which endocrine development 
is enhanced in pancreas lacking several Notch signaling components. It has been shown 
that defects in Notch signaling lead to an accelerated endocrine differentiation 
accompanied by a depletion in progenitor cells due to upregulation of Ngn3 [204, 249, 
313, 316]. Terminal differentiation of acinar cells is also blocked but not their initial 
commitment to the exocrine lineage. Moreover, forced expression of constitutively active 
Notch1 represses both endocrine and exocrine differentiation [204, 248] and Hes1 has 
been found co-expressed in Ptf1a precursors but absent from both mature exocrine [248] 
and endocrine cells, suggesting that Notch pathway regulates the recruitment of these 
cells from a common precursor pool.  In addition, in the Hes1 knockout mouse ectopic 
expression of Ngn3 is found in the biliary epithelium which differentiates into pancreatic 
tissue [321]. Together these results suggest that activation of Notch signaling is essential 
to prevent premature differentiation of pancreatic progenitors. 
Whereas Notch signals negatively regulate endocrine development, some members of 
TGFβ family have been shown to selectively promote endocrine differentiation. For 
example, embryonic mouse pancreatic explants treated in vitro with the ligand TGFβ1 
develop an increased number of islet cells and fewer acini [322]. TGFβ1 signals through 
SMAD proteins, which are also activated by ligands of the activin family. When early 
pancreatic buds are treated with the activin antagonist follistatin, the acinar differentiation 
is enhanced at the expense of the endocrine counterpart [303]. Moreover, mice either 
expressing a dominant negative form of the type II activin receptor in β cells or lacking 
this receptor display a severe reduction in islet mass, whereas the acinar tissue develops 
normally [323, 324], demonstrating that endogenous activin and TGFβ signaling play an 
important role in endocrine cell development.  
In conclusion, pancreatic endocrine and exocrine differentiation from the endoderm 
epithelium is a complex multistep process determined by the activity of various 
transcription factors, which are responsible for cell fate specification decisions in 
combination with signals coming from the surrounding mesenchyme. 
 57
I.3. PP and PYY 
 
Neuropeptide Y (NPY), peptide YY (PYY) and pancreatic polypeptide (PP) belong to the 
same gene family. This peptide family is an example of a multiple gene duplication event 
that gives rise to structurally related but functionally distinct gene products [325]. The 
analysis of the structure and location of NPY, Pyy and PP genes suggests that these genes 
arose from an initial duplication that generated NPY and Pyy genes, followed by a 
subsequent duplication of Pyy to create the PP gene [326, 327]. 
NPY is one of the most abundant neuropeptides in the mammalian nervous system and 
acts both centrally and peripherally to regulate a wide range of important physiological 
activities including appetite, blood pressure, central endocrine secretion, anxiety and 
reproduction [328, 329].  
PYY is an intestinal hormone, which inhibits gastric acid secretion, gastric emptying, 
pancreatic exocrine secretion and gut motility [330]. PYY is synthesized and released 
from specialized endocrine L cells, primarily found in the distal gastrointestinal tract 
[331]. In the pancreas, PYY-positive cells appear very early during development and 
some co-labeled glucagon/PYY cells can be observed as soon as the primary transition 
occurs [234]. It has been shown, by lineage tracing analyses [239, 240], that these cells 
do not represent precursors of mature islet cells but the role of PYY during pancreas 
development remains unclear. 
PP, secreted by the islets of Langerhans, specifically inhibits the secretion of enzymes 
and bicarbonate from the exocrine pancreas [332]. PP mRNA is expressed very early 
during pancreas development, as soon as E10.5 [235, 242]. However, the protein is not 
detected until E16-E18 in the endocrine compartment [238, 333]. PP expressing cells 
represent a very low proportion of cells, less than 2 % among the different cell types that 
form the islet of Langerhans, and are located at the periphery of adult mouse islets. PP 
cells are more abundant in the ventral region of the pancreas than in the dorsal part, 
whereas glucagon cells have the opposite expression pattern [217]. It has been proposed 
that PP expressing cells could be the precursors of insulin and somatostatin cell lineages, 
whereas glucagon cells arise independently. Using transgenic mice expressing the 
diphtheria toxin A chain under the control of the rat PP promoter, Herrera et al ablated 
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specifically PP expressing cells and strikingly, mutant embryos also lacked insulin and 
somatostatin containing cells [239]. These results suggested that PP expressing cells are 
important for the differentiation of insulin and somatostatin cells during pancreas 
development.  
To further investigate the relationship between insulin and PP-expressing cells, the same 
authors performed cell lineage tracing analyses using the Cre-loxP system to tag specific 
cell types within the islet. Transgenic mice expressing the Cre recombinase under the 
same PP promoter used in the previous study were crossed with reporter mice and, in 
adult islets, insulin cells appeared labeled with the reporter gene. These data showed that 
β cell progenitors can transcribe the pancreatic polypeptide gene and therefore it is very 
likely that insulin cells derive from precursors expressing PP.  
PP also plays a role in the control of insulin secretion and in the regulation of glucose 
metabolism. PP is secreted under vagal control, after food ingestion [334]. It has been 
shown that exogenous administration of PP inhibits insulin secretion in rodents [335-337] 
and transgenic mice overexpressing PP display impaired glucose tolerance and reduced 
insulin secretion after glucose challenge [338]. Moreover, basal plasma levels of PP have 
been reported to be increased in diabetic patients proportional to the degree of 
hyperglycemia and release of PP is stimulated upon hypoglycemia [339]. Defects in PP 
secretion have been associated with HNF4α mutation both in diabetic and non diabetic 
patients [340].  
PP and PYY are also known to act as anorectic hormones, i.e. negatively influencing the 
appetite. Physiological signals that regulate appetite have been divided into long-term 
regulators, such as leptin, which signal body energy stores and regulate body weight over 
months, and short-term regulators that act on food intake and regulate appetite on day to 
day basis [341]. Among these short-term regulators are the orexigenic hormone ghrelin, 
which enhances appetite and increases food intake [342], and two anorexigenic peptides 
having the opposite effect: PP and PYY.  
PP acts via neuropeptide Y4 receptors expressed within the brainstem and hypothalamus, 
key brain areas involved in the regulation of appetite [343]. However, the identity of the 
neuronal populations which express Y4 receptors and the mechanisms underlying the 
anorectic actions of PP remain to be determined. Peripheral administration of PP in 
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rodents has been shown to reduce food intake [344]. Furthermore, by using transgenic 
mice in which PP is overexpressed in pancreatic islets, Ueno and coauthors showed that 
these mice have reduced body weight and less adipose tissue compared with controls 
[345]. Transgenic animals exhibited a decreased rate of gastric emptying, which could 
explain their reduced feeding [346]. This was confirmed and deeply investigated in a 
subsequent study done by the same group [347], in which peripherally administered PP in 
mice induced negative energy balance by decreasing food intake and increasing energy 
expenditure. The mechanism of action involves a decrease in the expression of feeding-
stimulatory neuropeptides like NPY, a decrease in ghrelin mRNA expression as well as in 
leptin, and a decrease in gastric emptying. Moreover, repeated administrations of PP 
reduced body weight gain and improved glycemic control in ob/ob obese mice by 
producing a remarkable decrease of free fatty acid, cholesterol and triglycerides levels.  
In humans, PP has also been shown to reduce appetite and food intake [348]. PP plasma 
levels are decreased in cases of human obesity [349, 350] and increased in cases of 
anorexia nervosa [351]. For instance, children with Prader-Willi syndrome have low 
levels of PP; they are characterized by marked hyperphagia and obesity, which disappears 
with intravenous infusions of PP [352].  
The gut hormone PYY has also been shown to inhibit food intake and reduce body 
weight in rodents and humans. Interestingly this effect was observed by injecting 
physiological concentrations of PYY3-36, the peptide form that is normally released 
postprandially from the gastrointestinal tract. PYY3-36 functions as a ligand for the Y2 
receptors and regulates food intake by acting on hypothalamic neurons via Y2 to inhibit 
the orexigenic NPY system in the arcuate nucleus [353]. The same investigators 
demonstrated that this form of PYY is able to inhibit food intake in obese patients [354], 
showing that obesity is not associated with substantial resistance to PYY, contrary to 
leptin. Postprandial PYY release was lower in obese than in lean subjects, consistent with 
the hypothesis that a deficiency in circulating PYY may be involved in the pathogenesis 
of obesity.  
Recently, a novel role of PYY in inhibition of pancreatic tumor growth and inflammation 
has been suggested [355]. Growth of different pancreatic tumor cell lines was 
significantly reduced upon treatment with PYY. Moreover, administration of exogenous 
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PYY in vitro and in vivo decreases amylase secretion and cytokine release in different 
experimental models of pancreatitis, suggesting potential therapeutic implications for 
PYY.  
 
 
I.4. General aims of the thesis project 
Multiple factors are implicated in pancreas development and growth. 
The general aims of this thesis work were to answer the following questions: 
1. What is the role of Wnt signaling pathway, and more precisely of β-catenin 
activation, in pancreas growth and homeostasis? 
2. What is the role of the pancreatic hormone PP during pancreas development? 
The Results section is therefore composed by two parts: the first part focuses on β-catenin 
signaling, while the second part addresses the function of PP expressing cells during 
development. 
Most of the results presented in the next part are summarized in an article in press in the 
journal Development. 
In order to answer the questions above, we generated different transgenic animals.  
In the next part, we have investigated the consequences of APC inactivation in pancreas 
(i.e. mimicking a Wnt gain-of-function phenotype) at different time points during mice 
lifespan. 
The last part of the thesis is subdivided in three main chapters in which different 
experimental approaches were used to either inactivate PP (by RNA inteference or gene 
targeted ablation) or to follow the fate of PP expressing cells during pancreas 
development (by mean of cell lineage tracing analyses). 
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 II. Pancreatic APC Inactivation1 
 
II.1. Results 
 
The involvement of Wnt signaling during pancreas development was unclear and almost 
not investigated at the time we began this project. Expression of several Wnt signaling 
components has been detected in both pancreatic mesenchyme and epithelium [356, 357] 
and misexpression of Wnt1 and Wnt5a in the foregut of transgenic mice has been shown 
to cause pancreatic agenesis or hypoplasia, respectively. However, almost nothing was 
known on the function of Wnt signaling in the regulation of pancreas development and 
homeostasis. A potential role of this pathway in adult β cell function has been proposed 
by studies in which the LRP5 coreceptor was mutated in mice. In the absence of LRP5, 
these animals show impaired glucose tolerance due to perturbed insulin secretion, which 
develop upon high-fat diet in an age-dependent manner after six months [358]. 
In order to elucidate the role of the Wnt pathway in the pancreas, we use a conditional 
knockout approach in transgenic mice to allow for specific activation of the signaling in 
the pancreas, and study its effects at different time points during the knockout mice 
lifespan. 
 
II.1.1. Pancreas-specific APC inactivation induces postnatal pancreatomegaly 
Mice bearing two Apc alleles containing a loxP-flanked exon (Apcfl/fl animals [359]) were 
bred to a transgenic mouse strain generated in our laboratory, expressing Cre 
recombinase in all pancreatic cell types, the Pdx1-Cre strain [224, 240]. The timing of 
Pdx1-Cre recombination was assessed using the R26R reporter mouse [360], in which the 
recombined Pdx1-expressing cells can be visualized by X-gal staining (Fig. 14A). It is 
                                            
1 Most of the results reported here are part of a publication : « Unique mechanisms of growth 
regulation and tumor suppression upon APC inactivation in the pancreas » by A.Strom, C.Bonal, 
R.Ashery-Padan, N.Hashimoto, M.L.Campos, A.Trumpp, T.Noda, Y.Kido, F.X.Real, F.Thorel and 
P .L.Herrera, Development – In Press (2007). 
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important to note that this Pdx1-Cre strain is active as soon as E10.5, allowing for 
irreversible recombination in all pancreatic progenitors.  
In the pancreas of Apcfl/fl-Pdx1-Cre mice (called ApcP-/- thereafter), exon 15 of the Apc 
gene, containing the sites encoding the domains for Axin and β-catenin binding, was 
flanked by two loxP sequences and was therefore deleted upon Cre-mediated 
recombination, generating a truncated APC protein unable to downregulate β-catenin. 
The three main pancreatic cell types (acini, ducts and islets) were recombined in the adult 
pancreas, as assessed by genomic PCR using specific primers flanking the loxP sites of 
the Apc allele (Fig. 14B). The pancreatic Apc deletion was very efficient, as assessed by 
real-time RT-PCR on total pancreatic RNA extracted from two month-old ApcP-/- mice 
(Table 1). 
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vp
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s
d
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APC wt (floxed) allele
APC recombined allele
1 2 3 4 5 6
tail ducts
7 8 9 1110 12
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Figure 14. Pancreatic Apc inactivation. (A) E10.5 double transgenic R26R;Pdx1-Cre+/- embryo stained 
with X-gal (whole mount). Cre expression is driven by Pdx1 promoter and detected as β-galactosidase 
activity in both pancreatic buds. vp, dp, ventral and dorsal pancreatic primordia, respectively; s, stomach; 
d, duodenum. (B) Genomic PCR using DNA from tail biopsies, isolated acini, ducts or islets of control and 
knockout two month-old mice. Apc is efficiently recombined in all pancreatic cell types in ApcP-/-, as 
demonstrated by a 300 bp band (not recombined tissues yield a 1 kb-long PCR fragment) 
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. 
relative fold change (%) in ApcP-/-  pancreas
2 months
Apc TTGGAAGTGTGAAAGCATTGATG
AAGGCACTCAAAACGCTTTTG
β-catenin CAGATCTTGGACTGGACATTGG
AACGGTAGCTGGGATCATCCT
E-cadherin GAGCGTGCCCCAGTATCGT
GGCTGCCTTCAGGTTTTCATC
Tcf 4 GGCGAGCAGGAGGAGAAGA
GGACTTGACATCGGCTAAATCC
c-Jun CTGCATGCTATCATTGGCTCAT
CCACACCATCTTCTGGTGTACAG
c-Myc CCTAGTGCTGCATGAGGAGACA
CCTCATCTTCTTGCTCTTCTTCAGA
Cdk4 CCCACCTCTCCTTACGAGGTT
AGAAGACAGATACACCTGCCCTTTA
p21 GCAGACCAGCCTGACAGATTTC
GGCACTTCAGGGTTTTCTCTTG
Cyclin D2 CAGAAGGACATCCAACCGTACAT
CACTTTTGTTCCTCACAGACCTCTAG
up 2.8x
gene oligonucleotides 
up 4.4x
up 3.2x
up 2.3x
unchanged
dow n 21x (5%)
unchanged
unchanged
unchanged
 
Table 1. Expression profile (real-time RT-PCR) of selected genes in ApcP-/- pancreas. In two months-old 
ApcP-/- mice, β-catenin target genes are upregulated. Expression levels are relative to transcripts in control 
pancreas, calculated using 3 different housekeeping genes (see methods), and normalized to 1 (100%). Apc 
transcripts are measured using primers placed at the junction between exon 14 and 15 (floxed). n=5 mice 
per condition; P<0.01. 
 
Control (Apcfl/fl) and heterozygous (Apcfl/wt-Pdx1-Cre) mice showed undistinguishable 
phenotypes. The pancreas of ApcP-/- animals appeared normal throughout embryogenesis 
and at birth, but from three weeks of age, a marked pancreatomegaly ensued (Fig. 15A), 
with a pancreas:body weight ratio 3-5 fold higher than control mice (Fig. 15B). The body 
weight of ApcP-/- animals remained normal (Fig. 15C). This extremely increased 
pancreatic mass remained constant during the whole period of analysis, up to one year.  
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Figure 15. Apc inactivation induces pancreatomegaly. (A) Freshly dissected pancreas of two month-old 
control and ApcP-/- mice. p, pancreas; s, stomach; sp, spleen; d, duodenum. Bar is 0.5cm. (B) 
Pancreas:Body weight ratio. The pancreatic mass is increased about 4-fold in ApcP-/- mice whereas the 
body weight (C) remains similar to control animals. n=6 mice per group; P<0.001.  
 
II.1.2. Normal pancreas morphology in ApcP-/- mice 
Despite the increase in pancreatic mass, the histology of acinar, ductal and islet cells was 
normal in ApcP-/- (Fig. 16A). The overall expression of differentiation markers was 
maintained and correctly localized in the pancreas of knockout mice, as shown by 
immunohistochemistry: amylase was found in acinar cells, Pdx1 was only restricted to 
islets in adult pancreas as expected, and the staining for the four endocrine hormones was 
comparable to control pancreas. The islets of Langerhans appeared diluted in the enlarged 
exocrine compartment (Fig. 16B). Morphometrical analyses revealed that the relative β-
cell area in ApcP-/- pancreata was decreased compared to that of controls (Fig. 16C). 
However, since the pancreatic mass was increased in ApcP-/- mice, their overall β-cell 
mass appeared unchanged. Accordingly, the total pancreatic contents of insulin and 
glucagon in control and ApcP-/- mice were normal, as determined by immunoassays, even 
if the relative concentrations of both hormones appeared severely decreased in ApcP-/- 
pancreata (Fig.  17). Altogether these results showed that the pancreas of ApcP-/- mice had 
no morphological defects and that the endocrine compartment was not affected by the 
pancreatomegaly. 
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Figure 16. Pancreas differentiation in ApcP-/- mice is normal. (A) Immunofluorescence for amylase, Pdx1, 
insulin, glucagon, somatostatin and pancreatic polypeptide reveals normal localization of differentiation 
markers in mutant pancreata. Scale bars are 20 μm. (B) H/E staining of control and ApcP-/- pancreas. Note 
that islets appear diluted in the hyperplastic exocrine tissue in ApcP-/- mice. (C) Morphometrical analyses. 
The relative β-cell area in ApcP-/- pancreas is significantly decreased. Since the total pancreatic mass is 
increased, the total β-cell mass is unchanged when compared with controls. P<0.05. 
relative pancreatic insulin
Control Apc P-/-
0
100
200
300
*ng
 in
su
lin
 /
m
g 
pa
nc
re
as
relative pancreatic glucagon
Control Apc P-/-
0.0
2.5
5.0
**
ng
 g
lu
ca
go
n 
/
m
g 
pa
nc
re
as
total pancreatic insulin content
Control Apc P-/-
0
20
40
60
 in
su
lin
 ( μ
g)
total pancreatic glucagon content
Control Apc P-/-
0.0
0.2
0.4
0.6
0.8
1.0
1.2
gl
uc
ag
on
 ( μ
g)
 
Figure 17. Pancreatic hormonal content is unchanged in ApcP-/- mice. Immunoassays on pancreatic 
extracts from both control and Apc knockout animals. The relative content of insulin and glucagon is 
decreased in ApcP-/- mice but, due to their enlarged pancreatic mass, the total content of both hormones is 
unchanged. n=4 mice per group; P<0.01. 
 
II.1.3. Endocrine function of ApcP-/- pancreas 
To assess the function of the endocrine mass in ApcP-/- mice, we measured both glycemia 
and insulinemia in control and ApcP-/- mice and detected no variations (Fig. 18A-B). 
Glucose homeostasis revealed by glucose tolerance tests (GTT) was overall normal, 
although ApcP-/- at two months of age peaked higher than controls at 30 minutes (Fig. 
18C). This slight defect in regulating the glycemia was not due to a defect in insulin 
secretion, as the plasmatic insulin concentration was not significantly different from that 
of control mice after a glucose challenge (Fig. 18D). Furthermore, in older ApcP-/- mice 
GTT was completely normal (Fig. 18E), showing that the endocrine function was not 
affected in Apc mutants.  
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Figure 18. Endocrine function in ApcP-/- mice.  (A, B) Basal (fasting) plasma insulin (A) and glucose (B) 
concentrations. No changes are detected between control and mutant mice. n=4 mice per group. (C, E) 
Intraperitoneal glucose tolerance tests (GTT) in 2 and 12 months-old mice; young adults have higher peaks 
of glycemia after the glucose challenge, but recovery is optimal. n=7 mice per group; P<0.01. (D) Plasma 
insulin (ELISA) after i.p. injection of glucose, reveals no change in insulin secretion between ApcP-/- and 
control pancreata. n=4 mice per group.  
 
II.1.4. Exocrine function of ApcP-/- pancreas 
To assess the function of the exocrine mass, we measured amylase activity in two 
months-old ApcP-/- mice. Absolute pancreatic amylase activity was normal despite an 
enlarged acinar compartment (Fig. 19A), suggesting that the amylase content per cell was 
decreased. In comparison to controls, ApcP-/- mice had hyperamylasemia at two months of 
age (Fig. 19B), indicating that plasma amylase may be a good indicator of functional 
pancreatic mass. 
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Figure 19. Exocrine function in ApcP-/- mice. (A) Pancreatic amylase content showed normal absolute 
amylase activity despite an enlarged acinar compartment in ApcP-/- mice. (B) Plasmatic amylase levels 
were increased in mutants compare with control animals. n=4 mice per group; P<0.05. 
 
II.1.5. Apc deletion does not affect pancreas development 
APC regulates endogenous β-catenin levels. Therefore, Apc invalidation is expected to 
induce the accumulation of unphosphorylated β-catenin and trigger its nuclear 
localization [361]. We analyzed the pancreas of ApcP-/- embryos at E15.5, i.e. at the end 
of the secondary transition. At this stage, the pancreatic mass of ApcP-/- mice was 
comparable to that of control animals and surprisingly, the expression and distribution of 
β-catenin in ApcP-/- pancreas at E15.5, analyzed by immunohistochemistry using a pan-β-
catenin antibody, was the same as in controls (Fig. 20A-B). In both mutant and wild-type, 
very low levels of unphosporylated β-catenin were detected by Western blot, using a 
specific antibody that recognizes the unphosphorylated form of β-catenin, and β-catenin 
was always localized at the plasma membrane level in the whole pancreatic epithelium. 
Thus, despite the efficient pancreatic deletion of Apc triggered very early during 
embryogenesis (from E10.5), which was confirmed at E15.5 by real-time RT-PCR, β-
catenin did not accumulate in the developing ApcP-/- pancreas and transcription levels of 
β-catenin target genes were similar in ApcP-/- and control mice (Table 2). These results 
were unexpected but explain the lack of pancreatic phenotype in ApcP-/- mice during 
embryogenesis. Accordingly, pancreatic cell proliferation in ApcP-/- embryos, measured 
by BrdU incorporation, was equivalent to that of controls (Fig. 20C). The morphology of 
ApcP-/- pancreata at this stage was normal. 
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Figure 20. No effects of Apc deletion during embryogenesis. (A) Western blot of total pancreatic extracts 
from E15.5 embryos using anti-unphosphorylated β-catenin antibody. This form of β-catenin does not 
accumulate in ApcP-/- pancreas at this stage. β-tubulin shows equal loading. (B) Immunostaining of E15.5 
pancreata from control and Apc knockout embryos using pan- β-catenin antibody. β-catenin is located at 
the membrane in both genotypes. Scale bars are 20 μm. (C) Proliferation rate at E15.5, measured by BrdU 
incorporation, reveals normal cell proliferation during embryogenesis in ApcP-/- pancreas. n=3 animals per 
group. 
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relative fold change (%) in ApcP-/-  pancreas
E15.5
Apc
β-catenin
E-cadherin
Tcf 4
c-Jun
c-Myc
Cdk4
p21
Cyclin D2
gene
unchanged
unchanged
unchanged
dow n 4.3x (23%)
unchanged
unchanged
unchanged
up 1.5x
unchanged
 
 
Table 2. Expression profile (real-time RT-PCR) of selected genes in ApcP-/- embryonic pancreas. The 
level of β-catenin target genes in ApcP-/- mice are similar to control at E15.5, despite Apc downregulation. 
n=5 mice per condition; P<0.01. 
 
II.1.6. β-catenin accumulates in ApcP-/- pancreas from birth 
The pancreatic mass of ApcP-/- newborns was like in controls and pancreas morphology 
was normal. However, β-catenin already accumulated in acinar cells only in ApcP-/- 
newborns (Fig. 21A) whereas normally, in the pancreas of control animals, β-catenin is 
mainly found at the plasma membrane level, whether in islets or exocrine tissue. 
Moreover, pancreatic cell proliferation was increased (doubling) in Apc mutants at this 
stage (Fig 21B), which may account for the enlarged pancreatic mass that developed in 
the following weeks. 
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Figure 21. β-catenin accumulation and acinar cell hyperplasia in ApcP-/- neonates. (A) Immunostaining 
of neonatal pancreata using pan- β-catenin antibody. β-catenin accumulates in acinar cells from ApcP-/- 
mice at this stage. Scale bars are 20 μm. (B) Proliferation rate measured by Ki67 staining shows increased 
cell proliferation from birth in ApcP-/- pancreas. n=3 animals per group; P<0.01. 
 
We investigated β-catenin status in the enlarged adult ApcP-/- pancreas, both by Western 
blot and by immunohistochemistry. As expected, Apc loss triggered the stabilization and 
accumulation of unphosphorylated β-catenin in the pancreas of two month-old mutants 
(Fig. 22A). In the pancreas of adult ApcP-/- mice, β-catenin was localized also in the 
nuclei of acinar cells only, remaining membrane-bound in ductal and insular cells as in 
control pancreas (Fig. 22B). These results were striking in that they revealed that only 
acinar cells accumulate nuclear β-catenin upon Apc deletion, correlating with the fact that 
the pancreatomegaly only affected exocrine compartment (i.e. normal β cell mass and 
unchanged total pancreatic hormonal content). Accordingly, the unphosphorylated form 
of β-catenin was not detected by Western blot extracts of ApcP-/- isolated islets (Fig. 22C).   
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Figure 22. β-catenin accumulates in ApcP-/- acinar cells. (A) Western blot of total protein extracts from 
adult pancreas (two months-old mice) using anti-unphosphorylated β-catenin antibody. This form of β-
catenin accumulates in ApcP-/- mice. β-tubulin shows equal loading. (B) Anti-pan β-catenin 
immunofluorescence. In control mice, β-catenin staining is found close to cell membranes. In contrast, in 
ApcP-/- mice staining for β-catenin is mainly nuclear in acinar cells but remains peripheral in most islet and 
ductal cells, as in controls. Scale bars are 20μm. i, islet; d, duct. (C) Western blot of protein extracts from 
islets. Levels of pan- β-catenin are equivalent in control and mutant islets whereas the unphosphorylated 
form of β-catenin is not detected. Actin shows equal loading. 
 
II.1.7. Activation of β-catenin target genes in ApcP-/- pancreas 
Since β-catenin nuclear localization is normally associated with the transcriptional 
activation of specific genes mainly involved in cell proliferation, we analyzed the 
expression profile of different potential β-catenin target genes in the pancreas of ApcP-/- 
mice by using quantitative real-time RT-PCR (Table 1). This analysis revealed the 
upregulation, in two-month old mutant pancreata, of several well-established β-catenin 
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target genes, like cMyc, cJun, cyclin D2 and its partner cdk4. Hence, gene expression 
profiling showed that β-catenin signaling is activated in the pancreas of ApcP-/- mice. 
 
II.1.8. Acinar cell hyperplasia in ApcP-/- mice  
To further investigate the nature of pancreatomegaly in ApcP-/- mutants, we measured 
pancreatic cell proliferation in adult mice using Ki67 staining and observed a significant 
increase (almost doubling) in the rate of acinar cell proliferation at one month of age, 
which was maintained up to six months (Fig. 23A). Ductal and islet cell proliferation 
were normal (not shown). Cell density was comparable in control and ApcP-/- pancreata 
(Fig. 23B), indicating that acinar cell hyperplasia rather than acinar cell hypertrophy 
accounts for the increased pancreatic mass. This correlates with the nuclear accumulation 
of β-catenin in the acinar compartment of ApcP-/- mice and the increased transcription of 
β-catenin target genes.  
Surprisingly, the increase in ApcP-/- acinar cell proliferation was transient and, from six 
months of age, the proliferation index was similar to that of control pancreas. Since the 
increased size of the ApcP-/- pancreas remained stable from one month of age throughout 
the whole period of observation, we reasoned that proliferation might be counterbalanced 
by increased apoptosis. We observed the same transient profile as that of cell 
proliferation (TUNEL, Fig. 23C). At one month, cell death was strongly increased in 
ApcP-/- pancreas when compared with control, whereas apoptosis stopped concomitantly 
with the stabilization of cell proliferation, at six months of age. This may explain, at least 
in part, the stabilization of pancreatic mass in ApcP-/- mice. 
 
 74
A
B
C
Control Apc P-/-
0.000
0.002
0.004
0.006
0.008
0.010
0.012
0.014
nu
cl
ei
 / 
ar
ea
 ( μ
m
2 )
Apoptotic index
one month six months one year
0.0
2.5
5.0
7.5
10.0
12.5
15.0
17.5 **
**
Tu
ne
l /
pa
nc
re
as
 a
re
a
(m
m
2 )
Proliferation index
1 3 4 5 6 12
0
10
20
30
40
50
***
**
**
*
age (months)
K
i6
7/
pa
nc
re
as
 a
re
a
(m
m
2 )
 
 
Figure 23. Pancreas hyperplasia in ApcP-/- mice. (A) Cell proliferation rate measured by Ki67 staining in 
adult mice. ApcP-/- pancreata show increased proliferation compare to control, which return to normal 
levels after 5 months. n=3 animals per group; P<0.01. (B) The number of cells per pancreatic surface is 
unchanged, indicating no hypertrophy in ApcP-/- pancreas. (C) Cell death rate measured by TUNEL assay. 
A transient increase in apoptosis is observed in ApcP-/- mice at one month of age. n=3 animals per group; 
P<0.01. 
 
II.1.9. Islet-specific Apc inactivation 
When Apc is deleted in all pancreatic progenitors using Pdx1-Cre mice, β-catenin does 
not accumulate in islets. For this reason, the endocrine cell mass was unaffected in ApcP-/- 
mice. We have further investigated the refractoriness of islet cells to β-catenin signaling 
with mice bearing Apc inactivation exclusively in islets (Apcfl/fl;Pax6-Cre) [224, 278].  
In these animals, a different, islet-specific promoter (Pax6) was used to inactivate Apc. 
Islet mass (Fig. 24A) and morphology (Fig. 24B) at two months were normal. Moreover, 
endocrine cells accumulated β-catenin mostly in the cytoplasm (Fig. 24C) and 
transcriptional levels of β-catenin target genes, measured by real-time RT-PCR on 
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isolated islets from one month-old Apcfl/fl;Pax6-Cre, were similar to control islets despite 
an efficient Apc deletion (Table 3). 
These results confirm that, even when β-catenin signaling is permitted specifically in 
endocrine cells, there is a mechanism preventing its activation. This probably accounts 
for the absence of phenotype in Apcfl/fl;Pax6-Cre pancreata. 
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Figure 24. No phenotype upon Apc deletion in islets. (A) Morphometrical analyses. The relative β-cell 
area in Apcfl/fl;Pax6-Cre mice is similar to control. (B) Hematoxylin/Eosin (H/E) staining showing normal 
pancreas morphology in Apcfl/fl;Pax6-Cre mice. Scale bars are 50 μm. (C) β-catenin immunofluorescence. 
β-catenin accumulates in the cytoplasm of islet endocrine cells rather than in their nuclei (islets are 
outlined with dashed lines). Scale bars are 20μm. 
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Apc
β-catenin
Tcf 4
c-Jun
c-Myc
Cyclin D2 dow n 2.5x (40%)
gene
unchanged
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dow n 5.2x (19%)
unchanged
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Table 3. Expression profile (real-time RT-PCR) of selected genes in aged Apcfl/fl;Pax6-Cre pancreas. The 
level of β-catenin target genes in Apcfl/fl;Pax6-Cre mice is similar to control or downregulated at this stage. 
n=2 mice per condition (130 islets per group); P<0.05. 
 
II.1.10. Wnt-independent signaling in the pancreas? 
In the so called non-canonical pathway, β-catenin can also be activated in the absence of 
Wnt signals through different mechanisms, including phosphorylation of β-catenin at 
tyrosine 142 (phospho-Y142) by receptor tyrosine kinases of the Met family. This 
phosphorylation leads to its dissociation from the membrane and to nuclear translocation 
of (phospho-Y142) β-catenin [80]. We thus investigated whether this form of β-catenin is 
normally present in the pancreas. We found that (phospho-Y142) β-catenin was only 
detected in adult acinar cells (Fig. 25).  
Hence, this distribution perfectly correlates with the expression pattern of 
unphosphorylated β-catenin observed in ApcP-/- mice, suggesting that acinar pancreas 
growth may be modulated by Wnt-independent signaling. Interestingly, this possibility 
was already proposed by Dessimoz et al [362] due to the lack of Wnt pathway activity in 
acinar and ductal cells observed using transgenic reporter strains.  
This form of β-catenin is not regulated by Apc and therefore the expression pattern of 
(phospho-Y142) β-catenin in ApcP-/- extracts was similar to that of controls. 
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Figure 25. Wnt-independent signaling. Western blot of total protein extracts from E15.5, adult pancreas 
and isolated islets using anti-unphosphorylatedβ-catenin and anti-β-catenin-(phospho Y142) antibodies. 
β-catenin-(phospho Y142) is abundant in adult acini, but undetectable in developing primordia or in islets, 
whether control or ApcP-/-. β-tubulin and actin show equal loading. 
 
II.1.11. Deletion of cMyc in an ApcP-/- background: reversal of pancreatomegaly  
Since upregulation of cMyc occurred in response to β-catenin signaling in ApcP-/- 
pancreata (Table 1), we decided generating double mutants using, in addition, cMycfl/fl 
mice (Fig. 26A) [363].  
The pancreas of mice harboring one functional cMyc allele was morphologically and 
functionally normal (not shown).  Remarkably, mice lacking in pancreas the two Apc and 
cMyc alleles (ApcP-/-;cMycP-/-) displayed a reversal of ApcP-/- phenotype, with no 
pancreatomegaly (Fig. 26B-C), in spite of persistent β-catenin nuclear localization and 
accumulation of the unphosphorylated form in the ApcP-/- background (Fig. 26D-E).  
ApcP-/-;cMycP-/- two months-old mice were overall similar to wild-type animals, showing 
normal relative β-cell area (Fig. 27A), as well as pancreatic insulin and glucagon content 
(Fig. 27B).  
This result shows that the increased acinar cell proliferation upon β-catenin activation in 
ApcP-/- pancreas is mediated by cMyc.  
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Figure 26. Pancreatomegaly is cMyc-dependent. (A) Levels of cMyc transcript, measured by real-time RT-
PCR using primers spanning the floxed exons, in double Apc and cMyc knockout mice. cMyc expression is 
strongly reduced in ApcP-/- cMycP-/- extracts. n=3 animals per condition; P<0.01. (B) Freshly dissected 
pancreata from two month-old ApcP-/- and ApcP-/-; cMycP-/- mice. Pancreatomegaly is not present in the 
absence of the two cMyc alleles. (C) Pancreas:body weight ratio of ApcP-/- cMycP-/- mice is similar to 
controls. (D) Western blot of total protein extracts from adult pancreas using anti-unphosphorylated β-
catenin antibody. This form of β-catenin accumulates in ApcP-/- cMycP-/- pancreas as well as in ApcP-/- mice. 
β-tubulin shows equal loading. (E) Anti-pan β-catenin immunofluorescence shows that nuclear β-catenin is 
found in acinar cells from ApcP-/- cMycP-/- mice, as in ApcP-/- pancreas. Scale bars are 20 μm. 
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Figure 27. Normal endocrine compartment in ApcP-/- cMycP-/- mice. (A) Morphometrical analyses. The 
relative β-cell area in ApcP-/- cMycP-/- mice is similar to control. (B,C) Immunoassays on pancreatic 
extracts. The relative content of insulin and glucagon in ApcP-/- cMycP-/- mice is similar to control animals. 
n=3 animals per group. 
 
II.1.12. Blockade of β-catenin signaling in aged ApcP-/- mice 
We studied ApcP-/- mice over one year. Pancreatomegaly remained stable and mice were 
in good health, with unchanged enlarged pancreatic mass and normal endocrine function 
(GTT Fig. 18E). Nuclear β-catenin in acinar cells persisted in mature mutant mice (Fig. 
28A) and many islet cells contained cytoplasmic β-catenin. At this stage, hypertrophic 
acinar cells, with dysplastic nuclei, were observed locally. Moreover, during this period, a 
significantly augmented proportion of islets became dysplastic (10% vs. 3% in controls 
Fig. 28B), with slightly increased size (Fig. 28C) and irregular shape and architecture 
(Fig. 28D). However, E-cadherin expression was always normal with no signs of 
perturbed cell to cell junctions (Fig. 29A) and there were no evident signs of pancreatitis, 
fibrosis or tumor lesions, as revealed by aldehyde-fucsin counterstaining (Fig. 29B). 
Remarkably, the expression of cMyc and other β-catenin target genes upregulated in 
young ApcP-/- pancreata had returned to normal levels in aged mutants (Table 4). This 
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correlates with the normalization of acinar cell proliferation observed after five months of 
age (see Fig. 23A) and may explain the lack of pancreatic tumors in ApcP-/- mice. The 
persistence of nuclear β-catenin in acini of one year-old ApcP-/- mice, without increased 
transcription of target genes or cell proliferation, revealed a blockade of β-catenin/TCF 
activity at this stage. 
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Figure 28. Islet dysplasia in aged ApcP-/- mice. (A) Immunostaining of one year-old pancreata using pan- 
β-catenin antibody. β-catenin accumulates in acinar cells from ApcP-/- mice at this stage, as well as in islets. 
Scale bars are 20 μm. (B,C) Dysplastic ApcP-/- islets with an increased average diameter are observed 
locally in aged ApcP-/- mice. (D) Double immunofluorescence for insulin (red) and glucagon (green) 
indicates that the cellular architecture in aged ApcP-/- islets is perturbed: glucagon-containing cells are not 
preferentially located at the periphery. Scale bars are 20μm. 
. 
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Figure 29. No tumor lesions in aged ApcP-/- mice. (A) E-cadherin expression detected by 
immunofluorescence in one year-old pancreas. E-cadherin is found at the plasma membrane in both 
control and ApcP-/- mice. Scale bars are 20μm. (B) Aldehyde-fucsin counterstaining shows no signs of 
fibrosis or tumor lesion in ApcP-/- pancreata. 
 
relative fold change (%) in ApcP-/-  pancreas
8-10 months
Apc
β-catenin
E-cadherin
Tcf 4
c-Jun
c-Myc
Cdk4
p21
Cyclin D2
gene
unchanged
dow n 2.6x (38%)
dow n 15x (7%)
unchanged
unchanged
unchanged
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unchanged
unchanged
 
Table 4. Expression profile (real-time RT-PCR) of selected genes in aged ApcP-/- pancreas. The level of β-
catenin target genes in ApcP-/- mice is similar to control or downregulated at this stage. n=3 mice per 
condition; P<0.05. 
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II.1.13. Potential role of ICAT in the blockade of β catenin signaling  
We further investigated the possible mechanisms accounting for the blockade of the β-
catenin signaling that occurred in one year-old ApcP-/- mice, which probably prevented 
uncontrolled pancreatic growth and tumor development. Several mechanisms may 
account for the lack of β-catenin transcriptional activity, despite its nuclear accumulation 
[23] and among them we explored whether one candidate, ICAT (Inhibitor of β-catenin 
and Tcf-4), could contribute to this blockade. ICAT has been shown to prevent the 
binding of β-catenin and TCF in vitro [81, 110]. We investigated by immunostaining 
whether ICAT was differentially expressed in one year-old pancreata. In control mice, 
ICAT was strongly expressed in islets but only weakly in some acinar cells, whereas in 
aged mutants it was upregulated in the majority of acinar cells (Fig. 30). This difference 
suggested that ICAT may play a role in the blockade of β-catenin signaling observed 
from six months of age. This possibility should be explored using double APC; ICAT 
knockout animals. Of course, other mechanisms can also contribute to the lack of tumors 
observed in ApcP-/- pancreas and should be further investigated in vivo.  
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Figure 30. ICAT is upregulated in aged ApcP-/- pancreas. Immunofluorescence of the β-catenin inhibitor 
ICAT on one year-old pancreata from control and Apc knockout mice. ICAT is expressed at high levels in 
control islets and weakly in acinar cells, whereas it is strongly upregulated in acini of aged ApcP-/- mice. 
Scale bars are 20μm. 
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II.1.14. No pancreatic tumors develop after Apc and Smad4 inactivation 
We investigated whether Smad4 participates in protecting ApcP-/- mice from pancreatic 
tumors. Smad4 (also known as Dpc4-deleted in pancreatic cancer) is a tumor suppressor 
gene that is part of the TGFβ signaling. Mutations in Smad4 have been implicated in 
human pancreatic carcinomas [364-366]. It has been shown that mice bearing a 
concomitant deletion of one allele of both Apc and Smad4 develop abnormal foci in 
acinar cells upon carcinogen treatment [367], and these foci are precursors of pancreatic 
neoplasia. 
Therefore, we generated double mutants ApcP-/- Smad4 P-/- by crossing ApcP-/- mice with 
Smad4 fl/fl animals [368]. These mice developed a marked pancreatomegaly, just as ApcP-/- 
mutants (Fig. 31A), and showed normal endocrine function (Fig. 31B) as well as total 
pancreatic insulin content (Fig. 31C). One year-old ApcP-/- Smad4 P-/- did not develop 
pancreatic tumors (Fig. 31D). Therefore Smad4 does not appear to be involved in 
pancreas tumorigenesis, even in the absence of the tumor suppressor APC. 
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Figure 31. Pancreatomegaly without tumor upon Apc and Smad4 inactivation. (A) Pancreas:Body 
weight ratio. The pancreatic mass is increased about 4-fold in ApcP-/- Smad4P-/- mice, similar to single Apc 
knockout animals. n=4 animals per group; P<0.001. (B) Intraperitoneal glucose tolerance test (GTT) in 2 
months-old mice. The curve is similar to control. n=4 mice per group. (C) Immunoassays on pancreatic 
extracts. The total insulin content in ApcP-/- Smad4P-/- mice is similar to control animals. n=4 animals per 
group. (D) Aldehyde-fucsin counterstaining shows no signs of fibrosis or tumor lesion in ApcP-/- Smad4P-/- 
pancreata from one year-old mice. 
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II.2. Discussion and Perspectives 
 
The present study, which looked at the effects of deleting Apc in the pancreas, revealed 
an unexpected spatial and temporal restriction of β catenin signaling activation in the 
mutant pancreata.  
In ApcP-/- mice, we expected that β catenin degradation was impaired due to the inability 
of the truncated APC protein to participate in the complex that promotes β catenin 
downregulation, thus mimicking the effects of activated Wnt signaling pathway in the 
pancreas. Surprisingly, during embryogenesis, the unphosphorylated form of β catenin 
did not accumulate in the pancreas of ApcP-/- embryos and we did not observe any 
pancreatic phenotype in the absence of Apc. In agreement with this observation, 
transcription of β catenin target genes was found to be comparable to control mice in 
E15.5 ApcP-/- pancreata and proliferation rate was normal in mutant embryos at this stage. 
These results therefore point towards an inhibition of β catenin signaling activation in 
early pancreatic progenitors, even if potentially allowed by Apc inactivation. Currently, 
we do not understand the reasons for this blockade but we can hypothesize that some 
extrinsic signals or intrinsic factors present during pancreatic embryonic development 
impede the activation of β catenin signaling at this stage.  
Recently, it was shown that the definitive size of the pancreas is determined by a limited 
number of pancreatic progenitors and cannot be modulated later as it happens in other 
more proliferative organs like the liver [369].  
In ApcP-/- mice, a marked postnatal pancreatomegaly occurred and persisted during the 
whole period of observation, up to one year. This was due to a specific acinar hyperplasia 
mediated by activation of β-catenin selectively in the acini of ApcP-/- mice, but not in 
ducts or islets. The compartmentalization of β-catenin signaling was striking as the 
endocrine compartment was not affected by Apc deletion, with unchanged β cell mass as 
well as normal total content of pancreatic hormones in mutant animals and unaltered 
endocrine function. We could confirm that islet cells were refractory to β-catenin 
signaling using mice bearing Apc inactivation in islets only (Apcfl/fl;Pax6-Cre). In these 
mutants, islet size was normal and expression of β-catenin target genes was similar to that 
of control islets, revealing an inhibition of β-catenin activity in endocrine cells. Therefore, 
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by inactivating Apc we showed that the acinar compartment was the main target of β-
catenin signaling in the pancreas. 
Other laboratories have shown that modulation of Wnt/β-catenin signaling affects 
pancreatic growth, mainly altering the exocrine compartment. Edlund and colleagues 
studied the impact of perturbed Wnt signaling on pancreas development by 
overexpressing a dominant negative form of the Frizzled receptor 8 using the Pdx1 
promoter [370]. This Pdx1-Frz8CRD transgene acts as an antagonist of the Wnt signaling, 
by inhibiting the binding of Wnt ligands to Fz receptors in the pancreatic epithelium. 
Neonate mutants had a drastically reduced pancreas, due to a decrease in cell 
proliferation, while pancreatic specification and differentiation were not affected. 
Moreover, the reduction in pancreas size had no consequence on endocrine function, with 
normoglycemic mutants. Interestingly, the pancreatic phenotype obtained in this study by 
blocking Wnt signaling upstream of APC was fully reciprocal of what we observed in 
ApcP-/- mice (which activates the signaling downstream of Wnt): a perturbed pancreatic 
growth with no effect on the endocrine compartment and on glucose homeostasis. 
Other reports focus more precisely on the role of β-catenin signaling in pancreas 
development by deleting β-catenin in all pancreatic progenitors. Murtaugh and colleagues 
used a different Pdx1-Cre strain [222] to inactivate β-catenin in the pancreatic epithelium 
and observed a severe pancreatic hypoplasia at birth, with a specific loss of acinar cells 
[371]. This was due to a reduction in cell proliferation as soon as E11.5 in β-catenin 
depleted pancreata, accompanied by a decrease in cMyc expression. This phenotype was 
also reciprocal with that of ApcP-/- mutants, pointing again to the lineage to acini as the 
main target of β-catenin activity. However, β-catenin depletion affects acinar progenitors, 
whereas the increased acinar cell proliferation in ApcP-/- mice appears from birth. This 
difference may be related to the fact that the accumulation of β-catenin in cells after 
inactivation of Apc was indirect, and therefore delayed when compared with the reported 
direct β-catenin inactivation.  
A slight variation in the precise timing and extent of β-catenin inactivation, or activation, 
may yield completely different, and even opposing phenotypes. Heiser and colleagues 
used two different Pdx1-Cre mouse strains to remove the third β-catenin exon, which 
results in stabilization of the protein that can not be degraded [372]. Forced β-catenin 
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activation in pancreatic epithelium from very early stages of development with Pdx1-Cre 
strain [222] induced hypoplasia. However when another Pdx1-Cre strain, with a mosaic 
and slightly delayed Cre expression was used to stabilize β-catenin, the phenotype 
obtained was the opposite: an enlarged pancreas. The latter Pdx1-Cre strain was 
generated in our lab [223] and is not the Pdx1 transgene that I used for my studies [240]. 
The phenotype resulting from β-catenin stabilization using the second mosaic Pdx1-Cre 
strain was similar to what we observed in the ApcP-/- mice: a striking postnatal 
pancreatomegaly due to acinar cell proliferation, without endocrine phenotype. 
Remarkably, no pancreatic tumors were observed up to one year of age in mutant mice 
with stabilized β-catenin, as it was the case in ApcP-/- mutants.  
Variations in the timing or extent of β-catenin recombination lead to different phenotypes. 
Dessimoz and colleagues uncovered Wnt dependent and independent functions after 
depleting β-catenin in pancreatic progenitors [362]. Using mice bearing one null allele 
and one floxed allele of β-catenin, crossed with Pdx1-Cre strain [240], these authors 
obtained only partial recombination at the β-catenin locus at E12.5, which increased 
subsequently. In this mosaic situation, cells depleted for β-catenin had a competitive 
disadvantage as compared with non recombined cells. At birth, the size of the pancreas 
was normal due to compensation of wild-type cells, but the total islet mass was decreased 
and some regions of the mutant pancreas showed disorganized acinar tissue. Cell 
proliferation was also decreased in the absence of β-catenin. Adult pancreas was normal 
in size, with no defects in endocrine function. Overall this study confirmed the role of β-
catenin signaling in acinar cell proliferation.  
Recently, it was shown that ectopic activation of the Wnt signaling can stimulate β cell 
proliferation. In a recent study involving different transgenic mice to either induce an 
activated form of β-catenin or the negative regulator Axin specifically in insulin-
expressing cells, Rulifson and colleagues could enhance or inhibit the expression of β-
catenin target genes specifically in islets and found that they modulate β cell proliferation 
and insulin secretion postnatally [373].  
Wells and coworkers performed microarray analysis in the β-catenin depleted pancreas 
[374]. This approach revealed the downregulation of N-myc as well as that of acinar 
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specific genes at E16.5, when pancreatic hypoplasia was evident, suggesting once more 
that the balance between proliferation and differentiation is perturbed in the absence of β-
catenin.  
In our studies on ApcP-/- pancreata we also analyzed the expression of β-catenin target 
genes. We observed a marked upregulation of several cell proliferation promoting genes 
(such as cMyc) from birth until six months. We showed that pancreatomegaly was 
completely reversed in the absence of cMyc, demonstrating the cMyc is responsible of the 
acinar cell hyperplasia which develops in ApcP-/- mutants.  
Apc is a well known tumor suppressor gene in humans, not only implicated in colorectal 
cancers, but also in exocrine tumors. Apc truncations or β-catenin activating mutations 
were shown to be associated with ductal and acinar cell carcinomas [375-378]. Moreover, 
in several pancreatic and gastrointestinal cancers there is a marked association between 
nuclear or cytoplasmic β-catenin staining and tumor invasiveness ([379, 380]; reviewed 
by [381]). In ApcP-/- mice no pancreatic tumor developed, even if β-catenin activation was 
maintained in aged mice after one year of observation. In one year-old ApcP-/- mice, 
pancreatomegaly persisted as well as the accumulation of the unphosphorylated form of 
β-catenin and its nuclear localization in acinar cells. However, acinar cell proliferation 
returned to normal levels after six months in ApcP-/- pancreas. This was due to a blockade 
in β-catenin transcriptional activity, as cMyc and other β-catenin target genes were not 
upregulated in old ApcP-/- pancreata. The fact that activation of β-catenin was only 
transient in ApcP-/- mice is very likely responsible for the absence of pancreatic tumors, 
and defines a “β-catenin competence window” in the exocrine pancreas.  
The blockade may be mediated by different inhibitory mechanisms [23]. We investigated 
whether the β-catenin inhibitor ICAT was involved in this inhibition by determining its 
expression pattern in ApcP-/- pancreata from young and old animals. 
Immunohistochemical and immunofluorescence analyses revealed that ICAT staining 
was more abundant and intense in acinar cells of aged ApcP-/- mice than in control 
pancreata suggesting a potential role of ICAT in regulating β-catenin activity in the 
pancreas. 
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Sustained overexpression of cMyc in acinar cells using the elastase promoter is strongly 
tumorigenic [382]. Moreover, it was recently shown in Min (multiple intestinal neoplasia) 
mice, which are heterozygous for a truncating Apc mutation that induces colon tumors, 
that cMyc ablation suppresses intestinal tumorigenesis [383]. This highlights the essential 
role of cMyc in gastrointestinal tumors. More recently, another laboratory showed that 
concomitant cMyc and Apc loss in the small intestine rescued the phenotypes of perturbed 
differentiation, migration and apoptosis that occurred upon deletion of Apc [384]. These 
results, together with what we observed in the pancreas of Apc and cMyc double mutants, 
confirm that APC-dependent tumorigenesis results from hyperactivation of cMyc.  
The lack of tumors despite Apc inactivation reveals that the window of sensitivity to β-
catenin signaling activation in the pancreas is tightly controlled. This is not the case in 
other organs in which the use of the same Apc floxed mice to enhance β-catenin signaling 
lead to uncontrolled growth and finally to cancer. Shibata and colleagues, that generated 
the Apc floxed mice used in our study, were the first to demonstrate that Apc deletion in 
the mouse intestine leads to the rapid formation of colorectal adenomas, mimicking what 
happens in humans with FAP disease [359]. Sansom et al showed that the consequence of 
Apc loss in the mouse intestinal epithelium was the enhanced cell proliferation and 
apoptosis in the crypt compartment, with perturbed differentiation and migration of cells 
along the crypt-villus axis [385]. All these phenotypes are known to be associated with 
early colorectal tumor lesions. β-catenin signaling was activated in the Apc mutated 
intestinal epithelium, with a typical nuclear localization and the upregulation of different 
target genes, including cMyc. Similar results were obtained using an inducible Cre strain 
(Villin-CreERT) to inactivate Apc in mouse intestine [154], confirming that the crypt 
compartment is more sensitive than the villus to β-catenin signaling. 
Inappropriate activation of Wnt/β-catenin in liver has been implicated in the development 
of hepatocellular carcinomas in humans [85]. Apc deletion in mouse liver resulted in 
hepatomegaly, hepatocyte hyperplasia and eventually development of hepatocellular 
carcinomas [386]. These effects were shown to be mediated by activation of β-catenin 
signaling. 
The consequences of Apc inactivation were also investigated in the mouse kidney. 
Alterations in Wnt/β-catenin signaling have been linked to abnormal kidney development 
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and tumorigenesis in humans [387]. Using the same Apc floxed mice, two different 
laboratories showed that Apc loss induces renal carcinoma. In a first report, the authors 
showed that the majority of mice in which the Apc gene was deleted specifically in the 
kidney developed polycystic kidney disease and died at birth, whereas the few mutants 
that survived developed renal carcinomas [388]. Another study using a different Cre 
strain to inactivate Apc confirmed that Apc mutant mice develop renal carcinomas [389]. 
In all these tissues (colon, liver and kidney), the very same Apc inactivation leads to 
substained β-catenin activation and tumor formation. This is not the case for the pancreas, 
where signaling via β-catenin appears to be possible only during a restricted competent 
period, from birth until the sixth month of age thus blocking the development of tumors.  
The refractoriness of islet cells to convey growth signals through β-catenin may also help 
understand why insulinomas, which very often display a loss of APC protein expression 
[390], are largely benign tumors [391], and why β-cells do not transdifferentiate into 
ductal cells in pancreatic metaplastic lesions [392]. 
Like in pancreas, Apc inactivation alone in other organs is not sufficient to induce cancer. 
This has been shown for the mammary gland [393], where specific Apc deletion impaired 
the development of the ductal network, with formation of metaplastic nodules during 
lactation that do not progress to neoplasia. Mutant mammary glands were highly 
proliferative and contained nuclear β-catenin. Concomitant deletion of Tcf1 was required 
for tumor formation. 
We thus wondered whether the combined inactivation of Apc and other factors regulating 
β-catenin transcriptional activity would induce pancreatic tumors. The lack of tumors was 
found also in mice lacking another tumor suppressor gene in the pancreas, Smad4.  
Smad4 is a tumor suppressor gene of the TGFβ signaling pathway frequently mutated in 
human cases of juvenile polyposis of the entire gastrointestinal tract (reviewed in [394]) 
and in human pancreatic carcinomas [364-366]. Smad4 is known to associate with LEF1 
in order to promote the expression of β-catenin target genes [395-397]. It was previously 
shown that Apc (Min) and Smad4 mutant mice developed specific acinar cell foci upon 
carcinogen treatment, and that these foci were precursors of neoplastic lesions [367]. 
Here we showed that the concomitant deletion of Apc and Smad4 specifically in 
pancreatic progenitors is not tumorigenic after one year, showing that Smad4 inactivation 
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is not sufficient to bypass the β-catenin signaling blockade that occurs in aged ApcP-/- 
mice.  
Apart from the implication of Smad4 and TGFβ in regulating β-catenin activation, other 
pathways interfere with Wnt/β-catenin signaling. BMP signaling inhibits β-catenin 
activity in intestinal cells [398, 399], through the tumor suppressor PTEN, a negative 
regulator of the PI3K- Akt pathway. PTEN was shown to inhibit β-catenin nuclear 
accumulation and transcriptional activation [400] and PTEN inactivation leads to 
intestinal polyposis [401]. It will be interesting to explore whether PTEN, via the 
regulation of the PI3K-Akt pathway, is involved in the spatio-temporal restrictions of β-
catenin activity in ApcP-/- mice. 
Signaling through Notch may also alter β-catenin activity. Notch has been directly 
associated with β-catenin in Drosophila, modulating its transcriptional activity [402]. 
Therefore, the Notch signaling may function to establish a threshold of β-catenin 
activation, and it would be interesting to study its involvement in the pancreatic 
phenotype of ApcP-/- mutants. For instance, during somitogenesis expression of the Notch 
ligand Dll1 is directly regulated by Lef1. This directly links Wnt/β-catenin signaling to 
the Notch pathway [403]. Moreover, removal of Notch1 in skin leads to tumors 
associated with increased nuclear β-catenin levels [404].  
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Perspectives 
The molecular mechanisms underlying the absence of β-catenin activity during pancreas 
embryogenesis or in the endocrine compartment, as well as the blockade of β-catenin 
signaling in aged ApcP-/- mutants, deserve further investigation. For this purpose, it would 
be interesting to analyze the biochemical complexes linked to β-catenin at different time 
points during life, as well as in the different compartments of the mutant pancreas.  
We will also investigate the consequences of simultaneous loss of APC an ICAT using 
ICAT knockout mice [405] and floxed ICAT mice when available. 
Potential cross talk with other signaling pathways that regulate β-catenin activation (such 
as BMP or Notch) should also be explored.  
Moreover additional experiments, such as the conditional inactivation of Apc in acinar 
cells only, by using an inducible recombinase (elastase-CreER mice, for instance) [371], 
would be instrumental for further determining the time-frame during which cMyc activity 
triggers the pancreatic enlargement. 
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III. Role of PP during Pancreas Development 
 
III.1. Results 
 
In this part I will summarize three different projects concerning the PP gene and PP-
expressing cells, which were aimed at understanding their role in pancreas development. 
We envisioned three different strategies, namely: PP downregulation (knockdown), or 
gene inactivation (knock in) and PP cell lineage tracing studies in transgenic mice. 
 
III.1.1. PP knockdown using siRNA 
 
RNA interference (RNAi) is an evolutionarily conserved surveillance mechanism that 
responds to the presence of a double stranded RNA in the cell by specific gene silencing, 
through the rapid destruction of the mRNA containing identical sequences [406, 407]. A 
technique derived from RNAi uses small interfering RNAs (siRNAs) to allow for specific 
and efficient inhibition of gene expression [408-410]. Small interfering RNAs (siRNAs) 
are short molecules of 21 nucleotides that recognize and bind to a complementary region 
of an mRNA, leading to its degradation. These molecules mimic intermediates in the 
RNAi pathway without activating the non specific IFN pathway, which could be induced 
by the use of long double stranded RNAs. This strategy has been used both in vitro and in 
vivo and can be a complementary approach to gene targeting [411-413].  
Therefore, to downregulate PP gene expression during pancreas development, we used 
specific siRNAs directed to different regions of the PP transcript. In vitro and in vivo 
experiments were devised using lentiviral vectors.  
Lentiviral vectors can direct the efficient delivery, integration and long-term expression 
of transgenes, which can also encode for specific small interfering RNAs (siRNAs) [414, 
415].  
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III.1.1.1. Design of PP-siRNAs 
We selected different DNA sequences complementary to the coding region of the PP 
transcript using the siRNA target finder and design tool on the Ambion website 
(www.ambion.com). siRNA oligonucleotides were composed of these 21nt DNA 
sequences, a short and conserved spacer, and the reverse complement of the DNA 
sequences followed by five thymidines as a transcriptional stop signal. These siRNAs 
were cloned into the pSuper plasmid downstream of the H1 promoter, a compact RNA 
polymerase III promoter able to transcribe short RNA species [410]. siRNAs were tested 
by cotransfecting HeLa cells with different pSuper-PP siRNA constructs together with 
another plasmid containing a CMV promoter, a sequence coding for EGFP followed by 
the cDNA sequence of PP and a polyA signal.  
This would allow the production of a fusion EGFP-PP transcript and therefore permit to 
test the efficiency of the different PP-siRNA expressing cells by measuring the decrease 
in EGFP fluorescence. All the PP-siRNAs were analyzed by FACS and compared both 
with a negative control (only pSuper transfected cells) and with an efficient siRNA 
directed against the EGFP transcript (siGFP) (Fig. 32A). In our hand this siGFP was able 
to decrease the EGFP fluorescence by 70%, whereas the best PP-siRNA we could select 
was 50% efficient (si 9/10) in the same experiment. For subsequent studies we used this 
si 9/10 as well as two others PP-siRNAs, which also inhibited the reporter fluorescence 
but to a lower extent (si 3/4 and si 5/6).   
The three siRNAs selected against PP transcript, together with the H1 promoter, were 
subcloned into a lentiviral vector containing EGFP (see Method section) and three 
different lentiviruses expressing PP-siRNAs as well as the EGFP reporter molecule were 
produced (Fig. 32B). Due to the duplication of the LTR during reverse transcription, each 
resulting provirus would have two copies of the same siRNA so that, even in the case of a 
single integration event, target cells would acquire two transcription units of each siRNA. 
This would allow the downregulation of PP transcript both in vitro and in vivo during 
pancreas development. For in vitro studies we transduced embryonic pancreatic buds in 
culture with these lentiviruses expressing siPP, whereas for the in vivo strategy we used 
them directly to generate transgenic mice. 
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Figure 32. Knockdown PP expression using siRNAs. (A) FACS analysis of different pSuper-PP siRNA 
constructs transfected into HeLa cells to test the efficiency of PP downregulation. All the PP-siRNAs are 
compared both with a negative control (pSuper only) and with an efficient siRNA directed against the 
EGFP transcript (siGFP) (B) Lentiviral vector containing PP-siRNA (siPP) sequences. This construct is 
used to produce lentiviruses expressing PP-siRNAs as well as the EGFP reporter molecule. 
 
III.1.1.2. Culture of pancreatic buds 
Before starting to transduce pancreatic buds in culture, we verified that all the markers of 
pancreatic differentiation were expressed in our culture conditions. Both dorsal and 
ventral embryonic buds from E11.5 or E12.5 wild-type embryos were dissected and 
grown in vitro (Fig. 33A). In these conditions, buds grow and branch, mimicking the in 
vivo situation (Fig. 33B). The explants were cultured for a week and expression of 
different endocrine and exocrine markers was assessed by immunofluorescence. Cells 
expressing all maturation markers of pancreatic differentiation were present in buds after 
seven days of culture (Fig. 33C). Therefore, we were able to induce a complete 
differentiation of all pancreatic cell types in these embryonic explants and could thus use 
them to investigate the potential of PP-siRNA in vitro.  
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Figure 33. Culture of mouse pancreatic buds. (A) Dorsal and ventral pancreatic explants dissected from 
E11.5 embryos and placed in culture. (B) Pancreatic bud after 3 days in culture. Note the branching 
structure formed by the explant. (C) Immunofluorescence for amylase, insulin, glucagon, somatostatin and 
pancreatic polypeptide reveals the presence of all differentiation markers in the pancreatic explants after a 
week in culture. 
 
III.1.1.3. Transduction of pancreatic buds with PP-siRNA 
We infected E12.5 explants with different lentiviruses expressing the selected siRNAs 
against PP as well as EGFP. In order to monitor infection efficiency we used viruses 
expressing only the EGFP reporter molecule (Fig. 34A). Embryonic buds were 
transduced the day after the dissection and grown in culture for a week. The effects of PP 
downregulation were analyzed by immunofluorescence.  
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The proportion of infected cells in pancreatic explants was low (less than 20%), probably 
due to a reduced accessibility of the virus to the inner regions of the organ. Interestingly, 
in buds infected with PP-siRNA expressing viruses, no PP/EGFP double positive cell was 
ever observed and remaining PP cells had not been transduced (i.e. were EGFP negative) 
(Fig. 34B). This suggests that lentiviruses carrying PP-siRNAs were efficient and 
eliminated PP expression in infected cells.  
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Figure 34. Transduction of pancreatic buds with PP-siRNA expressing lentiviruses. (A) Pancreatic 
explants from E12.5 mouse embryos are transduced with a lentivirus expressing EGFP as well as the PP-
siRNA. Infected cells (EGFP fluorescent) can be observed under a microscope 48h after transduction. (B) 
Immunofluorescence for EGFP and PP on pancreatic explants after a week in culture. These buds are 
infected either with control lentiviruses expressing EGFP alone or with lentiviruses expressing PP-siRNA 
along with EGFP. The proportion of EGFP positive cells is low but PP expression is efficiently silenced in 
cells expressing the PP-siRNA. (C) Immunofluorescence for EGFP and insulin on transduced pancreatic 
explants after a week in culture. No insulin staining is observed in cells expressing the PP-siRNA. 
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Previous cell lineage tracing analyses suggested that PP expression could be a hallmark 
of insulin cell differentiation [239, 240]. Therefore, we reasoned that inhibiting PP could 
lead to the disappearance of insulin cells. We performed double immunostainings for 
EGFP and insulin on infected buds and could never observe any insulin staining in cells 
expressing the PP-siRNAs (Fig. 34C). Remaining insulin positive cells were found only 
in non infected cells, suggesting that PP downregulation may have prevented in this 
condition the expression of insulin. In the same condition we found the presence of cells 
positive for both glucagon and EGFP, indicating the specificity of the inhibitory role of 
PP-siRNA on insulin expression (not shown).  
 
III.1.1.4. In vivo expression of PP-siRNAs   
In vitro studies were encouraging, but the power of this approach was limited by the 
reduced efficiency of transfection. We thus decided to generate transgenic mice using the 
same lentiviruses expressing PP-siRNA used in vitro, to obtain a more homogenous 
expression of the siRNA, from the beginning of pancreas formation, in vivo. Therefore, 
we prepared high titers of lentiviruses (up to 107 PFU/ml) and injected them into the 
perivitelline space of single-cell mouse embryos. Infected blastocysts were transferred 
into pseudo-pregnant females and different transgenic F0 animals were analyzed at E17.5 
(n= 35) or a day after birth (n=25). Genotyping was performed using primers specific for 
EGFP and among all the injected embryos, about a third were positive for the transgene.  
Unfortunately, we could not detect EGFP expression in any of the transgenics. 
Accordingly, PP expression was not downregulated in these transgenic animals, 
indicating that siRNAs were not properly expressed. The reasons for the lack of 
expression were not clear. Perhaps the use of a pancreas specific promoter (like Pdx1) 
instead of an ubiquitous promoter (CMV-β actin) could have yielded higher efficiency.  
Overall, the results obtained using siRNA approaches prompted us to start a more 
ambitious project: the gene targeting experiments devised to inactivate PP.   
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III.1.2. PP and PYY knockout mice2 
 
Generating a knockout mouse is a major undertaking requiring multiple steps: cloning the 
targeting vector, homologous recombination in ES cells, selection of the positive clones 
followed by their injection into blastocyst to generate germline chimeras [417]. 
We first performed an accurate analysis of the genomic region of interest.  In mouse, the 
pancreatic polypeptide (PP) gene is located on chromosome 11 and, using the Ensembl 
genome browser, we found that the Pyy gene was at close proximity, only 5.6 Kb apart. 
Therefore the two genes form a cluster on the chromosome 11, whereas the other member 
of the family, neuropeptide Y (NPY), was located on chromosome 6. The same 
segregation was also present in the human genome, where Pyy and PP genes were found 
nearby on the same chromosome whereas NPY mapped to a different one. This correlates 
with the origin of the three members of the PP-fold family, which arise from subsequent 
gene duplication, with a tandem duplication of PYY being responsible for the creation of 
PP [326]. The mouse PP gene is described in the NCBI database as 1.4 Kb long and is 
composed of four exons, the second and the third are coding exons whereas the others 
represent untranslated regions (5’UTR and 3’UTR). Pyy gene bears the same structural 
organization and is located upstream of PP in the positive transcription strand. Therefore, 
we devised a targeting vector to hit the entire region comprising both Pyy and PP genes, 
to avoid any functional redundancy upon inactivation of PP only. 
 
III.1.2.1. Construction of the targeting vector 
We found no coding sequence in the region going from 10 Kb upstream Pyy to 10 Kb 
downstream PP using Ensembl, Blast or Genescan browsers, only repetitive elements 
were present (LINE and SINE).  
We decided to replace the genomic region, comprising both Pyy and PP coding 
sequences, with a cassette expressing Cre recombinase followed by an ires (internal 
                                            
2 A manuscript describing the inactivation of PYY and PP in mice was published 
416. Schonhoff, S., et al., Energy homeostasis and gastrointestinal endocrine differentiation 
do not require the anorectic hormone peptide YY. Mol Cell Biol, 2005. 25(10): p. 4189-99. two 
years after we started this project. 
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ribosome entry site) and EGFP in order to generate a PYY knockin allele that should also 
function as a knockout for PP (Fig. 35). This strategy would allow subsequent cell 
lineage tracing analysis via Cre expression under the control of PYY promoter. Such 
PYY-Cre mice could be crossed with a floxed reporter strain to specifically follow the 
fate of PYY-expressing cells during pancreas development. Moreover, the GFP tag would 
allow the identification of the PYY-PP knockout cells, to assess their contribution in the 
generation of the different pancreatic cell types during development. Rabbit β globin 
intronic and polyA sequences were placed after the EGFP to stabilize the transcript and 
ensure its correct translation. 
Cre ires EGFP     intron poly A       FRT- PGK-neor- FRT - Lox Targeting vector
5.6 Kb
PYY- PP cluster
PYYPYY promoter PP promoter PP
I II III IVI II III IV
 
Figure 35. Targeting the PYY-PP genomic region. Schematic view of the genomic region comprising the 
Pyy and PP coding sequences. The targeting vector will replace, after homologous recombination, the 
entire region with a cassette encoding the Cre recombinase, generating at the same time a PYY-Cre 
knockin as well as a PP knockout allele. 
 
III.1.2.2. Screening of a 129 BAC library 
The first step in constructing the targeting vector was to choose and clone into 
pBluescript II KS (-) (pBSKS) the homology arms corresponding to the genomic region 
before Pyy and after PP. The purpose was targeting of the correct genomic region, 
necessary for the subsequent homologous recombination of the construct in ES cells. 
Most ES cell lines used for generating knockout animals derive from 129Sv mouse 
embryos. Therefore, in order to avoid polymorphisms and facilitate recombination, the 
homologous arms were chosen in the same genetic background. As the genomic 
sequences available were only of C57Bl/6 genetic background (not 129Sv), we had to 
screen a genomic library containing different BAC clones from a 129Sv background 
(RPCI-22 129 mouse BAC library, kindly provided by Ivan Rodriguez), and more 
specifically from a 129Svj because this was the genetic background of the ES cell line 
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(kindly provided by Peter Gruss, Max Planck Institute) we subsequently used for 
recombination.  
In order to screen this library, we prepared specific probes of the corresponding regions 
(using DNA of 129Svj mice as template for PCR with specific primers) and hybridized 
them with a filter from the 129Svj library. Each filter contains 36.864 colonies which 
represents 18.432 independent clones that have been spotted in duplicate. We could find 
three positive spots (duplicated) corresponding to three different BAC clones (RP22-7I4, 
RP22-6D15 and RP22-32A11) (Fig. 36), which we ordered at the “bacpac” resource 
(www.chori.org). We verified that these BACs contained the entire genomic region of 
interest using specific primers. 
 
 
Figure 36. Screen of the RPCI-22 129 mouse BAC library. Specific spots corresponding to different BAC 
clones containing the genomic region of interest (see Fig. 37) revealed after filter hybridization using 
specific probes.  
 
In the meantime, we performed an accurate analysis of this genomic region to find 
restriction sites that we could use to clone the homologous arms into the plasmid 
backbone. Each BAC was digested with the adequate enzymes, isolated and the specific 
fragments cloned into the pBSKS backbone (cf. Methods). We obtained many colonies 
and screened the positive ones, which contained the homologous regions, by PCR using 
specific primers. They were also sequenced for comparison with the available C57Bl/6 
sequences. The first homologous arm corresponding to the genomic area before Pyy was 
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6.3 Kb long and the second, corresponding to the region located after PP, was of 2.9 Kb. 
The steps required for the assembly of the targeting vector are described in detail in the 
Method section. We added a neomycin resistance cassette (PGK-neo) to allow for 
positive selection of the clones after homologous recombination. This cassette was 
flanked by two FRT sites in order to be removed upon flipase treatment in the knockout 
mice. The final size of the targeting vector was 17.6 Kb. 
 
III.1.2.3. Homologous recombination in ES cells 
ES cells have to be cultured using special media containing LIF and need embryonic 
fibroblasts as feeders to avoid differentiation. Therefore, we prepared fibroblasts from 
E14.5 neomycin transgenic embryos and inactivated them using mytomicin C to block 
their proliferation. Low passage (10 passages) ES cells were electroporated with 20μg of 
previously linearized targeting vector. After neomycin selection, only 30 individual 
colonies could be hand-picked, which did not grow properly. A second round of 
electroporation with 10ug of targeting vector allowed us to obtain 200 individual colonies 
which were grown in 96well plates. Plates were duplicated and the original’s frozen. 
Homologous recombinant clones were screened by Southern blot with a probe located 
just outside the second homologous region.  
While we were screening our clones, a paper was published describing the knockout of 
PYY, with a similar knockin strategy using a LacZ reporter instead of EGFP [416]. In 
this mouse strain, PP transcript and protein were undetectable in the pancreas, indicating 
the inactivation of both Pyy and PP, as we had planned. The authors also combined their 
analysis with cell lineage tracing analyses using Pyy-Cre transgenic animals. These 
results will be described in the Discussion section. Since our main interest was to analyze 
the role of PP and PYY during pancreas development, whereas these authors focused 
only on the adult pancreatic and gastrointestinal phenotypes, we decided to stop the 
screening and obtain this knockout mouse. We have at this time received these mice and 
we will analyze their pancreata at different embryonic stages.  
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III.1.3. Lineage tracing analyses using BAC-mediated transgenesis 
 
In order to follow the fate of PP expressing cells during pancreas development, we 
modified the PP genomic region contained in a BAC such that either Cre recombinase or 
its inducible form (CreERT2) would be expressed instead of the endogenous PP gene. 
For this purpose we used ET recombination in bacteria to modify the BAC and then used 
this recombinant BAC to generate transgenic mice expressing Cre ires EGFP or CreERT2 
ires EGFP under the control of the PP promoter.  
A BAC clone from C57Bl/6 genetic background (named RP23-328F7) was selected using 
the Ensembl genome browser. It bore the entire genomic region of interest comprising the 
PP gene as well as its 5’ and 3’ flanking regions, containing the PP promoter and other 
elements important for the regulation of its expression. Two sequences of 500 nucleotides 
long, flanking the PP coding region, were amplified by PCR using the BAC as a template, 
and cloned in a vector containing the Cre (or CreERT2) ires EGFP cassette, as well as a 
kanamycin gene for subsequent selection (see Methods for detail). These two 
homologous arms flanked each side of the cassette and this plasmid was used to 
recombine the BAC (Fig. 37).  
Cre          ires EGFP            FRT Kanr FRT
PP gene
in BAC RPCI23-398F7
ATG
CreERT2       ires EGFP        FRT Kanr FRT
 
Figure 37. BAC recombination to generate PP-Cre or PP-CreERT transgenic mice. Schematic 
representation of the PP genomic region contained in a BAC and of the targeting cassette that will replace 
the PP coding sequence after ET recombination. 
 
BAC recombination was achieved as follows. First, a special bacterial strain (cf Methods) 
was transformed with the BAC RP23-328F7 and chloramphenicol-resistant colonies 
containing the BAC DNA were selected. Competent bacterial cells containing the BAC 
were then electroporated with the linearized plasmid constructed before, and 
recombination was induced by shifting these bacteria to 42°C. Recombinant BAC clones 
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were resistant to both chloramphenicol and kanamycin selection. Finally the kanamycin 
selection cassette, flanked by FRT sites, was excised by inducing the flipase activity in 
these bacteria. In recombined BAC clones, PP coding region was replaced by the Cre (or 
CreERT2) ires EGFP cassette.  
Currently we have obtained different founder mice by pronuclear microinjection of these 
two BACs. F1 animals are being crossed with R26R reporter mice. This will allow to 
trace the PP cell lineage during pancreas development. Using constitutive Cre expression, 
all cells that have expressed PP will be marked with the lacZ reporter gene and with this 
approach we would like to confirm previous results obtained in our lab using a short rat 
PP promoter fragment [240]. By expressing CreERT2 under the control of PP promoter, 
the contribution of PP-expressing cells at different time points during pancreas 
differentiation will also be addressed in the near future.   
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III.2. Discussion and Perspectives 
 
III.2.1. PP-siRNAs 
Our principal interest was to study the role of PP during pancreas development. We used 
small interfering RNAs to downregulate PP expression. As a tool to deliver these siRNAs, 
lentiviral vectors were produced that contained specific sequences directed against the 
pancreatic polypeptide coding region. These sequences were tested in vitro and the most 
efficient in downregulating a PP-EGFP fusion transcript were selected. This strategy has 
been shown, by different groups, to knockdown efficiently other transcripts both in vitro 
[410] and in vivo [414, 418, 419]. We produced lentiviruses expressing PP-siRNAs and 
used them both on pancreatic embryonic buds in culture and to generate transgenic mice.  
Regarding the culture and transduction of pancreatic explants, we could show by 
immunohistochemistry that infected (EGFP positive) cells did not express PP, meaning 
that PP was efficiently downregulated following siRNA expression. Moreover, in these 
cells expressing PP-siRNAs we could never observe any insulin staining, suggesting that 
PP downregulation prevented insulin expression. These data were concordant with 
previous studies in our lab [239, 240] and suggested that PP expression is a feature of the 
β cell differentiation program. However, we could not further investigate this possibility 
due to the low efficiency of infection of cultured pancreatic primordia (only 20% of 
EGFP positive cells), probably caused by the scarce accessibility of the virus to the whole 
explant.  
Therefore, we decided to use the same lentiviruses to transduce single-cell embryos and 
generated transgenic mice expressing PP-siRNAs. Unfortunately, we could never detect 
any siRNA-expressing cell in the pancreas of transgenic animals, neither during 
embryogenesis nor in newborns.  
As a perspective, we could improve the targeting of these PP-siRNAs by using a 
pancreas-specific promoter and it would be interesting to use an inducible system to 
deliver these siRNAs only at a specific time during pancreas embryogenesis. Moreover, it 
has been shown that longer interfering RNAs (shRNAs) are more efficient to knockdown 
a specific target gene [420]. The use of a new generation of lentiviral vectors that mimic 
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the environment of endogenous microRNAs for shRNA expression [421] could also be 
an important improvement of the system.  
 
III.2.2. PP and PYY knockout mice 
In view of the results obtained with the downregulation of PP expression by siRNA, we 
used a gene targeting approach to delete PP by homologous recombination in ES cells. 
Due to the fact that Pyy and PP form a cluster on the same genomic region, both genes 
could be deleted by a single recombination event. We generated a targeting vector which 
contained two regions homologous to those flanking Pyy and PP, that we cloned by 
screening a genomic library of 129Sv BAC clones. The targeting construct also contained 
a Cre ires EGFP cassette that we wanted to insert to replace the deleted genomic region in 
order to perform cell lineage tracing analyses, so that Pyy promoter region would drive 
the expression of the Cre recombinase. Before we could obtain any positive recombinant 
ES cell clones another laboratory generated a double PYY/PP knockout mouse that we 
have obtained and we will use in further analysis [416]. 
Schonhoff and coauthors reported the generation of PYY null mice, in which the coding 
region of Pyy was replaced with a bacterial lacZ gene to identify cells that transcribed the 
targeted allele (similar to the ires EGFP tag that we used in our targeting vector). Their 
aim was to elucidate the role of PYY in the regulation of energy homeostasis and in 
gastrointestinal endocrine differentiation. Surprisingly, despite the role of PYY3-36 in 
inhibition of food intake [353], PYY knockout mice displayed no difference in either 
food intake or body weight compared to control littermates. Moreover, these mice had no 
increased sensitivity to PYY3-36 and showed no compensatory changes in energy 
expenditure that could explain their normal feeding behavior despite PYY absence.  
PYY expression is an early marker of endocrine differentiation in the developing 
gastrointestinal tract as well as in pancreatic islets. Upon Pyy loss, no defects in gut 
endocrine cell differentiation were detected, and islet architecture was normal.  However, 
no PP-expressing cells could be found in these islets and no PP transcripts were detected. 
PP expression was not restored upon treatment with PYY3-36, indicating that the lack of 
PP was not dependent on Pyy loss. It is likely that, during homologous recombination, 
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some sequences located within the targeted region, and important for PP expression, 
were deleted, generating artefactually a double PYY/PP knockout mouse.  
Interestingly, despite the absence of both anorexigenic peptides, no effect on food intake 
was observed in these animals indicating a possible genetic redundancy in the hormonal 
control of feeding. These results are consistent with other studies of mice lacking ghrelin 
[422] or NPY [423], which do not exhibit any defect on basal feeding behavior. 
Histologically, the absence of PP did not influence the differentiation of other islet cell 
types. The role of PP on pancreas homeostasis and during development was surprisingly 
not assessed in this study. 
In the same study, the authors used recombinant PYY BAC clones, expressing Cre 
recombinase under the control of Pyy promoter, to follow the fate of PYY progenitor 
cells by crossing with a reporter mouse. In adult islets, approximately 40% of glucagon, 
some insulin and all somatostatin and PP-expressing cells were labeled with the reporter 
transgene, suggesting that a significant fraction of α cells as well as somatostatin and PP 
cells arise from PYY positive precursors. In the gastrointestinal tract, these studies 
demonstrated that PYY expressing cells give rise to L-type enteroendocrine cells, which 
secrete glycentin. Overall, this cell lineage tracing analysis confirmed that a significant 
amount of pancreatic and intestinal endocrine cells derive from PYY precursors.  
Two other laboratories also reported the effects of Pyy deletion, with quite different 
results. Boey and coauthors designed a targeting vector which allowed the Pyy promoter-
driven expression of Cre recombinase under the control of the inducible tetracycline 
promoter [424]. The expression of PP gene was not affected in these mice. Interestingly, 
in aged (28 weeks-old) PYY knockout females under normal diet, a significant increase in 
body weight resulting from a 50% increase in fat mass was observed, whereas knockout 
males under the same conditions were resistant to obesity. However, under high-fat diet, 
mutant males became fatter and glucose intolerant. Both PYY knockout males and 
females had higher serum insulin levels than control but did not show any increase in 
food intake. The hyperinsulinemia could contribute to the development of increased 
adiposity in PYY knockout animals, and this is probably due to the lack of PYY 
inhibitory action directly on Y1 receptors in the pancreas [425, 426] as well as indirectly 
to the lack of stimulation of Y2 receptors in the brainstem [427]. Therefore, in this PYY 
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knockout model, hyperinsulinemia and obesity developed under particular conditions, 
such as ageing or long term consumption of high-fat diet, parameters that were not 
examined in the previous study.   
Recently, Batterham and coauthors generated a different PYY knockout mouse, which 
developed a marked obesity [428]. These mice were hyperphagic and were hypersensitive 
to the anorexigenic effects of exogenous PYY3-36. Moreover, chronic treatment with PYY 
reversed their obesity. This was quite different from the other two PYY knockout models 
generated before and could be explained by many features. First, in the targeted allele 
from Batterham et al, the PYY locus was deleted without retaining any exogenous genetic 
material. The authors comment that the expression of Cre may induce per se adverse 
effects in some cell types. This could provide a possible explanation for the 
hyperinsulinemia observed in PYY null mice from Boey and coauthors. Moreover, Pyy 
knockout mice from Batterham et al were backcrossed several times onto a C57Bl/6 
background whereas Schonhoff and colleagues used an FVB strain, resistant to obesity, 
to delete their neomycin selection cassette. Furthermore, Pyyfl/fl mice with an intact Pyy 
locus and a genetic background similar to that of knockout mice were used as internal 
controls. Importantly, these animals were undistinguishable from wild-type littermates. 
All these considerations are important to exclude that the obesity phenotype of the PYY 
knockout mice described by Batterham and coauthors could be due either to genetic 
background, to the presence of an additional obesity gene linked to Pyy locus, or to a 
feature of the gene-targeting strategy. Like in the previous PYY knockout model, PP 
gene expression was unaffected by Pyy deletion.  
The generation of Pyyfl/fl mice by Batterham and coauthors is very interesting as these 
animals, together with PPfl/fl mice (not currently available), could be used to further 
elucidate the role of these two peptides in pancreas development and glucose homeostasis, 
by crossing them with different cell-type specific Cre strains (like Pdx1-Cre or RIP-Cre). 
 
III.2.3. BAC-mediated transgenesis 
Finally, to be able to follow the fate of PP cells, we devised lineage tracing experiments 
and for this purpose we generated PP-Cre and PP-CreERT2 transgenic mice using BAC 
recombineering. We modified the pancreatic polypeptide coding region contained in a 
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BAC by inserting a cassette encoding either Cre or CreERT2 followed by an ires EGFP. 
These mice will be useful to see whether PP-expressing cells are involved in the 
formation of other endocrine cell types during pancreas development, for example insulin 
cells as suggested previously [239, 240]. Moreover, by inducing activation of the Cre 
recombinase in a time-specific manner, using tamoxifen administration in PP-CreERT2 
transgenics, we will investigate whether PP cells contribute to the specification of other 
pancreatic cell types in the adult pancreas, for example during regeneration after loss of 
insulin cells. 
It was recently shown that misexpression of Arx, a transcription factor involved in 
pancreatic α fate specification, was sufficient to reprogram the fate of mature β cells to 
acquire α and PP phenotypes [274]. Using Arx knockout animals, the same authors 
showed that this factor inhibited the formation of insulin and somatostatin expressing 
cells [273]. Conversely, previous experiments in our laboratory demonstrated that, upon 
PP cell ablation, a selective loss of β and δ cells occurred [239] and cell lineage tracing 
analyses suggested that PP cells could be the progenitors of insulin producing cells [240]. 
It will be interesting to use our PP-Cre and PP-CreERT2 transgenic mice to better 
understand the conversion of insulin cells into PP cells observed through ectopic 
activation of Arx in Pdx1 or Pax6 expressing cells [274]. Furthermore these mice could 
be useful to investigate the role of Arx in the genesis of PP cells. 
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IV. Concluding remarks 
 
During the last years, I have been able to study two different aspects of the biology of 
pancreas development and homeostasis, with different degrees of success.  
In particular, I focused my efforts on addressing the role of β-catenin signaling in 
defining the growth rate, and thus the final size, of the pancreas. These studies also shed 
some lights, albeit modestly, on our understanding of the mechanisms of pancreas 
tumorigenesis. 
In the second part, where more work remains to be done, I wanted to further explore the 
role of PP-expressing cells in early pancreas cell fate specification process. In particular, I 
have been able to generate two new strains of transgenic mice, whose final validation is 
being performed at this time (PP-Cre and PP-CreERT), which should be valuable in 
future experiments. 
In both projects, many questions remain to be answered. Ultimately, this is the common 
theme of any scientific progress: the constant formulation of new challenges. 
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V. Methods 
 
All experiments were approved by the Faculty of Medicine’s Animal Ethics Committee 
and the Office Vétérinaire Cantonal of the State of Geneva. The appearance of the 
vaginal plug was considered as day 0.5 of gestation (E0.5). 
 
Genotyping transgenic mice 
A little piece of mice tail was cutted at weaning, putted in eppendorf tubes and 500μl of 
lysis buffer and 0.2mg/ml of Proteinase K were added. Tubes were putted overnight in 
waterbath at 55°C to allow digestion of the tissue. Genomic DNA was then extracted as 
follow: the same volume of phenol-chloroform (500μl) was added, after centrifugation 
the resulting supernatant was collected and precipitated by adding 600μl of isopropanol. 
After centrifugation, DNA pellets were washed by adding 200μl of ethanol 70%, tubes 
were centrifuged again and ethanol was aspirated. After let the DNA pellets dry, they 
were finally resuspended in 200-500μl TE. 2μl of this genomic DNA was used for 
subsequent PCR analyses, using primers specific fro the transgene of interest. 
To genotype Pdx1-cre mice we used Cre1 and Pdx1 as primers, for the floxed animals we 
used APC43 and APC45 for Apcfl/fl (as already published in the original paper describing 
this mice [359]), cMyc 5’ and cMyc 3’ for cMyc fl/fl, Smad4b and Smad4c for Smad4 fl/fl, 
cre1 and cre3 for Pax6-cre genotyping, and for PP-cre ires GFP and PP-creERT ires GFP 
mice we used either cre1 and cre3, cre3 and ERT1 rev, ires5’ and ires3’ or EGFP sens 
and EGFP rev M. 
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Primer Séquence
APC 43 (for) GTT CTG TAT CAT GGA AAG ATA GGT GGT C
APC 45 (rev) CAC TCA AAA CGC TTT TGA GGG TTG ATT C
APC p5 (rev) GAG TAC GGG GTC TCT GTC TCA GTG AA
cMyc5' CAC CGC CTA CAT CCT GTC CAT TC
cMyc3' TAC AGT CCC AAA GCC CCA GCC AAG
Cre1 CCT GTT TTG CAC GTT CAC CG
Cre3 ATG CTT CTG TCC GTT TGC CG
EGFP sens GAC GTA AAC GGC CAC AAG TTC
EGFP rev M GTC GCC CTC GAA CTT CAC CTC 
ERT1 rev GGG CTC AGC ATC CAA CAA GG
Ires5' TAC CTT CTG GGC ATC CTT CA
Ires3' GAA GCC GCT TGG AAT AAG GC
Pdx1 ACT ACA TCT TGA GTT GCA GGC
Smad4 b (rev) GGG CAG CGT AGC ATA TAA GA
Smad4 c (for) GAC CCA AAC GTC ACC TTC AG  
 
 
Lysis buffer 
50mM Tris-HCl pH 8 
10mM EDTA pH 7.4 
1% SDS 
20mM NaCl 
Add distilled water up to 500ml and autoclave the solution before use. 
 
PCR program used for tails genotyping: 
1. 94°C   4min  
2. 94°C   30sec  
3. 60°C (-1°C each cycle) 30sec  
4. 67°C   1min   } repeat 10 times cycles from 2 to 4  
5. 94°C   30sec 
6. 52°C   30sec 
7. 67°C   1min (+1sec each cycle)   } repeat 30 times cycles from 5 to 7 
8. 67°C   5 min 
9. 4°C     forever 
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Special PCR program used for genotyping APC floxed animals: 
1. 94°C 3min 
2. 94°C 1min 
3. 55°C 2min 
4. 75°C 2min    } repeat 40 times cycles from 2 to 4 
5. 72°C 5min 
6. 4°C forever 
 
RNA extraction of adult mice pancreata (modification of Glisin protocol) 
Falcon tubes with 2.5ml of homomix and 1g of CsCl were prepared previous to dissection 
and kept on ice. Pancreata were dissected away from the mice as quickly as possible, 
putted in those tubes and homogenized. Homogenates were layered on 2ml of CsCl 
cushion in ultraclear tubes, well equilibrated and centrifuged at 35 000 rpm for 20h at 
20°C. Then supernatants were removed and RNA pellets were resuspended in 300μl of 
TES, transferred in eppendorf tubes and kept 10min at 4°C to let them dissolve well. 
RNA was extracted twice by adding 300μl of phenol-chloroform on each tube. After 
centrifugation, supernatants were collected and organic phases were extracted from the 
same tubes by adding 100μl of TES. All the aqueous phases were finally pooled and 
RNA was precipitated by adding 1/10 volume of sodium acetate pH 4.7 and 1ml of 100% 
ethanol. Precipitation was let overnight at -20°C. 
After centrifugation at 13 000 rpm for 15min at 4°C, RNA pellets were washed with 
ethanol 70%, centrifuged again and ethanol was aspirated. RNA pellets were let dry on 
ice 10min, and then resuspended in DEPC water (100μl or more, depending on the size of 
the pellet) before being stored at -80°C. 
 
Homomix  
4M guanidine thiocyanate 
0.1M Tris-HCl pH 7.4  
0.2M β-mercaptoethanol 
Add distilled water up to 50ml and dissolve at 37°C for 10min, then store in the dark at 
4°C for no longer than 15 days. 
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 CsCl cushion 
5.7M CsCl 
0.1M EDTA pH 7.4 
Add distilled water up to 50ml and store at room temperature  
The final density of the CsCl cushion should be 1.7-1.71g/ml. 
 
TES 
10mM Tris-HCl pH 7.4 
5mM EDTA pH 7.4 
10% SDS 
 
cDNA Synthesis and Real-Time RT-PCR 
RNA was extracted from dissected pancreata of adult mice by a modification of the 
procedure of Glisin [429], whereas for embryonic stages (E15.5 buds) and isolated islets 
we used the RNeasy micro kit (Qiagen). Total RNA was DNase-I-treated according to the 
manufacturer protocol (Ambion Inc.). First-strand cDNA synthesis was carried out 
following the manufacturer's instructions by using SuperScript II Reverse Transcriptase 
(Invitrogen Life Technologies). Primer design for real-time RT-PCR was carried out with 
the software Primer express 2.0 (Applied Biosystems) by using default parameters such 
that they spanned exon boundaries. The specificity of each primer pair as well as the 
efficiency of the amplification step were tested by assaying serial dilutions of cDNA 
oligonucleotides specific for target. Three different housekeeping genes were used as 
internal controls for normalization (EEF1A1, RpS9 and β-tubulin). PCR reactions were 
carried out in triplicate, on five specimens per condition, labeled by using the SYBR 
green master mix (Applied Biosystems), and the fluorescence was quantified with a Prism 
7900 HT sequence detection system (Applied Biosystems). Raw Ct values obtained with 
SDS 2.0 (Applied Biosystems) were imported into Excel to calculate the normalization 
factor and the fold changes with the geNorm script as published [430]. No change was 
scored when p>0.05. 
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Statistics  
All results are reported as means ± standard errors of the means (SEM) for equivalent 
groups. Results were compared with independent t tests (unpaired and two-tailed) 
reported as P values. 
  
Immunohistochemistry 
Fetuses at different developmental stages, and adult pancreata, were harvested in cold 
PBS and fixed in 4% PFA overnight at 4 °C. Then, the tissues were embedded in paraffin 
and 5 μm-thick tissue sections were mounted on adhesive-coated slides. 
The slides were dewaxed and rehydrated. When required, nuclear membranes were 
permeabilized for 20 min with 0.1% Triton X-100 in PBS. For BrdU labeling and ICAT 
staining, the slides were soaked in 10 mM citrate buffer (pH 6) in a microwave oven at 
600 W for 10 min, and then an additional 20 min at room temperature (‘antigen retrieval’ 
procedure). For Ki67 labeling and β-catenin staining, slides were soaked in TEG buffer 
(Tris EGTA pH 9) in a microwave oven at 600 W for 5 min, then at 200 W for another 15 
min, and then an additional 20 min at room temperature.  
For immunohistochemistry on cryosections, embryonic and adult pancreata were 
harvested in 0.1 M cold phosphate buffer (pH 7.4) and fixed for 1 h in 4% PFA. Tissues 
were then washed with phosphate buffer and incubated overnight at 4°C in 25% sucrose, 
0.1 M phosphate buffer (pH 7.4), embedded in OCT (Tissues Tek), and frozen in liquid 
nitrogen. 8 μm-thick cryostat sections were mounted on adhesive polylysine slides. 
Antibody detection was performed on slides incubated with 0.1% Triton in PBS for 10 
min and rinsed 5 min twice in PBS.  
Non-specific binding sites were blocked by treating the sections for 30 min with 3% BSA, 
0.1% Tween in PBS. Primary antibodies were then incubated in blocking reagent either 
for 2 h at room temperature or overnight at 4°C.  
The antibodies and their dilution used in the present analysis were as follows: rabbit anti-
Pdx1 (gift from C.Wright, 1/5000), rabbit anti- human amylase (Sigma, 1/250), guinea 
pig anti-porcine insulin (Dako, dilution 1/400), mouse anti-porcine glucagon (Sigma, 
1/1000), rabbit anti-human somatostatin (Sigma, 1/200), rabbit anti-human PP (Bachem, 
1/200), rabbit anti-GFP (1/200, Molecular Probes), mouse monoclonal anti-bromo-
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deoxyuridine (clone BU-1 from Amersham), mouse anti-human Ki67 (BD Transduction 
Laboratories, 1/200), mouse anti-β-catenin (BD Transduction Laboratories, 1/100), 
mouse anti-E-cadherin (BD Transduction Laboratories, 1/100), affinity purified rabbit 
anti-ICAT antibody (gift from F.X. Real, 1/500). Sections were washed and incubated for 
1 h at room temperature with specific secondary antibodies (1/500) coupled either to 
Alexa 488 (Molecular Probes) or to Cy3 (Jackson Immunoresearch). For ICAT 
immunostaining, the tyramide signal amplification system (TSA, Molecular Probes) was 
used. 
The specificity of the different immunostainings was confirmed by controls in which 
primary antibodies were omitted. Sections were examined and photographed with a 
Nikon epifluorescence microscope (Eclipse TE200) equipped with a Nikon digital sight 
DS-L1 camera, or with a Zeiss LSM 510 confocal microscope. 
 
Dewaxing and rehydratation procedure 
Put the paraffin slides into a xilene solution (twice for 5minutes), then for 3 min in 
subsequently decreasing ethanol solutions to rehydrate the slides (begin with twice 100% 
ethanol for 3 min, then 95%, 70%, 50% and 30% ethanol) and finish by washing 5 min in 
PBS, before beginning the immunostaining.    
 
TEG buffer  
1.2g Trizma base 
0.19g EGTA 
Add distilled water up to 1L and adjust the pH at 9. 
 
Citrate buffer 10mM 
2.9g Sodium Citrate tribasic Dihydrate 
Add distilled water up to 1L, adjust the pH at 6 and filter. 
 
Islet isolation  
Islets of Langerhans were isolated from pancreata of one month old mice by collagenase 
digestion and purification on a Ficoll gradient as previously described [431, 432]. 
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Briefly, the pancreata were removed, without ductal injection or distention, cut into small 
pieces, and washed three times with ice-cold Hanks’ balanced salt solution (HBSS) to 
remove released trypsin. The resulting pieces were suspended in 3 ml of HBSS, 
containing 4.5 mg collagenase Type V (Sigma C-9263) and digested with shaking at 
37°C for 7 min. The digested sample was washed three times with cold HBSS + 3% BSA 
to inactivate the collagenase. Islet purification was performed by centrifugation at 800g 
for 15 min at 4°C on a discontinuous Ficoll/HBSS gradient (Sigma Histopaque 1077, 
density 1,077 mg/ml). Islets were aspirated from the Ficoll/HBSS interface and washed 
with cold HBSS. Fishing of isolated islets was performed under a light microscope.  
 
Morphometric analyses 
For quantitation of β cell area, 3 animals of each genotype were analyzed at 8 weeks of 
age. Sections of paraffin-embedded pancreas were immunostained with anti-insulin 
antibody at 200-μm intervals to avoid measurement of the same islets twice. Images of β 
cells and of the entire pancreas were obtained with a digital camera (EOS D30; Canon 
Inc.) and analyzed with the use of NIH Image 1.60 softwares, as described previously 
[433]. The β cell area was expressed as a percentage of the total pancreatic area surveyed. 
 
BrdU treatment 
In order to label S-phase nuclei, animals were given BrdU (Sigma 50 μg/g of body 
weight) intraperitoneally (i.p.), 2 hours prior sacrifice. The total number of cells 
(visualized by DAPI staining) and the number of BrdU-positive cells per field were 
counted to calculate the proliferation index. At least three different sections per mouse 
were analyzed. A total of about 2000 cells were counted per condition. 
 
Western blotting 
Pancreata of Apcfl/fl, Apcfl/fl/Pdx1-Cre and cMycfl/fl / Apcfl/fl / Pdx1-Cre mice were 
homogenized using a polytron in lysis buffer (50mM Tris-HCl, pH 7.5, 250mM NaCl, 
1% Triton X-100, 1mM EDTA, 1mM DTT) containing 1x complete protease inhibitors 
(Roche) and incubated 30 min on ice. Lysates were clarified by centrifugation and the 
protein concentration was determined. Samples were fractionated by SDS-PAGE and 
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transferred to Immobilon P membranes (Millipore). Membranes were then 
immunoblotted with the mouse monoclonal anti-active-β-catenin 8E7 antibody (Upstate, 
1/400), or with rabbit anti-β-catenin (phospho Y142) (Abcam, 1/500) and with rabbit 
polyclonal anti-β-tubulin antibody (Abcam, 1/2000). Detection was performed using 
peroxidase-conjugated anti-mouse or anti-rabbit IgGs (Promega, 1/5000). Bands were 
visualized by chemiluminescence (ECL, Amersham) according to the manufacturer’s 
instructions. 
 
Preparation of pancreatic extracts for radioimmunoassay 
Pancreata were dissected and weighted, putted in falcon tubes on ice and homogenized. 
After shaking slowly overnight at 4°C, they were sonicated for 15sec and let them 
shaking slowly again overnight at 4°C. The samples were then centrifuged at 800 rpm for 
5min at 4°C and supernatants were collected and centrifuged at 4000 rpm for 20min. 
Supernatants were ready to use for radioimmunoassay experiments or can be stored at -
80°C for subsequent use. 
 
Acid-ethanol solution 
75% ethanol 
HCl 37%: 15ml 
Add distilled water up to 1L 
Store at -20°C several months. 
 
Pancreatic glucagon and insulin content 
Total pancreata were dissected from adult mice and protein extracts were prepared by 
adding acid-ethanol solution (74% ethanol, 1.4% HCl) and homogenization. After 
samples sonication and centrifugation, the supernatant was used for radioimmunoassay 
experiments using either Glucagon RIA Kit (Linco) to measure glucagon concentration or 
ELISA (Kit Mercodia Ultrasensitive Rat Insulin ELISA) for insulin detection. Protocol 
was performed according to manufacturer’s instructions. 
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Glucose and insulin tolerance tests 
Animals that had fasted overnight (16 hours) were injected intraperitoneally with 2 grams 
of glucose (Fluka) per kilogram of body weight. Glucose levels were measured at 0, 30, 
60, 90, and 120 minutes with Glucometer DEX (Bayer). For determination of plasma 
insulin concentrations during glucose tolerance tests, overnight fasted animals were 
injected with 2 grams of glucose per kilogram of body weight and blood was collected 
from the tail vein at 0 and 15 minutes after injection. Plasma insulin measurements were 
performed by ELISA (Kit Mercodia Ultrasensitive Rat Insulin ELISA).  
 
Amylase activity measurements 
Pancreata from adult mice were homogenized in 3ml of PBS and centrifuged for 1min at 
3000rpm. Plasmatic samples were collected from the retro-orbital sinus in lithium heparin 
treated vial, centrifuged for 5 minutes at 10000 rpm. The amylase activity of pancreatic 
lysates and plasmatic samples was assessed by enzymatic photometric test using the α-
Amylase CC FS (y) (DiaSys) relative to the protein content measured by Bradford test. 
 
X-gal staining 
Total embryos at E10.5 were harvested in cold phosphate buffer (pH 7.4), fixed for 30 
minutes at 4 °C in 4% PFA, and then incubated overnight at 37 °C in X-Gal substrate.  
 
X-Gal substrate 
5 mM K4Fe(CN)6  
5 mM K3Fe(CN)6  
2 mM MgCl2  
0.01% Na deoxycholate  
0.02% NP40  
1 mg/ml X-Gal in phosphate buffer, pH 7.4 
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Targeting contruct 
The targeting vector was assembled as follow: a 2.9 Kb SphI-XbaI fragment, homologous 
to the genomic region located after PP (second homologous arm) and derived from 
RP22-6D15 bac clone, was subcloned into a pBluescript KSII (-) which MCS was 
modified to contain a SphI restriction site. Clones which contained the homologous 
region were screened by PCR using specific primers (Ale11-12) and sequenced. A novel 
MCS was further subcloned into SphI sites to insert additional restriction sites (AscI, 
SpeI, HindIII, SalI, NheI, NotI) upstream, necessary for subsequent cloning. A 6.3 SpeI-
HindIII fragment, homologous to the genomic region located before Pyy (first 
homologous arm) and derived from either RP22-6D15 or RP22-32A11 bac clones, was 
then inserted and positive clones were screened by PCR (primers Ale9-10) and 
sequencing. A XhoI-NheI cassette containing Cre-ires GFP-β globin intron- β globin 
polyA was subcloned back into SalI-NheI, residing therefore in between the first and 
second homologous regions. Finally a blunt Kpn-SacI neomycin cassette (FRT PGK Neo 
FRT) was inserted into blunted NheI site, creating a final targeting vector of 17.6 Kb. 
 
Southern blot and probes preparation 
10 ug of genomic DNA were digested using 80 U of either Spe or EcoRI at 37°C 
overnight. Digested DNA was loaded in a 1% agarose gel and fragments were separated 
by electrophoresis at 70 V during 5 h. The gel was then washed as follow: 250 mM HCl 
for 10min; water; 1.5 M NaCl, 0.5 M NaOH for 10min and again for 20min; water; 3 M 
NaCl, 0.5 M Tris pH 7.5 two times for 15min each. Finally the gel was pre-equilibrated 
in 2X SSC solution then placed in a 20X SSC solution. DNA was transferred on a Nylon 
Membrane positively charged (Roche) overnight at room temperature using 20X SSC as 
transfer solution and fixed on the membrane by UV crosslink at 1200 J.  
Different probes located either inside or outside the targeting vector were prepared from 
purified tail genomic DNA of a 129Sv mouse strain and amplified by PCR using specific 
primers (Ale 5-6 for the region between Pyy and PP and Ale 7-8 for outside the targeting 
vector). Purification of the probes was done using Qiagen Gel extraction purification kit. 
50 ng of the probes were dCTP [a-P32] labeled with the Kit Prime-It Random Primer 
Labeling (Stratagene), then purified on probequant G50 micro columns (Pharmacia). The 
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membrane was prehybridized with QuickHyb Hybridization (Stratagene) solution at 68°C 
during 20min then hybridized by adding one denatured probe (1–2.106 cpm/ml) to the 
QuickHyb solution. Hybridization was done for 2 h at 68°C. The membrane was washed 
successively with 2X SSC, 0.1% SDS for 10min at room temperature, then with the same 
solution at 68°C for 10min and finally with 0.5X SSC, 0.1% SDS for 15min at 68°C. 
Autoradiography was performed using photo sensible film (Kodak) overnight at -80°C. 
 
Primer Séquence
Ale 5 GTC ATT TCG ATC TAT TGG GTT G
Ale 6 CGG TTT TAA GGA TCC GGG TTT CCA G
Ale 7 CTG CTC TGT ATC TAG AAC TAG G
Ale 8 GAA TGG AAC AGG TAG AGG AAG ATG GC
Ale 9 ACT GCT CTT CCA GAG GTC CTG
Ale 10 AGG CTA GAC TTG AAA TCG TAC A
Ale 11 AGG CTG ATG CTG GGC TCA GCA
Ale 12 CTA AGG GTT CAA TTC ATT CTC  
 
Screening of a genomic BAC library 
The screening of the RPCI-22 129 mouse library (kindly provided by professor Ivan 
Rodriguez) was done as described in the chori (childrens’ hospital Oakland research 
institute) website (www.chori.org). Briefly, high density replica filters were placed in bag 
with 30 ml of Church buffer and 100ug/ml of salmon sperm DNA, sealed and let pre-
hybridize 1h at 65°C. Labeled probes (the same used for southern blot) were added so 
that the total cpm (count per minute) of each probe is 10.106 and hybridization was 
performed overnight at 65°C under slow agitation. Probes were labeled using random 
priming and dCTP (α-P32), as for southern blot analysis. After hybridization, filters were 
washed with solution I at 65°C five times for 10min each time to remove most of the 
non-bound probe, then with wash II solution 3 times for 10min each at 65°C. Finally, 
after a quick rinse in water, filters were wrapped individually and placed into a cassette. 
After overnight exposure at -80°C, the signal was revealed by autoradiography using 
photo sensible films (Kodak). The duplicated spots that appeared correspond to specific 
BAC clones and were interpreted following the protocol and grids supplied with the 
filters. Once identified, the BAC clones were ordered on the bacpac resource center on 
the chori web site. 
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Church buffer 
10g BSA 
1mM EDTA 
0.5M Na2HPO4 pH 7.2 
7% SDS 
Add distilled water up to 1L 
Aliquot and store at -20°C. 
 
Wash I solution 
10g BSA 
0.5mM EDTA 
40mM Na2HPO4 pH 7.2 
5% SDS 
Add distilled water up to 1L 
 
Wash II solution 
1mM EDTA 
40mM Na2HPO4 pH 7.2 
1% SDS 
Add distilled water up to 1L 
 
Preparation of primary mouse embryonic fibroblasts 
ES cells need to be cultured on a feeder layer of embryonic fibroblasts to maintain their 
undifferentiated potential. Mouse embryonic fibroblasts were prepared from both wild-
type and neomycin transgenic embryos at E14.5. Skin was isolated from whole embryos, 
placed in a flask with 50 ml of PBS and 0.05% trypsin-EDTA, to allow its digestion for 
1h at 37°C under constant agitation. The supernatant was transferred in a flask with 10% 
FCS and centrifuged 5min at 270g. The pellet was resuspended into 40 ml of culture 
media (DMEM +10% FCS + antibiotics) and divided into multiple flasks for subsequent 
amplification. Embryonic fibroblasts have only a restricted proliferative capacity, 
therefore they need to be frozen quickly (after the second or third passage) at -80°C or in 
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liquid nitrogen, using a media containing 40% FCS 10% DMSO and 50% DMEM. Those 
embryonic fibroblasts were inactivated by mytomicin C treatment to avoid their 
continuous growth while putted in culture with ES cells. 
 
ES cell culture 
ES cells from low passages were putted in culture in special media, maintained at 37% 
with 6% CO2, using inactivated embryonic fibroblasts as feeders and amplified before 
electroporation of the targeting construct as described by [434].  ES cells were passaged 
each 2-3 days, being careful to avoid cell to cell contact between colonies that will trigger 
their differentiation. Neomycin selection was started 24h after electroporation and 
maintained for 8-10 days before picking the resistant colonies. Those clones are amplified, 
duplicated and master plates are frozen at -80°C, whereas the duplicated ones are 
subcultured in order to have enough DNA for screening the positive colonies (correctly 
recombined) by southern blot. 
 
ES medium 
DMEM containing 4.5g/L of glucose 
2mM glutamine 
2mM b-mercaptoethanol 
1% stock solution of non essential amino acids 
1mM n pyruvate  
15% FCS 
500 U/ml LIF 
Antibiotics (PenStrep) 
The vast majority of the components were from Specialty media, the FCS specific for ES 
cells was from Hyclone. 
 
Freezing medium for ES cells (2X) 
80% FCS 
20% DMSO 
Filter and add ES medium to obtain 1X freezing media.  
 124
siRNA sequences: cloning and testing 
Specific sequences of 21 nucleotides were selected against the coding region of the PP 
transcript using Ambion website (www.ambion.com). PP-siRNA oligonucleotides were 
composed of these 21nt DNA sequences, a short and conserved spacer, and the reverse 
complement of the DNA sequences followed by five thymidines as a transcriptional stop 
signal. PP-siRNAs oligonucleotides also included BglII and HindIII restriction sites to 
allow their subsequent cloning. After annealing of the paired oligonucleotides for 3h at 
room temperature, they were cloned into the pSuper plasmid containing the H1 promoter, 
a compact RNA polymerase III promoter able to transcribe short RNA species [410].   
In the mean time, PP cDNA prepared from pancreatic ventral buds of E15.5 embryos was 
amplified using specific primers (PP1 and PP2) containing SalI and XbaI restriction sites 
and subcloned in the TOPO cloning vector (Invitrogen). After sequencing, the 300 bp PP 
cDNA fragment was digested with SalI and XbaI and subcloned into a plasmid 
containing a CMV promoter, an EGFP coding sequence and a polyA tail. The PP cDNA 
was cloned just upstream of the polyA in order to allow the expression of an EGFP-PP 
fusion transcript.  
The two constructs (pSuper PP-siRNA and pEGFP-PP) were cotransfected in a 1:10 ratio 
in HeLa cells using PolyFect reagents and following the manufacturer protocol (Quiagen). 
The EGFP fluorescence levels were measured by FACS analysis and evaluated using the 
median. 
 
Primer Séquence
PP1 GTC GAC ACA GGA TGG CCG TCG CAT A
PP2 TCT AGA TGC CTT CAG CTC CAG  
 
Preparation of lentiviral vectors expressing PP-siRNA and virus production  
The H1 promoter-PP siRNA cassette was excised from the pSuper construct by EcoRI 
and ClaI digestion and subcloned in a lentiviral vector, just before the LTR sequence. The 
resulting provirus will then acquire two copies of this cassette due to duplication of the 
LTR during reverse transcription so that, even in case of a single integration event, target 
cells will have two transcriptional units of this cassette. Lentiviral vectors used in this 
study are based on self-inactivating (SIN) vectors, characterized by transcriptional 
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inactivation of the integrated virus because of 3’LTR deletion mutation [435]. Apart from 
the H1-siRNA cassette, these vectors contained also an EGFP reporter sequence. To 
allow ubiquitous EGFP expression, a cytomegalovirus (CMV) enhancer followed by an 
artificially modified chicken β-actin gene (CAG) promoter were used. Moreover, a 
woodchuck hepatitis virus post-transcriptional regulatory element (WPRE) was placed 
after the EGFP sequence to enhance its expression. Finally, these vectors carried the 
central polypurine tract (cPPT) of the pol gene of HIV-1, which has been shown to 
enhance nuclear translocation of HIV-1 DNA [436, 437]. (cf Fig 23B for a schematic 
view of the provirus composition).  
To generate lentiviruses expressing PP-siRNAs, 293T cells were cotransfected with the 
corresponding lentiviral vector, the packaging plasmid and the one coding for the VSV-G 
envelope protein, using calcium phosphate method. Infectious lentiviruses were harvested 
at 48h and 72h posttransfection, centrifuged at 2 500 rpm for 5min and filtered through 
0.22μm-pore cellulose acetate filters. Lentiviruses were concentrated and purified by 
ultracentrifugation on a 20% sucrose gradient at 26 000 g for 1h30 at 4°C. Pellet were 
resuspended in a minimum volume of 50μl and titrated. The multiplicity of infection 
(MOI) of lentiviruses was determined by infecting HeLa cells with serial dilutions of the 
virus and flow cytometric quantification of EGFP positive cells. 
These lentiviruses were used either in vitro to transduce embryonic pancreatic buds in 
culture or in vivo to generate transgenic mice by perivitellin injection of single-cell 
embryos [438]. 
 
Culture of pancreatic buds and lentiviral infection 
Dorsal and ventral pancreatic buds from E11.5 or E12.5 embryos were cultured on a filter 
(Millicell culture plate inserts, Millipore) which is in contact with a specific culture 
media (DMEM containing 4.5g/L of glucose, 2mM glutamine, 10% FCS and antibiotics). 
Cell media was changed every two days and culture was maintained for a week, to a stage 
corresponding to E19.5 in mice. Infection with lentiviruses was performed the day after 
dissection by putting viral particles directly on the top of the pancreatic bud. Cell medium 
was replaced after 24h to wash the excess of virus, and 48h after infection GFP 
fluorescence could be observed under the microscope. After a week in culture, infected 
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pancreatic buds were fixed in PAF 4% for 30min at 4°C and pre-embedded in 4% 
agarose (type VII low gelling temperature Sigma) before final embedding in paraffin. 
Immunostainings were performed as usual on paraffin sections. 
 
ET cloning  
ET cloning was first described as a strategy that makes use of RecE and RecT proteins 
from E. coli to engineer DNA in bacteria by homologous recombination [439]. This E. 
coli recombination system was modified to be more efficient for BAC engineering by 
using a defective prophage to supply functions that protect and recombine the 
electroporated linear DNA that otherwise will be degraded by the intracellular 
exonucleases of the bacterial cells [440]. A temperature-sensitive repressor tightly 
controls prophage expression so that recombination only occurs transiently when 
bacterial cultures are shifted at 42°C for 15min. The efficient prophage recombination 
system depends primarily on Exo, Beta and Gam functions expressed from the defective 
prophage. Exo and Beta generate recombination activity whereas Gam inhibits E. coli 
nucleases from attacking the electroporated linear DNA.  
To allow recombination of the linearized DNA targeting cassette with its substrate 
sequence contained in a BAC we used a modified E. coli strain described in [441]. This 
EL250 strain was maintained at 32°C because of the temperature-inducible prophage, and 
contained an arabinose inducible promoter which drives the expression of the flipase 
recombinase gene. 
 
Preparation of competent EL250 cells for BAC electroporation 
EL250 were cultured overnight at 30°C. Saturated cultures were centrifuged at 4000 rpm 
8min at 4°C, the pellet was resuspended in ice-cold 10% glycerol and centrifuged again. 
This was repeated twice more and the bacteria were electroporated with 700ng of purified 
RP23-328F7 BAC. Electroporated cells were plated on chloramphenicol bacterial plates 
and, after overnight growth at 30°C, positive colonies were isolated and tested using 
specific primers for the PP coding region. The EcoRI digestion pattern of the positive 
clones was also compared with that of RP23-328F7 BAC to be sure that no BAC 
rearrangement occurred in EL250. 
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 Cloning of the targeting construct for ET recombination 
DNA sequences homologous to the PP coding region were amplified by PCR (Expand 
high fidelity, Roche) using specific primers (KIPP16-17 and KIPP 18-19) and the RP23-
328F7 BAC as a template. The selected genomic regions were 500nt long and separated 
by 40nt in the mouse genome. Primers were designed to include specific restriction sites 
used for subsequent cloning of these sequences into the backbone.  
The targeting cassette was assembled as follow: the first homologous region was digested 
by KpnI-XhoI and inserted into a modified pBSKS backbone. The second BglII-SacII 
homologous sequence was subcloned back into this vector. Sequencing was performed 
after each cloning step, to avoid point mutations that could inhibit homologous 
recombination. An XhoI-BglII fragment containing Cre ires EGFP was then inserted. In 
the case of CreERT2 ires EGFP, this cassette was digested with EcoRI, blunted and 
subcloned back into blunt XhoI. Finally, HincII kanamycin selection cassette (FRT-kan-
FRT) was subcloned into either blunted BglII or PmeI sites, to obtain the definitive 
targeting constructs.  
The first homologous sequence amplified from the RP23-328F7 BAC was selected to 
overlap the ATG translation start site of PP located in exon 2, so that PP expression was 
replaced by Cre (or CreERT2) after ET recombination. Therefore Cre (or CreERT2) 
expression should be regulated exactly as the endogenous PP. 
 
Primer Séquence
KIPP 16 CGG GGT ACC GCT AGC TCC TTG TTC ATT AGA TGG C
KIPP 17 CCG CTC GAG GGA GAG CTG CAC TCC AGG AA
KIPP 18 CCG CTC GAG AGA TCT TCT GCG CCC TGG AGC TGA A
KIPP 19 TCC CCG CGG GCT AGC GGA GGA GCT AGA TGG TTT A  
 
BAC recombination in EL250 bacteria 
The targeting cassette was excised from the plasmid by NheI digestion. Competent 
EL250 cells containing the BAC were prepared as described [440] and recombination 
was induced by shifting these cells 15min at 42°C. After electroporation with 300ng of 
purified NheI fragment, cells were plated on chloramphenicol and kanamycin bacterial 
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plates. After overnight growth at 30°C, positive colonies were isolated and tested using 
specific primers both for the targeting cassette and the BAC. 
To delete the kanamycin resistant cassette, overnight culture of the bacteria containing 
the recombinant BAC were diluted 50 fold and let at 32°C until they reach an OD600 of 
0.5. Upon incubation with 0.2% of L-arabinose for 1h to induce flipase excision of the 
FRT flanked kanamycin cassette, cells were plated on chloramphenicol in parallel with 
kanamycin plates and let grow overnight at 30°C. Colonies that recovered from 
chloramphenicol plates only are positive and contained the recombinant BAC without the 
kanamycin resistance. 
 
Injection of recombinant BAC  
Recombinant BAC containing either the Cre ires EGFP or the CreERT2 ires EGFP 
cassette inserted in the PP coding region (without the kanamycin resistance) were used to 
generate transgenic mice. 1-2ng/μl of purified recombinant BAC resuspended in a 
specific solution was injected into the pronucleus of zygotic embryos that were 
transferred into pseudopregnant females and carried to term.  
 
Solution for BAC injection 
10mM Tris HCL pH 7.5 
0.1mM EDTA  
100mM NaCl 
Filter the solution and store at RT.  
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